APPROVED DRUG PRODUCTS
With Therapeutic Equivalence Evaluations

The "Orange Book"

FDA data supplied by DrugPatentWatch.com

CUMULATIVE SUPPLEMENT 6
June 2011



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

31st EDITION

Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs

2011

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

31st EDITION

Cumulative Supplement 6

June 2011

CONTENTS

PAGE

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

31st EDITION

CUMULATIVE SUPPLEMENT 6
June 2011

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 30th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 31st Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
  - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.

- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
SHIONOGI PHARMA INC (SHIONOGI PHARMA)	SHIONOGI INC (SHIONOGI INC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752)tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable

Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://bookstore.gpo.gov; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2008) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2010	MAR 2011	JUN 2011	SEPT 2011	DEC 2011
DRUG PRODUCTS LISTED	13838	14029	14309		
SINGLE SOURCE	2482 (17.9%)	2477 (17.7%)	2468 (17.2%)		
MULTISOURCE	11267 (81.4%)	11463 (81.7%)	11752 (82.1%)		
THERAPEUTICALLY EQUIVALENT	11107 (80.3%)	11301 (80.6%)	11592 (81.0%)		
NOT THERAPEUTICALLY EQUIVALENT	160 (1.2%)	162 (1.2%)	160 (1.1%)		
EXCEPTIONS[1]	89 (0.6%)	89 (0.6%)	89 (0.6%)		
NEW MOLECULAR ENTITIES APPROVED	8	6	8		
NUMBER OF APPLICANTS	752	768	784		

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by “N” is a New Drug Application (NDA or innovator). The application number preceded by an “A” is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.

CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ABIRATERONE ACETATE

TABLET; ORAL

ZYTIGA

+	CENTOCOR ORTHO	250MG	N202379	001	Apr 28, 2011	Apr	NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

AA	MIRROR PHARMS	325MG;50MG;40MG	A040864	001	Dec 01, 2008	Mar	CAHN
AA		500MG;50MG;40MG	A040883	001	Dec 23, 2008	Mar	CAHN

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

AA	WRASER PHARMS LLC	356.4MG;30MG;16MG	A040688	001	Apr 03, 2007	Jan	CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA	BOCA PHARMA	300MG;5MG	A090415	001	Jan 24, 2011	Feb	CTEC
AB		300MG;5MG	A090415	001	Jan 24, 2011	Jan	NEWA
AA		300MG;7.5MG	A090415	002	Jan 24, 2011	Feb	CTEC
AB		300MG;7.5MG	A090415	002	Jan 24, 2011	Jan	NEWA
AA		300MG;10MG	A090415	003	Jan 24, 2011	Feb	CTEC
AB		300MG;10MG	A090415	003	Jan 24, 2011	Jan	NEWA
AA	+ MIKART	300MG;5MG	A040658	001	Jan 19, 2006	Mar	CRLD
AA		300MG;5MG	A040658	001	Jan 19, 2006	Feb	CTEC
AA	+	300MG;7.5MG	A040556	002	Mar 24, 2006	Feb	CTEC
AA	+	300MG;10MG	A040556	001	Jun 23, 2004	Feb	CTEC
	@ RANBAXY	500MG;5MG	A040825	001	Aug 16, 2007	May	DISC
	@	500MG;10MG	A040824	001	Aug 16, 2007	May	DISC
	@ RANBAXY LABS LTD	325MG;10MG	A040826	001	Aug 16, 2007	May	DISC
	@	750MG;7.5MG	A040822	001	Aug 16, 2007	May	DISC

LORTAB

AA	UCB INC	500MG;5MG	A087722	001	Jul 09, 1982	Jan	CAHN

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN

	@ VINTAGE PHARMS	650MG;65MG	A040507	001	Jul 30, 2003	Mar	DISC

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

DARVOCET-N 100

	@ XANODYNE PHARM	650MG;100MG	N017122	002		Jan	DISC

DARVOCET-N 50

	@ XANODYNE PHARM	325MG;50MG	N017122	001		Jan	DISC

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

	@ CORNERSTONE	325MG;100MG	A076743	001	May 07, 2004	Mar	DISC
	@	500MG;100MG	A076750	001	Jun 28, 2004	Mar	DISC
	@ MIRROR PHARMS	650MG;100MG	A077821	001	Feb 11, 2008	Apr	DISC
AB		650MG;100MG	A077821	001	Feb 11, 2008	Mar	CAHN
	@ TEVA	650MG;100MG	A074119	001	Dec 19, 1994	Mar	DISC

TABLET; ORAL
PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

	@	VINTAGE PHARMS	325MG;50MG	A074843	002	Feb 15, 2001	Mar	DISC
	@		650MG;100MG	A074843	001	Feb 12, 1997	Mar	DISC

ACETYLCHOLINE CHLORIDE

FOR SOLUTION; OPHTHALMIC
MIOCHOL-E

>A>	+	BAUSCH AND LOMB	20MG/VIAL	N020213	001	Sep 22, 1993	Jun	CAHN
>D>	+	NOVARTIS	20MG/VIAL	N020213	001	Sep 22, 1993	Jun	CAHN

ACYCLOVIR

CAPSULE; ORAL
ACYCLOVIR

AB		MYLAN	200MG	A074977	001	Apr 13, 1998	Feb	CAHN

TABLET; ORAL
ACYCLOVIR

AB		MYLAN	400MG	A074976	001	Apr 13, 1998	Feb	CAHN
AB			800MG	A074976	002	Apr 13, 1998	Feb	CAHN

ACYCLOVIR SODIUM

INJECTABLE; INJECTION
ACYCLOVIR SODIUM

	@	HOSPIRA	EQ 50MG BASE/ML	A075065	001	Feb 25, 1999	Feb	DISC

ACYCLOVIR; HYDROCORTISONE

CREAM; TOPICAL
XERESE

	+	MEDA PHARMS	5%;1%	N022436	001	Jul 31, 2009	May	CTNA

ALBENDAZOLE

TABLET; ORAL
ALBENZA

>A>	+	COREPHARMA	200MG	N020666	001	Jun 11, 1996	Jun	CAHN
>D>	+	GLAXOSMITHKLINE LLC	200MG	N020666	001	Jun 11, 1996	Jun	CAHN

ALCAFTADINE

SOLUTION/DROPS; OPHTHALMIC
LASTACAFT

>A>	+	ALLERGAN	0.25%	N022134	001	Jul 28, 2010	Jun	CAHN
>D>	+	VISTAKON PHARMS LLC	0.25%	N022134	001	Jul 28, 2010	Jun	CAHN

ALCLOMETASONE DIPROPIONATE

OINTMENT; TOPICAL
ACLOVATE

AB	+	NYCOMED US	0.05%	N018702	001	Dec 14, 1982	Mar	CAHN

ALENDRONATE SODIUM

TABLET; ORAL
ALENDRONATE SODIUM

AB		MYLAN	EQ 35MG BASE	A078638	001	Aug 04, 2008	Feb	CAHN
AB			EQ 70MG BASE	A078638	002	Aug 04, 2008	Feb	CAHN
	@	SANDOZ	EQ 5MG BASE	A075871	001	Apr 22, 2009	Mar	DISC
	@		EQ 10MG BASE	A075871	002	Apr 22, 2009	Mar	DISC
	@		EQ 35MG BASE	A075871	004	Apr 22, 2009	Mar	DISC
	@		EQ 40MG BASE	A075871	003	Apr 22, 2009	Mar	DISC

TABLET; ORAL
ALENDRONATE SODIUM

@	SANDOZ	EQ 70MG BASE	A075871	005	Apr 22, 2009	Mar	DISC

ALLOPURINOL

TABLET; ORAL
ALLOPURINOL

AB	IPCA LABS LTD	100MG	A090637	001	Mar 16, 2011	Feb	NEWA
AB		300MG	A090637	002	Mar 16, 2011	Feb	NEWA

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL
ALPRAZOLAM

AB	AUROBINDO PHARMA USA	0.5MG	A090871	001	Jun 07, 2011	May	NEWA
AB		1MG	A090871	002	Jun 07, 2011	May	NEWA
AB		2MG	A090871	003	Jun 07, 2011	May	NEWA
AB		3MG	A090871	004	Jun 07, 2011	May	NEWA

ALPROSTADIL

SUPPOSITORY; URETHRAL
MUSE

	MEDA PHARMS	0.125MG	N020700	001	Nov 19, 1996	May	CAHN
		0.25MG	N020700	002	Nov 19, 1996	May	CAHN
		0.5MG	N020700	003	Nov 19, 1996	May	CAHN
+		1MG	N020700	004	Nov 19, 1996	May	CAHN

AMLODIPINE BESYLATE

TABLET; ORAL
AMLODIPINE BESYLATE

AB	EPIC PHARMA LLC	EQ 2.5MG BASE	A078552	001	Apr 08, 2009	Apr	CAHN
AB		EQ 5MG BASE	A078552	002	Apr 08, 2009	Apr	CAHN
AB		EQ 10MG BASE	A078552	003	Apr 08, 2009	Apr	CAHN
AB	HIKMA PHARMS	EQ 2.5MG BASE	A077771	001	Apr 12, 2011	Mar	NEWA
AB		EQ 5MG BASE	A077771	002	Apr 12, 2011	Mar	NEWA
AB		EQ 10MG BASE	A077771	003	Apr 12, 2011	Mar	NEWA
AB	PURACAP PHARM	EQ 2.5MG BASE	A078131	001	Sep 04, 2007	May	CAHN
AB		EQ 5MG BASE	A078131	002	Sep 04, 2007	May	CAHN
AB		EQ 10MG BASE	A078131	003	Sep 04, 2007	May	CAHN
AB	SECAN PHARMS	EQ 5MG BASE	A090752	001	Apr 15, 2011	Apr	NEWA
AB		EQ 10MG BASE	A090752	002	Apr 15, 2011	Apr	NEWA

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

>A>	AB	DR REDDYS LABS INC	EQ 5MG BASE;40MG	A090149	001	Jul 05, 2011	Jun	NEWA
>A>	AB		EQ 10MG BASE;40MG	A090149	002	Jul 05, 2011	Jun	NEWA
>A>	AB	LUPIN PHARMS	EQ 5MG BASE;40MG	A078466	005	Jul 05, 2011	Jun	NEWA
>A>	AB		EQ 10MG BASE;40MG	A078466	006	Jul 05, 2011	Jun	NEWA
>A>	AB	MYLAN	EQ 5MG BASE;40MG	A079047	001	Jul 05, 2011	Jun	NEWA
>A>	AB		EQ 10MG BASE;40MG	A079047	002	Jul 05, 2011	Jun	NEWA
>A>	AB	TEVA PHARMS	EQ 5MG BASE;40MG	A077179	005	Jul 05, 2011	Jun	NEWA
>A>	AB		EQ 10MG BASE;40MG	A077179	006	Jul 05, 2011	Jun	NEWA
>A>	AB	WATSON LABS INC	EQ 5MG BASE;40MG	A090364	001	Jul 05, 2011	Jun	NEWA
>A>	AB		EQ 10MG BASE;40MG	A090364	002	Jul 05, 2011	Jun	NEWA

LOTREL

AB	NOVARTIS	EQ 5MG BASE;40MG	N020364	007	Apr 11, 2006	Jan	CFTG

CAPSULE; ORAL
LOTREL

AB	+	NOVARTIS	EQ 10MG BASE;40MG	N020364	006	Apr 11, 2006	Jan	CFTG

AMOXICILLIN

CAPSULE; ORAL
AMOXICILLIN

AB		AM ANTIBIOTICS	250MG	A062058	001		Feb	CDFR
AB			500MG	A062058	002		Feb	CDFR

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE, TABLET; ORAL
OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

>A>	+	GASTROENTERO	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG	N050824	001	Feb 08, 2011	Jun	CAHN

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE; ORAL
OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

>D>	+	DAVA PHARMS INC	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG	N050824	001	Feb 08, 2011	Jun	CAHN
	+		500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG	N050824	001	Feb 08, 2011	Feb	NEWA

AMPHOTERICIN B

INJECTABLE; INJECTION
AMPHOTERICIN B

>D>	AP	X GEN PHARMS	50MG/VIAL	A063206	001	Apr 29, 1992	Jun	CRLD
>A>	AP	+	50MG/VIAL	A063206	001	Apr 29, 1992	Jun	CRLD
>D>		FUNGIZONE						
>D>	AP	+ APOTHECON	50MG/VIAL	A060517	001		Jun	DISC
>A>		@	50MG/VIAL	A060517	001		Jun	DISC

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION
AMPICILLIN AND SULBACTAM

AP		AUROBINDO PHARMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090340	001	Sep 20, 2010	Apr	CAIN
AP			EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090349	001	Sep 20, 2010	Apr	CAIN
AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090340	002	Sep 20, 2010	Apr	CAIN
AP			EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090349	002	Sep 20, 2010	Apr	CAIN
AP			EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A090339	001	Sep 20, 2010	Apr	CAIN

ANASTROZOLE

TABLET; ORAL
ANASTROZOLE

AB		SANTOS BIOTECH	1MG	A078944	001	Jun 28, 2010	Feb	CAHN

ARGATROBAN

INJECTABLE; IV (INFUSION)

>A>		ARGATROBAN IN SODIUM CHLORIDE						
>A>	+	EAGLE PHARMS	50MG/ML (50MG/ML)	N022434	001	Jun 29, 2011	Jun	NEWA
	+	SANDOZ	125MG/125ML (1MG/ML)	N022485	001	May 09, 2011	May	NEWA

SOLUTION; IV (INFUSION)
ARGATROBAN IN DEXTROSE

	@	SANDOZ	125MG/125ML (1MG/ML)	N201743	001	May 09, 2011	May	DISC

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

>D>		@ PHARMERAL	325MG;50MG;40MG	A087048	002	Dec 09, 1983	Jun	CAHN
>A>		@ PURACAP PHARM	325MG;50MG;40MG	A087048	002	Dec 09, 1983	Jun	CAHN

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

AB		MIRROR PHARMS	325MG;200MG	A040832	001	Jan 07, 2010	Mar	CAHN
AB		PROSAM LABS	325MG;200MG	A040252	001	Dec 10, 1997	Feb	CAHN

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB		MIRROR PHARMS	325MG;200MG;16MG	A040860	001	Jan 07, 2010	Mar	CAHN
AB		PROSAM LABS	325MG;200MG;16MG	A040283	001	Dec 29, 1998	Feb	CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ASPIRIN

AA		COASTAL PHARMS	325MG;4.8355MG	A091670	001	Mar 16, 2011	Feb	NEWA
AA		WATSON LABS	325MG;4.8355MG	A090084	001	Mar 22, 2011	Mar	NEWA

PERCODAN

AA	+	ENDO PHARMS	325MG;4.8355MG	N007337	007	Aug 05, 2005	Feb	CFTG

ATENOLOL

TABLET; ORAL

ATENOLOL

AB		MYLAN	25MG	A074126	003	Aug 26, 1998	Feb	CAHN
AB			50MG	A074126	001	Mar 23, 1994	Feb	CAHN
AB			100MG	A074126	002	Mar 23, 1994	Feb	CAHN

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET; ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

AB		GLENMARK GENERICS	250MG;100MG	A091211	001	Jan 12, 2011	Jan	NEWA

MALARONE

AB	+	GLAXOSMITHKLINE	250MG;100MG	N021078	001	Jul 14, 2000	Jan	CFTG

AZILSARTAN MEDOXOMIL

TABLET; ORAL

EDARBI

		TAKEDA PHARMS	40MG	N200796	001	Feb 25, 2011	Feb	NEWA
	+		80MG	N200796	002	Feb 25, 2011	Feb	NEWA

AZTREONAM

INJECTABLE; INJECTION

AZTREONAM

AP		BEDFORD	1GM/VIAL	A065286	001	Mar 23, 2011	Mar	NEWA
AP			2GM/VIAL	A065286	002	Mar 23, 2011	Mar	NEWA

BACITRACIN

OINTMENT; OPHTHALMIC

BACITRACIN

	+	FERA PHARMS	500 UNITS/GM	A061212	001		Feb	CAHN
	+	NYCOMED US	500 UNITS/GM	A061212	001		Jan	CAHN

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

AT		FERA PHARMS	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060764	002		Feb	CAHN
AT		NYCOMED US	400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A060764	002		Jan	CAHN

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN ZINC AND POLYMYXIN B SULFATE

AT		FERA PHARMS	500 UNITS/GM;10,000 UNITS/GM	A065022	001	Feb 27, 2002	Feb	CAHN
AT		NYCOMED US	500 UNITS/GM;10,000 UNITS/GM	A065022	001	Feb 27, 2002	Jan	CAHN

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

	+	FERA PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166	002		Feb	CAHN
	+	NYCOMED US	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062166	002		Jan	CAHN

BACLOFEN

INJECTABLE; INTRATHECAL

GABLOFEN

AP		CNS THERAPS INC	0.05MG/ML	N022462	001	Nov 19, 2010	Feb	CTEC
AP			0.5MG/ML	N022462	002	Nov 19, 2010	Feb	CTEC
AP			2MG/ML	N022462	003	Nov 19, 2010	Feb	CTEC

LIORESAL

AP	+	MEDTRONIC	0.05MG/ML	N020075	003	Nov 07, 1996	Feb	CTEC
AP	+		0.5MG/ML	N020075	001	Jun 17, 1992	Feb	CTEC
AP	+		2MG/ML	N020075	002	Jun 17, 1992	Feb	CTEC

TABLET; ORAL

BACLOFEN

AB		PROSAM LABS	10MG	A077089	001	Oct 31, 2007	Feb	CAHN
AB			20MG	A077088	001	Oct 31, 2007	Feb	CAHN

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

AB		PRINSTON PHARM LLC	5MG	A076118	001	Feb 11, 2004	May	CAHN
AB			10MG	A076118	002	Feb 11, 2004	May	CAHN
AB			20MG	A076118	003	Feb 11, 2004	May	CAHN
AB			40MG	A076118	004	Feb 11, 2004	May	CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		MYLAN	5MG;6.25MG	A076612	001	Feb 11, 2004	Feb	CAHN
AB			10MG;12.5MG	A076612	002	Feb 11, 2004	Feb	CAHN

TABLET; ORAL
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		MYLAN	20MG;12.5MG	A076612	003	Feb 11, 2004	Feb	CAHN
AB			20MG;25MG	A076612	004	Feb 11, 2004	Feb	CAHN

BENZTROPINE MESYLATE

INJECTABLE; INJECTION
BENZTROPINE MESYLATE

AP		LUITPOLD	1MG/ML	A091152	001	Mar 29, 2010	Feb	CAHN

BETAMETHASONE VALERATE

LOTION; TOPICAL
BETAMETHASONE VALERATE

AB		STI PHARMA LLC	EQ 0.1% BASE	A070052	001	Jul 31, 1985	Apr	CAHN

BICALUTAMIDE

TABLET; ORAL
BICALUTAMIDE

AB		ROXANE	50MG	A078285	001	Mar 24, 2011	Mar	NEWA

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE; ORAL
PYLERA

>A>	+	AXCAN	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Jun	CAHN
>D>	+	AXCAN SCANDIPHARM	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Jun	CAHN

BOCEPREVIR

CAPSULE; ORAL
VICTRELIS

	+	SCHERING	200MG	N202258	001	May 13, 2011	May	NEWA

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION
>D> BRETYLIUM TOSYLATE

>D>	+	HOSPIRA	50MG/ML	N019030	001	Apr 29, 1986	Jun	DISC
>A>	@		50MG/ML	N019030	001	Apr 29, 1986	Jun	DISC

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC
BROMDAY

	+	ISTA PHARMS INC	0.09%	N021664	002	Oct 16, 2010	Mar	CRLD

BROMFENAC SODIUM

		COASTAL PHARMS	0.09%	A201211	001	May 11, 2011	Apr	NEWA

XIBROM

	@	ISTA PHARMS INC	0.09%	N021664	001	Mar 24, 2005	Mar	DISC

BUDESONIDE

CAPSULE; ORAL
BUDESONIDE

AB		MYLAN	3MG	A090410	001	May 16, 2011	May	NEWA

ENTOCORT EC

AB	+	ASTRAZENECA	3MG	N021324	001	Oct 02, 2001	May	CFTG

BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

DUOCAINE

>D>		@ AMPHASTAR	EQ 0.375% (37.5MG/10ML);EQ 1% (100MG/10ML)	N021496	001	May 23, 2003	Jun	CAHN
>A>		@ AMPHASTAR PHARMS INC	EQ 0.375% (37.5MG/10ML);EQ 1% (100MG/10ML)	N021496	001	May 23, 2003	Jun	CAHN

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL

APLENZIN

>D>		BIOVAIL LABS INTL	174MG	N022108	001	Apr 23, 2008	Jun	CAHN
>D>	+		348MG	N022108	002	Apr 23, 2008	Jun	CAHN
>D>			522MG	N022108	003	Apr 23, 2008	Jun	CAHN
>A>		VALEANT INTL	174MG	N022108	001	Apr 23, 2008	Jun	CAHN
>A>	+		348MG	N022108	002	Apr 23, 2008	Jun	CAHN
>A>			522MG	N022108	003	Apr 23, 2008	Jun	CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

AB1		ANCHEN PHARMS	100MG	A091459	001	Jun 09, 2011	May	NEWA
AB1			150MG	A091459	002	Jun 09, 2011	May	NEWA
AB2			150MG	A091520	001	Jun 09, 2011	May	NEWA
AB1			200MG	A091459	003	Jun 09, 2011	May	NEWA
AB1		WATSON LABS FLORIDA	100MG	A079095	001	Mar 24, 2009	May	CAHN
AB2			150MG	A079094	001	Mar 24, 2009	May	CAHN
AB1			150MG	A079095	002	Mar 24, 2009	May	CAHN
AB1			200MG	A079095	003	Mar 24, 2009	May	CAHN

CALCIPOTRIENE

SOLUTION; TOPICAL

CALCIPOTRIENE

AT		G AND W LABS INC	0.005%	A078468	001	Mar 24, 2011	Mar	NEWA

CALCIUM ACETATE

SOLUTION; ORAL

PHOSLYRA

	+	FRESENIUS MEDCL	EQ 169MG CALCIUM/5ML	N022581	001	Apr 18, 2011	Apr	NEWA

TABLET; ORAL

CALCIUM ACETATE

AB		PADDOCK LABS	EQ 169MG CALCIUM	A091561	001	Apr 13, 2011	Mar	NEWA

ELIPHOS

AB	+	CYPRESS PHARM	EQ 169MG CALCIUM	A078502	001	Nov 25, 2008	Mar	CTEC

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

AB		PRINSTON PHARM LLC	12.5MG	A074477	001	Feb 13, 1996	May	CAHN
AB			25MG	A074477	002	Feb 13, 1996	May	CAHN
AB			50MG	A074477	003	Feb 13, 1996	May	CAHN
AB			100MG	A074477	004	Feb 13, 1996	May	CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB		NOSTRUM	100MG	A076697	001	May 20, 2011	May	NEWA
AB			200MG	A076697	002	May 20, 2011	May	NEWA
AB			300MG	A076697	003	May 20, 2011	May	NEWA

CARBATROL

AB		SHIRE	100MG	N020712	003	Sep 30, 1997	May	CFTG
AB			200MG	N020712	001	Sep 30, 1997	May	CFTG
AB	+		300MG	N020712	002	Sep 30, 1997	May	CFTG

TABLET, CHEWABLE; ORAL

CARBAMAZEPINE

		@ JUBILANT CADISTA	100MG	A071940	001	Feb 01, 1988	Jan	CAHN

CARBIDOPA; LEVODOPA

TABLET; ORAL

SINEMET

AB		MERCK SHARP DOHME	10MG;100MG	N017555	001		Jan	CAHN
AB			25MG;100MG	N017555	003		Jan	CAHN
AB	+		25MG;250MG	N017555	002		Jan	CAHN

TABLET, EXTENDED RELEASE; ORAL

SINEMET CR

AB		MERCK SHARP DOHME	25MG;100MG	N019856	002	Dec 24, 1992	Jan	CAHN
AB	+		50MG;200MG	N019856	001	May 30, 1991	Jan	CAHN

CARBINOXAMINE MALEATE

TABLET; ORAL

CARBINOXAMINE MALEATE

AA		RIVERS EDGE PHARMS	4MG	A090756	001	May 27, 2011	May	NEWA

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA		MIRROR PHARMS	350MG	A040823	001	Oct 22, 2008	Mar	CAHN
AA		PROSAM LABS	350MG	A040188	001	Mar 07, 1997	Feb	CAHN

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN SODIUM

AP		HOSPIRA INC	EQ 500MG BASE/VIAL	A065226	001	Apr 21, 2005	Jan	CAHN
AP			EQ 1GM BASE/VIAL	A065244	001	Aug 12, 2005	Jan	CAHN
AP			EQ 1GM BASE/VIAL	A065226	002	Apr 21, 2005	Jan	CAHN
AP			EQ 10GM BASE/VIAL	A065247	001	Aug 12, 2005	Jan	CAHN

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

AP		HOSPIRA INC	EQ 500MG BASE/VIAL	A065369	001	Jun 18, 2007	Jan	CAHN
AP			EQ 1GM BASE/VIAL	A065369	002	Jun 18, 2007	Jan	CAHN
AP			EQ 2GM BASE/VIAL	A065369	003	Jun 18, 2007	Jan	CAHN

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CEFOTAXIME SODIUM

AP		HOSPIRA INC	EQ 500MG BASE/VIAL	A065290	001	Aug 11, 2006	Jan	CAHN

INJECTABLE; INJECTION
CEFOTAXIME SODIUM

AP		HOSPIRA INC	EQ 1GM BASE/VIAL	A065290	002	Aug 11, 2006	Jan	CAHN
AP			EQ 1GM BASE/VIAL	A065293	001	Aug 10, 2006	Jan	CAHN
AP			EQ 2GM BASE/VIAL	A065293	002	Aug 10, 2006	Jan	CAHN
AP			EQ 2GM BASE/VIAL	A065290	003	Aug 11, 2006	Jan	CAHN
AP			EQ 10GM BASE/VIAL	A065292	001	Aug 10, 2006	Jan	CAHN

CEFOXITIN SODIUM

INJECTABLE; INJECTION
CEFOXITIN

AP		HOSPIRA INC	EQ 1GM BASE/VIAL	A065313	001	Jan 23, 2006	Jan	CAHN
AP			EQ 2GM BASE/VIAL	A065313	002	Jan 23, 2006	Jan	CAHN
AP			EQ 10GM BASE/VIAL	A065312	001	Feb 13, 2006	Jan	CAHN

CEFPODOXIME PROXETIL

TABLET; ORAL
CEFPODOXIME PROXETIL

AB	+	SANDOZ	EQ 200MG BASE	A065462	002	May 28, 2008	Jan	CRLD

VANTIN

	@	PHARMACIA AND UPJOHN	EQ 100MG BASE	N050674	001	Aug 07, 1992	Jan	DISC
	@		EQ 200MG BASE	N050674	002	Aug 07, 1992	Jan	DISC

CEFTAZIDIME

INJECTABLE; INJECTION
CEFTAZIDIME IN DEXTROSE CONTAINER

>A>		B BRAUN	EQ 1GM BASE	N050823	001	Jun 13, 2011	Jun	NEWA
>A>	+		EQ 2GM BASE	N050823	002	Jun 13, 2011	Jun	NEWA

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV
CEFTRIAXONE

AP		HOSPIRA INC	EQ 250MG BASE/VIAL	A065230	001	Aug 02, 2005	Jan	CAHN
AP			EQ 500MG BASE/VIAL	A065230	002	Aug 02, 2005	Jan	CAHN
AP			EQ 1GM BASE/VIAL	A065230	003	Aug 02, 2005	Jan	CAHN
AP			EQ 2GM BASE/VIAL	A065230	004	Aug 02, 2005	Jan	CAHN

INJECTABLE; INJECTION
CEFTRIAXONE

AP		HOSPIRA INC	EQ 1GM BASE/VIAL	A065231	001	Aug 02, 2005	Jan	CAHN
AP			EQ 2GM BASE/VIAL	A065231	002	Aug 02, 2005	Jan	CAHN
AP			EQ 10GM BASE/VIAL	A065232	001	Aug 02, 2005	Jan	CAHN
AP	+	SANDOZ	EQ 10GM BASE/VIAL	A065168	001	May 17, 2005	Jan	CRLD

CEFUROXIME AXETIL

TABLET; ORAL
CEFUROXIME AXETIL

AB		ALKEM LABS LTD	EQ 250MG BASE	A065496	001	Jun 07, 2010	May	CAHN
AB			EQ 500MG BASE	A065496	002	Jun 07, 2010	May	CAHN
>A> AB		APOTEX	EQ 250MG BASE	A065069	001	Oct 02, 2002	Jun	CAHN
>A> AB			EQ 500MG BASE	A065069	002	Oct 02, 2002	Jun	CAHN
>D> AB		APOTEX INC	EQ 250MG BASE	A065069	001	Oct 02, 2002	Jun	CAHN
>D> AB			EQ 500MG BASE	A065069	002	Oct 02, 2002	Jun	CAHN

CEFUROXIME SODIUM

INJECTABLE; IM-IV
CEFUROXIME SODIUM

AB	HIKMA FARMACEUTICA	EQ 750MG BASE/VIAL	A065048	001	Jan 09, 2004	Mar	CTEC
AP	HOSPIRA INC	EQ 750MG BASE/VIAL	A065483	001	Oct 15, 2008	Jan	CAHN

INJECTABLE; INJECTION
CEFUROXIME SODIUM

AP	HOSPIRA INC	EQ 1.5GM BASE/VIAL	A065503	001	Oct 15, 2008	Jan	CAHN
AP		EQ 1.5GM BASE/VIAL	A065483	002	Oct 15, 2008	Jan	CAHN
AP		EQ 7.5GM BASE/VIAL	A065484	001	Oct 15, 2008	Jan	CAHN

CEPHALEXIN

FOR SUSPENSION; ORAL
CEPHALEXIN

	@ ACS DOBFAR	EQ 100MG BASE/ML	A062117	001		Jan	CAHN
AB		EQ 125MG BASE/5ML	A062117	002		Jan	CAHN
AB	+	EQ 250MG BASE/5ML	A062117	003		Jan	CAHN

CHLORHEXIDINE GLUCONATE

SOLUTION; DENTAL
CHLORHEXIDINE GLUCONATE

AT	LYNE	0.12%	A074291	001	Dec 28, 1995	Feb	CAHN

CHLOROQUINE PHOSPHATE

TABLET; ORAL
CHLOROQUINE PHOSPHATE

AA	NATCO PHARMA LTD	EQ 150MG BASE	A091621	001	Jan 21, 2011	Jan	NEWA
AA		EQ 300MG BASE	A090612	001	Jan 21, 2011	Jan	NEWA

>A> CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

>A> SOLUTION; ORAL
>A> ZUTRIPRO

>A>	+ CYPRESS PHARM	4MG/5ML;5MG/5ML;60MG/5ML	N022439	001	Jun 08, 2011	Jun	NEWA

CHOLESTYRAMINE

POWDER; ORAL
CHOLESTYRAMINE

AB	+ SANDOZ	EQ 4GM RESIN/PACKET	A074557	001	Aug 15, 1996	Apr	CRLD

CHOLESTYRAMINE LIGHT

AB	+ SANDOZ	EQ 4GM RESIN/PACKET	A074558	001	Aug 15, 1996	Apr	CRLD

QUESTRAN

	@ BRISTOL MYERS	EQ 4GM RESIN/PACKET	N016640	001		Apr	DISC
	@	EQ 4GM RESIN/SCOOPFUL	N016640	003		Apr	DISC

QUESTRAN LIGHT

	@ BRISTOL MYERS	EQ 4GM RESIN/PACKET	N019669	001	Dec 05, 1988	Apr	DISC
	@	EQ 4GM RESIN/SCOOPFUL	N019669	003	Dec 05, 1988	Apr	DISC
AB	+	EQ 4GM RESIN/PACKET	N019669	001	Dec 05, 1988	Mar	CRLD

CICLOPIROX

SHAMPOO; TOPICAL
CICLOPIROX

AT	TARO	1%	A090269	001	Feb 23, 2011	Feb	NEWA

CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
PROQUIN XR

		@ DEPOMED INC	EQ 500MG BASE	N021744	001	May 19, 2005	May	DISC

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
CIPROFLOXACIN EXTENDED RELEASE

>D>		@ ANCHEN PHARMS	212.6MG;EQ 287.5MG BASE	A078166	002	Nov 27, 2007	Jun	CMFD
>A>	AB		212.6MG;EQ 287.5MG BASE	A078166	002	Nov 27, 2007	Jun	CMFD
>D>		@	425.2MG;EQ 574.9MG BASE	A078166	001	Nov 27, 2007	Jun	CMFD
>A>	AB		425.2MG;EQ 574.9MG BASE	A078166	001	Nov 27, 2007	Jun	CMFD

CISPLATIN

INJECTABLE; INJECTION
PLATINOL

>D>		+ BRISTOL MYERS	50MG/VIAL	N018057	002		Jun	DISC
>A>		@	50MG/VIAL	N018057	002		Jun	DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL
CITALOPRAM HYDROBROMIDE

	AB	MYLAN	EQ 10MG BASE	A077042	001	Nov 05, 2004	Apr	CAHN
	AB		EQ 20MG BASE	A077042	002	Nov 05, 2004	Apr	CAHN
	AB		EQ 40MG BASE	A077042	003	Nov 05, 2004	Apr	CAHN

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL
CLINDAMYCIN HYDROCHLORIDE

	AB	MATRIX LABS LTD	EQ 75MG BASE	A091225	001	May 31, 2011	May	NEWA
	AB		EQ 150MG BASE	A091225	002	May 31, 2011	May	NEWA
	AB		EQ 300MG BASE	A091225	003	May 31, 2011	May	NEWA

CLINDAMYCIN PHOSPHATE

GEL; TOPICAL
CLINDAGEL

	BT	+ GALDERMA LABS LP	EQ 1% BASE	N050782	001	Nov 27, 2000	Mar	CRLD

SOLUTION; TOPICAL
CLINDAMYCIN PHOSPHATE

		@ COREPHARMA	EQ 1% BASE	A064108	001	Sep 27, 1996	Apr	CAHN

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL
OLUX

	AB	+ STIEFEL LABS INC	0.05%	N021142	001	May 26, 2000	May	CAHN

CREAM; TOPICAL
CLOBETASOL PROPIONATE

		@ COREPHARMA	0.05%	A075338	001	Feb 09, 2001	Apr	CAHN

CLOBETASOL PROPIONATE (EMOLLIENT)

		@ COREPHARMA	0.05%	A075733	001	Aug 22, 2001	Apr	CAHN

OINTMENT; TOPICAL
CLOBETASOL PROPIONATE

		@ COREPHARMA	0.05%	A075057	001	Aug 12, 1998	Apr	CAHN

SHAMPOO; TOPICAL
CLOBETASOL PROPIONATE

AB		ACTAVIS MID ATLANTIC	0.05%	A078854	001	Jun 07, 2011	May	NEWA

CLOBEX

AB	+	GALDERMA LABS	0.05%	N021644	001	Feb 05, 2004	May	CFTG

SOLUTION; TOPICAL
CLOBETASOL PROPIONATE

AT		NYCOMED US	0.05%	A075391	001	Feb 08, 1999	Apr	CAHN

SPRAY; TOPICAL
CLOBETASOL PROPIONATE

AT		PADDOCK LABS	0.05%	A090898	001	Jun 16, 2011	May	NEWA

CLOBEX

>D>	+	GALDERMA LABS LP	0.05%	N021835	001	Oct 27, 2005	Jun	CTEC
>A> AT	+		0.05%	N021835	001	Oct 27, 2005	Jun	CTEC
	+		0.05%	N021835	001	Oct 27, 2005	May	CFTG

CLOCORTOLONE PIVALATE

CREAM; TOPICAL
CLODERM

>D>	+	DOW PHARM SCIENCES	0.1%	N017765	001		Jun	CAHN
>A>	+	PROMIUS PHARMA LLC	0.1%	N017765	001		Jun	CAHN

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
CLONIDINE HYDROCHLORIDE

>A> AP		APP PHARMS	1MG/10ML (0.1MG/ML)	A200673	001	Jul 08, 2011	Jun	NEWA
>A> AP			5MG/10ML (0.5MG/ML)	A200673	002	Jul 08, 2011	Jun	NEWA
AP		WEST WARD	1MG/10ML (0.1MG/ML)	A200300	001	Jan 26, 2011	Jan	NEWA
AP			5MG/10ML (0.5MG/ML)	A200300	002	Jan 26, 2011	Jan	NEWA

CODEINE SULFATE

>A> SOLUTION; ORAL
>A> CODEINE SULFATE

>A>	+	ROXANE	30MG/5ML	N202245	001	Jun 30, 2011	Jun	NEWA

COLCHICINE; PROBENECID

TABLET; ORAL
PROBENECID AND COLCHICINE

AB		MIRROR PHARMS	0.5MG;500MG	A040618	001	May 13, 2008	Mar	CAHN

COSYNTROPIN

INJECTABLE; INJECTION
CORTROSYN

>D> AP	+	AMPHASTAR	0.25MG/VIAL	N016750	001		Jun	CAHN
>A> AP	+	AMPHASTAR PHARMS INC	0.25MG/VIAL	N016750	001		Jun	CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
AMRIX

AB		ANESTA AG	15MG	N021777	001	Feb 01, 2007	Apr	CFTG
AB	+		30MG	N021777	002	Feb 01, 2007	Apr	CFTG

CYCLOBENZAPRINE HYDROCHLORIDE

AB		MYLAN	15MG	A090738	001	Apr 18, 2011	Apr	NEWA
AB			30MG	A090738	002	Apr 18, 2011	Apr	NEWA

TABLET; ORAL
CYCLOBENZAPRINE HYDROCHLORIDE

AB		JUBILANT CADISTA	5MG	A077563	001	Apr 19, 2006	Jan	CAHN
AB			10MG	A077563	002	Apr 19, 2006	Jan	CAHN
AB		KVK TECH	5MG	A078048	001	Feb 28, 2011	Feb	NEWA
AB			10MG	A078048	002	Feb 28, 2011	Feb	NEWA
AB		PROSAM LABS	5MG	A077291	001	Feb 03, 2006	Feb	CAHN
AB			10MG	A077209	001	Oct 04, 2005	Feb	CAHN

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE; ORAL
ENABLEX

		WARNER CHILCOTT LLC	EQ 7.5MG BASE	N021513	001	Dec 22, 2004	May	CAHN
	+		EQ 15MG BASE	N021513	002	Dec 22, 2004	May	CAHN

DARUNAVIR ETHANOLATE

TABLET; ORAL
PREZISTA

		@ TIBOTEC	EQ 300MG BASE	N021976	001	Jun 23, 2006	May	DISC

DAUNORUBICIN CITRATE

INJECTABLE, LIPOSOMAL; INJECTION
DAUNOXOME

>A>	+	GALEN (UK)	EQ 2MG BASE/ML	N050704	002	Apr 08, 1996	Jun	CAHN
>D>	+	GILEAD	EQ 2MG BASE/ML	N050704	002	Apr 08, 1996	Jun	CAHN

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL
DECLOMYCIN

		@ COREPHARMA	75MG	N050261	001		May	CAHN
AB			150MG	N050261	002		May	CAHN
AB	+		300MG	N050261	003		May	CAHN

DEMECLOCYCLINE HYDROCHLORIDE

AB		VERSAPHARM	150MG	A065389	001	Dec 01, 2008	May	CAHN
AB			300MG	A065389	002	Dec 01, 2008	May	CAHN

DESLORATADINE

TABLET; ORAL
DESLORATADINE

AB		DR REDDYS LABS LTD	5MG	A078365	001	Mar 08, 2011	Feb	NEWA

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL
CLARINEX D 24 HOUR

AB	+	SCHERING	5MG;240MG	N021605	001	Mar 03, 2005	Apr	CFTG

DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR

AB		DR REDDYS LABS LTD	5MG;240MG	A078366	001	Apr 26, 2011	Apr	NEWA

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL
STIMATE

		@ CSL BEHRING	0.15MG/SPRAY	N020355	001	Mar 07, 1994	May	DISC

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

EMOQUETTE

AB	VINTAGE	0.15MG;0.03MG	A076675	001	Feb 25, 2011	Feb	NEWA

DESOXIMETASONE

GEL; TOPICAL

DESOXIMETASONE

AB	VERSAPHARM	0.05%	A090727	001	Mar 10, 2011	Feb	NEWA

OINTMENT; TOPICAL

TOPICORT

+	TARO PHARMS NORTH	0.05%	N018594	001	Jan 17, 1985	May	CMFD

DEXAMETHASONE

ELIXIR; ORAL

DEXAMETHASONE

>A>	LYNE	0.5MG/5ML	A090891	001	Jul 12, 2011	Jun	NEWA
AA	VINTAGE PHARMS	0.5MG/5ML	A091188	001	May 11, 2011	Apr	NEWA

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP	PFIZER	EQ 4MG PHOSPHATE/ML	A040803	001	Aug 29, 2008	May	CAHN
AP		EQ 10MG PHOSPHATE/ML	A040802	001	Aug 29, 2008	May	CAHN

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE

AT	FERA PHARMS	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062938	001	Jul 31, 1989	Feb	CAHN
AT	NYCOMED US	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A062938	001	Jul 31, 1989	Jan	CAHN

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

FOCALIN XR

	NOVARTIS	25MG	N021802	008	Apr 21, 2011	May	NEWA
		35MG	N021802	007	Apr 21, 2011	May	NEWA

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXEDRINE

>A>	AB	COREPHARMA	5MG	N017078	001		Jun	CAHN
>A>	AB		10MG	N017078	002		Jun	CAHN
>A>	AB	+	15MG	N017078	003		Jun	CAHN
>D>	AB	SMITHKLINE BEECHAM	5MG	N017078	001		Jun	CAHN
>D>	AB		10MG	N017078	002		Jun	CAHN
>D>	AB	+	15MG	N017078	003		Jun	CAHN

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA	AMNEAL PHARMS	15MG/5ML;6.25MG/5ML	A090575	001	Feb 08, 2011	Jan	NEWA

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

>A>	AP		BAXTER HLTHCARE	5GM/100ML;75MG/100ML	N017634	004		Jun	CAHN
>D>	AP		BRISTOL MYERS SQUIBB	5GM/100ML;75MG/100ML	N017634	004		Jun	CAHN

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER

>A>	AP		BAXTER HLTHCARE	5GM/100ML;150MG/100ML	N017634	001		Jun	CAHN
>D>	AP		BRISTOL MYERS SQUIBB	5GM/100ML;150MG/100ML	N017634	001		Jun	CAHN

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER

>A>	AP		BAXTER HLTHCARE	5GM/100ML;224MG/100ML	N017634	003		Jun	CAHN
>D>	AP		BRISTOL MYERS SQUIBB	5GM/100ML;224MG/100ML	N017634	003		Jun	CAHN

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

>A>	AP		BAXTER HLTHCARE	5GM/100ML;300MG/100ML	N017634	002		Jun	CAHN
>D>	AP		BRISTOL MYERS SQUIBB	5GM/100ML;300MG/100ML	N017634	002		Jun	CAHN

DICLOFENAC SODIUM

TABLET, EXTENDED RELEASE; ORAL

DICLOFENAC SODIUM

	AB		VALEANT INTL	100MG	A075492	001	Feb 11, 2000	Apr	CAHN

DIFLUPREDNATE

EMULSION; OPHTHALMIC

DUREZOL

	+		ALCON PHARMS LTD	0.05%	N022212	001	Jun 23, 2008	May	CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

CARDIZEM CD

>D>	AB3		BIOVAIL	120MG	N020062	001	Aug 10, 1992	Jun	CAHN
>D>	AB3			180MG	N020062	002	Dec 27, 1991	Jun	CAHN
>D>	AB3			240MG	N020062	003	Dec 27, 1991	Jun	CAHN
>D>	AB3	+		300MG	N020062	004	Dec 27, 1991	Jun	CAHN
>D>	BC	+		360MG	N020062	005	Aug 24, 1999	Jun	CAHN
>A>	AB3		VALEANT INTL	120MG	N020062	001	Aug 10, 1992	Jun	CAHN
>A>	AB3			180MG	N020062	002	Dec 27, 1991	Jun	CAHN
>A>	AB3			240MG	N020062	003	Dec 27, 1991	Jun	CAHN
>A>	AB3	+		300MG	N020062	004	Dec 27, 1991	Jun	CAHN
>A>	BC	+		360MG	N020062	005	Aug 24, 1999	Jun	CAHN

DILTIAZEM HYDROCHLORIDE

	AB3		VALEANT INTL	120MG	A075116	001	Dec 23, 1999	Apr	CAHN
	AB3			180MG	A075116	002	Dec 23, 1999	Apr	CAHN
	AB3			240MG	A075116	003	Dec 23, 1999	Apr	CAHN
	AB3			300MG	A075116	004	Dec 23, 1999	Apr	CAHN

TIAZAC

>D>	AB4		BIOVAIL	120MG	N020401	001	Sep 11, 1995	Jun	CAHN
>D>	AB4			180MG	N020401	002	Sep 11, 1995	Jun	CAHN
>D>	AB4			240MG	N020401	003	Sep 11, 1995	Jun	CAHN
>D>	AB4			300MG	N020401	004	Sep 11, 1995	Jun	CAHN
>D>	AB4			360MG	N020401	005	Sep 11, 1995	Jun	CAHN
>D>	AB4	+		420MG	N020401	006	Oct 16, 1998	Jun	CAHN
>A>	AB4		VALEANT INTL	120MG	N020401	001	Sep 11, 1995	Jun	CAHN
>A>	AB4			180MG	N020401	002	Sep 11, 1995	Jun	CAHN
>A>	AB4			240MG	N020401	003	Sep 11, 1995	Jun	CAHN
>A>	AB4			300MG	N020401	004	Sep 11, 1995	Jun	CAHN
>A>	AB4			360MG	N020401	005	Sep 11, 1995	Jun	CAHN

CAPSULE, EXTENDED RELEASE; ORAL
TIAZAC

>A>	AB4	+	VALEANT INTL	420MG	N020401	006	Oct 16, 1998	Jun	CAHN

TABLET; ORAL
CARDIZEM

>D>	AB		BIOVAIL LABS INTL	30MG	N018602	001	Nov 05, 1982	Jun	CAHN
>D>	AB			60MG	N018602	002	Nov 05, 1982	Jun	CAHN
>D>	AB			90MG	N018602	003	Dec 08, 1986	Jun	CAHN
>D>	AB	+		120MG	N018602	004	Dec 08, 1986	Jun	CAHN
>A>	AB		VALEANT INTL	30MG	N018602	001	Nov 05, 1982	Jun	CAHN
>A>	AB			60MG	N018602	002	Nov 05, 1982	Jun	CAHN
>A>	AB			90MG	N018602	003	Dec 08, 1986	Jun	CAHN
>A>	AB	+		120MG	N018602	004	Dec 08, 1986	Jun	CAHN

TABLET, EXTENDED RELEASE; ORAL
CARDIZEM LA

>D>	AB		BIOVAIL LABS INTL	120MG	N021392	001	Feb 06, 2003	Jun	CAHN
>D>	AB			180MG	N021392	002	Feb 06, 2003	Jun	CAHN
>D>	AB			240MG	N021392	003	Feb 06, 2003	Jun	CAHN
>D>	AB			300MG	N021392	004	Feb 06, 2003	Jun	CAHN
>D>	AB			360MG	N021392	005	Feb 06, 2003	Jun	CAHN
>D>	AB	+		420MG	N021392	006	Feb 06, 2003	Jun	CAHN
>A>	AB		VALEANT INTL	120MG	N021392	001	Feb 06, 2003	Jun	CAHN
>A>	AB			180MG	N021392	002	Feb 06, 2003	Jun	CAHN
>A>	AB			240MG	N021392	003	Feb 06, 2003	Jun	CAHN
>A>	AB			300MG	N021392	004	Feb 06, 2003	Jun	CAHN
>A>	AB			360MG	N021392	005	Feb 06, 2003	Jun	CAHN
>A>	AB	+		420MG	N021392	006	Feb 06, 2003	Jun	CAHN

DIPYRIDAMOLE

TABLET; ORAL
DIPYRIDAMOLE

AB		PROSAM LABS	25MG	A040542	001	Apr 21, 2006	Feb	CAHN
AB			50MG	A040542	002	Apr 21, 2006	Feb	CAHN
AB			75MG	A040542	003	Apr 21, 2006	Feb	CAHN

DISULFIRAM

TABLET; ORAL
ANTABUSE

AB		ODYSSEY PHARMS	250MG	A088482	001	Dec 08, 1983	Mar	CTEC
AB	+		500MG	A088483	001	Dec 08, 1983	Mar	CTEC

DISULFIRAM

AB		SIGMAPHARM LABS LLC	250MG	A091619	001	Mar 28, 2011	Mar	NEWA
AB			500MG	A091619	002	Mar 28, 2011	Mar	NEWA

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS; ORAL
DIVALPROEX SODIUM

AB		MYLAN	EQ 125MG VALPROIC ACID	A090407	001	Mar 28, 2011	Mar	NEWA

TABLET, DELAYED RELEASE; ORAL
DIVALPROEX SODIUM

AB		AUROBINDO PHARMA LTD	EQ 125MG VALPROIC ACID	A090554	001	Apr 21, 2011	Apr	NEWA
AB			EQ 250MG VALPROIC ACID	A090554	002	Apr 21, 2011	Apr	NEWA
AB			EQ 500MG VALPROIC ACID	A090554	003	Apr 21, 2011	Apr	NEWA
AB		UNICHEM LABS LTD	EQ 125MG VALPROIC ACID	A079163	001	Apr 05, 2011	Mar	NEWA
AB			EQ 250MG VALPROIC ACID	A079163	002	Apr 05, 2011	Mar	NEWA
AB			EQ 500MG VALPROIC ACID	A079163	003	Apr 05, 2011	Mar	NEWA

TABLET, DELAYED RELEASE; ORAL
DIVALPROEX SODIUM

AB	WATSON LABS FLORIDA	EQ 500MG VALPROIC ACID	A079080	001	Feb 25, 2011	Feb	NEWA

DOCETAXEL

INJECTABLE; INJECTION
DOCEFREZ

+	SUN PHARMA GLOBAL	20MG/VIAL	N022534	001	May 03, 2011	May	NEWA
+		80MG/VIAL	N022534	002	May 03, 2011	May	NEWA

DOCETAXEL

>A>	ACCORD HLTHCARE	20MG/0.5ML (40MG/ML)	N201195	001	Jun 08, 2011	Jun	NEWA
>A>		80MG/2ML (40MG/ML)	N201195	002	Jun 08, 2011	Jun	NEWA
>D>	+ HOSPIRA INC	20MG/2ML (10MG/ML)	N022234	001	Mar 08, 2011	Jun	CTEC
>A> AP	+	20MG/2ML (10MG/ML)	N022234	001	Mar 08, 2011	Jun	CTEC
	+	20MG/2ML (10MG/ML)	N022234	001	Mar 08, 2011	Mar	NEWA
>D>	+	80MG/8ML (10MG/ML)	N022234	002	Mar 08, 2011	Jun	CTEC
>A> AP	+	80MG/8ML (10MG/ML)	N022234	002	Mar 08, 2011	Jun	CTEC
	+	80MG/8ML (10MG/ML)	N022234	002	Mar 08, 2011	Mar	NEWA
>D>	+	160MG/16ML (10MG/ML)	N022234	003	Mar 08, 2011	Jun	CTEC
>A> AP	+	160MG/16ML (10MG/ML)	N022234	003	Mar 08, 2011	Jun	CTEC
	+	160MG/16ML (10MG/ML)	N022234	003	Mar 08, 2011	Mar	NEWA
>A> AP	SANDOZ	20MG/2ML (10MG/ML)	N201525	001	Jun 29, 2011	Jun	NEWA
>A> AP		80MG/8ML(10MG/ML)	N201525	002	Jun 29, 2011	Jun	NEWA
>A> AP		160MG/16ML (10MG/ML)	N201525	003	Jun 29, 2011	Jun	NEWA

TAXOTERE

@	SANOFI AVENTIS US	40MG/ML	N020449	001	May 14, 1996	Mar	DISC

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL
DONEPEZIL HYDROCHLORIDE

AB	ACTAVIS PHARMA	5MG	A090551	001	May 31, 2011	May	NEWA
AB		10MG	A090551	002	May 31, 2011	May	NEWA
AB	APOTEX	5MG	A078841	001	Jun 02, 2011	May	NEWA
AB		10MG	A078841	002	Jun 02, 2011	May	NEWA
AB	AUROBINDO	5MG	A090056	001	May 31, 2011	May	NEWA
AB		10MG	A090056	002	May 31, 2011	May	NEWA
AB	CIPLA LTD	5MG	A077518	001	May 31, 2011	May	NEWA
AB		10MG	A077518	002	May 31, 2011	May	NEWA
AB	DR REDDYS LABS LTD	5MG	A201001	001	May 31, 2011	May	NEWA
AB		10MG	A201001	002	May 31, 2011	May	NEWA
AB	HIKMA PHARMS	5MG	A090247	001	May 31, 2011	May	NEWA
AB		10MG	A090247	002	May 31, 2011	May	NEWA
AB	HUAHAI US INC	5MG	A200292	001	May 31, 2011	May	NEWA
AB		10MG	A200292	002	May 31, 2011	May	NEWA
AB	JUBILANT LIFE	5MG	A090768	001	May 31, 2011	May	NEWA
AB		10MG	A090768	002	May 31, 2011	May	NEWA
AB	MATRIX LABS LTD	5MG	A090521	001	May 31, 2011	May	NEWA
AB		10MG	A090521	002	May 31, 2011	May	NEWA
AB	PLIVA HRVATSKA DOO	5MG	A090425	001	May 31, 2011	May	NEWA
AB		10MG	A090425	002	May 31, 2011	May	NEWA
AB	ROXANE	5MG	A078662	001	May 31, 2011	May	NEWA
AB		10MG	A078662	002	May 31, 2011	May	NEWA
AB	SANDOZ	5MG	A090290	001	May 31, 2011	May	NEWA
AB		10MG	A090290	002	May 31, 2011	May	NEWA
AB	SUN PHARM INDS	5MG	A090493	001	May 31, 2011	May	NEWA
AB		10MG	A090493	002	May 31, 2011	May	NEWA

TABLET; ORAL
DONEPEZIL HYDROCHLORIDE

AB		TEVA	5MG	A077344	001	May 31, 2011	May	NEWA
AB			10MG	A077344	002	May 31, 2011	May	NEWA
AB		TORRENT PHARMS	5MG	A090686	001	May 31, 2011	May	NEWA
AB			10MG	A090686	002	May 31, 2011	May	NEWA
AB		WOCKHARDT	5MG	A091267	001	May 31, 2011	May	NEWA
AB			10MG	A091267	002	May 31, 2011	May	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL
DONEPEZIL HYDROCHLORIDE

AB		SANDOZ	5MG	A091198	001	May 10, 2011	Apr	NEWA
AB			10MG	A091198	002	May 10, 2011	Apr	NEWA
AB		ZYDUS PHARMS USA INC	5MG	A090175	001	May 10, 2011	Apr	NEWA
AB			10MG	A090175	002	May 10, 2011	Apr	NEWA

DOXYCYCLINE

CAPSULE; ORAL
DOXYCYCLINE

AB		IMPAX LABS INC	EQ 150MG BASE	A200065	001	Feb 17, 2011	Jan	NEWA
AB		MYLAN	40MG	A090855	001	Jul 01, 2010	Jan	CDFR
AB	+	PAR PHARM	EQ 150MG BASE	A065055	003	Jul 15, 2005	Feb	CTEC
AB	+		EQ 150MG BASE	A065055	003	Jul 15, 2005	Jan	CTEC

DOXYCYCLINE HYCLATE

CAPSULE; ORAL
DOXYCYCLINE HYCLATE

AB		WATSON LABS FLORIDA	EQ 50MG BASE	A062031	002	Oct 13, 1982	May	CAHN
AB			EQ 100MG BASE	A062031	001		May	CAHN

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET; ORAL
LORYNA

AB		SANDOZ	3MG;0.02MG	A079221	001	Mar 28, 2011	Mar	NEWA

TABLET; ORAL-28
SYEDA

AB		SANDOZ	3MG;0.03MG	A090114	001	Mar 28, 2011	Mar	NEWA

ENALAPRIL MALEATE

TABLET; ORAL
VASOTEC

>D>	AB		BIOVAIL LABS INTL	2.5MG	N018998	005	Jul 26, 1988	Jun	CAHN
>D>	AB			5MG	N018998	001	Dec 24, 1985	Jun	CAHN
>D>	AB			10MG	N018998	002	Dec 24, 1985	Jun	CAHN
>D>	AB	+		20MG	N018998	003	Dec 24, 1985	Jun	CAHN
>A>	AB		VALEANT INTL	2.5MG	N018998	005	Jul 26, 1988	Jun	CAHN
>A>	AB			5MG	N018998	001	Dec 24, 1985	Jun	CAHN
>A>	AB			10MG	N018998	002	Dec 24, 1985	Jun	CAHN
>A>	AB	+		20MG	N018998	003	Dec 24, 1985	Jun	CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
VASERETIC

>D>	AB		BIOVAIL LABS INTL	5MG;12.5MG	N019221	003	Jul 12, 1995	Jun	CAHN
>D>	AB	+		10MG;25MG	N019221	001	Oct 31, 1986	Jun	CAHN
>A>	AB		VALEANT INTL	5MG;12.5MG	N019221	003	Jul 12, 1995	Jun	CAHN
>A>	AB	+		10MG;25MG	N019221	001	Oct 31, 1986	Jun	CAHN

ENOXAPARIN SODIUM

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

LOVENOX

		SANOFI AVENTIS US	300MG/3ML (100MG/ML)	N020164	009	Jan 23, 2003	Feb	CDFR

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ELESTAT

AT	+	ALLERGAN	0.05%	N021565	001	Oct 16, 2003	Feb	CFTG

EPINASTINE HYDROCHLORIDE

AT		CYPRESS PHARM	0.05%	A090870	001	Mar 14, 2011	Feb	NEWA

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

AP		MUSTAFA NEVSAT	50MG/25ML (2MG/ML)	A090266	001	Apr 15, 2011	Apr	NEWA
AP			200MG/100ML (2MG/ML)	A090266	002	Apr 15, 2011	Apr	NEWA

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYTHROMYCIN

AB		ARBOR PHARMS INC	250MG	A062746	001	Dec 22, 1986	Jan	CAHN

GEL; TOPICAL

E-GLADES

AT		COREPHARMA	2%	A065009	001	Mar 18, 2002	Apr	CAHN

OINTMENT; OPHTHALMIC

ERYTHROMYCIN

AT	+	FERA PHARMS	0.5%	A062447	001	Sep 26, 1983	Feb	CAHN
AT	+	NYCOMED US	0.5%	A062447	001	Sep 26, 1983	Jan	CAHN

SOLUTION; TOPICAL

ERYDERM

		@ ARBOR PHARMS INC	2%	A062290	001		Jan	CAHN

ERYTHROMYCIN

		@ COREPHARMA	2%	A064127	001	Feb 14, 1997	Apr	CAHN

SWAB; TOPICAL

ERYTHROMYCIN

		@ COREPHARMA	2%	A064128	001	Jul 03, 1996	Apr	CAHN

TABLET; ORAL

ERYTHROMYCIN

		ARBOR PHARMS INC	250MG	A061621	001		Jan	CAHN
	+		500MG	A061621	002		Jan	CAHN

TABLET, COATED PARTICLES; ORAL

PCE

		ARBOR PHARMS INC	333MG	N050611	001	Sep 09, 1986	Jan	CAHN
	+		500MG	N050611	002	Aug 22, 1990	Jan	CAHN

TABLET, DELAYED RELEASE; ORAL

E-MYCIN

		@ ARBOR PHARMS INC	250MG	A060272	001		Jan	CAHN
		@	333MG	A060272	002		Jan	CAHN

ERY-TAB

	+	ARBOR PHARMS INC	250MG	A062298	001		Jan	CAHN
	+		333MG	A062298	003	Mar 29, 1982	Jan	CAHN
	+		500MG	A062298	002		Jan	CAHN

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL

E.E.S.

AB		ARBOR PHARMS INC	EQ 200MG BASE/5ML	N050207	001		Jan	CAHN

ERYPED

AB		ARBOR PHARMS INC	EQ 200MG BASE/5ML	N050207	003	Mar 30, 1987	Jan	CAHN
	+		EQ 400MG BASE/5ML	N050207	002		Jan	CAHN

SUSPENSION; ORAL

E.E.S. 200

AB		ARBOR PHARMS INC	EQ 200MG BASE/5ML	A061639	001		Jan	CAHN

E.E.S. 400

AB	+	ARBOR PHARMS INC	EQ 400MG BASE/5ML	A061639	002		Jan	CAHN

PEDIAMYCIN

AB		ARBOR PHARMS INC	EQ 200MG BASE/5ML	A062304	001		Jan	CAHN

PEDIAMYCIN 400

AB		ARBOR PHARMS INC	EQ 400MG BASE/5ML	A062304	002		Jan	CAHN

TABLET; ORAL

E.E.S. 400

BX	+	ARBOR PHARMS INC	EQ 400MG BASE	A061905	002	Aug 12, 1982	Jan	CAHN
	@		EQ 400MG BASE	A061905	001		Jan	CAHN

ERYTHROMYCIN ETHYLSUCCINATE

BX	+	ARBOR PHARMS INC	EQ 400MG BASE	A061904	001		Jan	CAHN

TABLET, CHEWABLE; ORAL

E.E.S.

	@	ARBOR PHARMS INC	EQ 200MG BASE	N050297	002		Jan	CAHN

ERYPED

	@	ARBOR PHARMS INC	EQ 200MG BASE	N050297	003	Jul 05, 1988	Jan	CAHN

ERYTHROMYCIN STEARATE

TABLET; ORAL

ERYTHROCIN STEARATE

	@	ARBOR PHARMS INC	EQ 125MG BASE	A060359	002		Jan	CAHN
			EQ 250MG BASE	A060359	001		Jan	CAHN
	+		EQ 500MG BASE	A060359	003		Jan	CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

ACTIVELLA

AB		NOVO NORDISK INC	0.5MG;0.1MG	N020907	002	Dec 28, 2006	Mar	CTEC

ESTRADIOL AND NORETHINDRONE ACETATE

AB		BRECKENRIDGE PHARM	0.5MG;0.1MG	A078324	002	Jun 09, 2011	May	NEWA

ESTROPIPATE

CREAM; VAGINAL

OGEN

	@	PHARMACIA AND UPJOHN	1.5MG/GM	A084710	001		Apr	DISC

ESZOPICLONE

TABLET; ORAL

ESZOPICLONE

>D>								
>D>	AB	TEVA	1MG	A091169	001	May 23, 2011	Jun	DISC
>A>	@		1MG	A091169	001	May 23, 2011	Jun	DISC
	AB		1MG	A091169	001	May 23, 2011	May	NEWA
>D>	AB		2MG	A091169	002	May 23, 2011	Jun	DISC
>A>	@		2MG	A091169	002	May 23, 2011	Jun	DISC

		TABLET; ORAL								
>D>		ESZOPICLONE								
	AB	TEVA	2MG		A091169	002	May 23, 2011	May	NEWA	
>D>	AB		3MG		A091169	003	May 23, 2011	Jun	DISC	
>A>		@	3MG		A091169	003	May 23, 2011	Jun	DISC	
	AB		3MG		A091169	003	May 23, 2011	May	NEWA	
		LUNESTA								
>D>	AB	SUNOVION PHARMS INC	1MG		N021476	001	Dec 15, 2004	Jun	CTEC	
>A>			1MG		N021476	001	Dec 15, 2004	Jun	CTEC	
	AB		1MG		N021476	001	Dec 15, 2004	May	CFTG	
>D>	AB		2MG		N021476	002	Dec 15, 2004	Jun	CTEC	
>A>			2MG		N021476	002	Dec 15, 2004	Jun	CTEC	
	AB		2MG		N021476	002	Dec 15, 2004	May	CFTG	
>D>	AB	+	3MG		N021476	003	Dec 15, 2004	Jun	CTEC	
>A>		+	3MG		N021476	003	Dec 15, 2004	Jun	CTEC	
	AB	+	3MG		N021476	003	Dec 15, 2004	May	CFTG	
		ETHINYL ESTRADIOL; LEVONORGESTREL								
		TABLET; ORAL								
		LEVONORGESTREL AND ETHINYL ESTRADIOL								
	AB	WATSON LABS	0.02MG;0.09MG		A079218	001	Jun 06, 2011	May	NEWA	
		LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL								
	AB	WATSON LABS	0.03MG,0.01MG;0.15MG,N/A		A078834	001	May 31, 2011	May	NEWA	
		LYBREL								
	AB	+ WYETH PHARMS INC	0.02MG;0.09MG		N021864	001	May 22, 2007	May	CFTG	
		SEASONIQUE								
	AB	+ TEVA WOMENS	0.03MG,0.01MG;0.15MG,N/A		N021840	001	May 25, 2006	May	CFTG	
		TABLET; ORAL-28								
		ORSYTHIA								
	AB1	VINTAGE PHARMS	0.02MG;0.1MG		A077099	001	May 11, 2011	Apr	NEWA	
		ETHINYL ESTRADIOL; NORETHINDRONE								
		TABLET; ORAL-28								
		BRIELLYN								
	AB	GLENMARK GENERICS	0.035MG;0.4MG		A090538	001	Mar 22, 2011	Mar	NEWA	
		TABLET, CHEWABLE; ORAL								
		NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE								
>D>		+ WARNER CHILCOTT	0.025MG;0.8MG		N022573	001	Dec 22, 2010	Jun	CAHN	
		+	0.025MG;0.8MG		N022573	001	Dec 22, 2010	Jan	CRLD	
>A>		+ WATSON LABS INC	0.025MG;0.8MG		N022573	001	Dec 22, 2010	Jun	CAHN	
		ETHINYL ESTRADIOL; NORETHINDRONE ACETATE								
		TABLET; ORAL								
		LO LOESTRIN FE								
		+ WARNER CHILCOTT CO	0.01MG,0.01MG;1MG,N/A		N022501	001	Oct 21, 2010	May	CRLD	
		TABLET; ORAL-28								
		GILDESS FE 1.5/30								
	AB	VINTAGE	0.03MG;1.5MG		A077075	001	Apr 28, 2005	Jan	CTNA	
		GILDESS FE 1/20								
	AB	VINTAGE	0.02MG;1MG		A077077	001	May 20, 2005	Jan	CTNA	
		ETHINYL ESTRADIOL; NORGESTIMATE								
		TABLET; ORAL								
		NORGESTIMATE AND ETHINYL ESTRADIOL								
>A>	AB	GLENMARK GENERICS	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG		A200494	001	Jun 17, 2011	Jun	NEWA	

	TABLET; ORAL-28								
	NORGESTIMATE AND ETHINYL ESTRADIOL								
AB	WATSON LABS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG		A090479	001	Mar 09, 2011	Feb	NEWA

ETHOSUXIMIDE

	CAPSULE; ORAL								
	ETHOSUXIMIDE								
AB	VERSAPHARM	250MG		A040686	001	May 28, 2008	May	CAHN

ETODOLAC

	CAPSULE; ORAL								
	ETODOLAC								
	@ MYLAN	200MG		A075071	001	Sep 30, 1998	Feb	CAHN
	@	300MG		A075071	002	Sep 30, 1998	Feb	CAHN
	TABLET; ORAL								
	ETODOLAC								
	@ MYLAN	400MG		A075012	001	Sep 30, 1998	Feb	CAHN
	@	500MG		A075012	002	Sep 30, 1998	Feb	CAHN

ETONOGESTREL

	IMPLANT; IMPLANTATION								
	NEXPLANON								
	+ ORGANON USA INC	68MG/IMPLANT		N021529	002	May 31, 2011	May	NEWA

ETRAVIRINE

	TABLET; ORAL								
	INTELENCE								
	TIBOTEC	100MG		N022187	001	Jan 18, 2008	Jan	CRLD
	+	200MG		N022187	002	Dec 22, 2010	Jan	NEWA

EXEMESTANE

	TABLET; ORAL								
	AROMASIN								
AB	+ PHARMACIA AND UPJOHN	25MG		N020753	001	Oct 21, 1999	Mar	CFTG
	EXEMESTANE								
AB	ROXANE	25MG		A077431	001	Apr 01, 2011	Mar	NEWA

EZOGABINE

>A>	TABLET; ORAL								
>A>	POTIGA								
>A>	VALEANT PHARMS	50MG		N022345	001	Jun 10, 2011	Jun	NEWA
>A>		200MG		N022345	002	Jun 10, 2011	Jun	NEWA
>A>		300MG		N022345	003	Jun 10, 2011	Jun	NEWA
>A>	+	400MG		N022345	004	Jun 10, 2011	Jun	NEWA

FAMCICLOVIR

	TABLET; ORAL								
	FAMCICLOVIR								
AB	AUROBINDO PHARMA LTD	125MG		A091114	001	Mar 21, 2011	Mar	NEWA
AB		250MG		A091114	002	Mar 21, 2011	Mar	NEWA
AB		500MG		A091114	003	Mar 21, 2011	Mar	NEWA
AB	MYLAN	125MG		A201333	001	Mar 24, 2011	Mar	NEWA
AB		250MG		A201333	002	Mar 24, 2011	Mar	NEWA
AB		500MG		A201333	003	Mar 24, 2011	Mar	NEWA
AB	ROXANE	125MG		A090128	001	Mar 21, 2011	Mar	NEWA

TABLET; ORAL
FAMCICLOVIR

AB	ROXANE	250MG	A090128	002	Mar 21, 2011	Mar	NEWA
AB		500MG	A090128	003	Mar 21, 2011	Mar	NEWA
AB	WATSON LABS	125MG	A078278	001	Mar 21, 2011	Mar	NEWA
AB		250MG	A078278	002	Mar 21, 2011	Mar	NEWA
AB		500MG	A078278	003	Mar 21, 2011	Mar	NEWA

FAMOTIDINE

INJECTABLE; INJECTION
FAMOTIDINE

AP	PFIZER	10MG/ML	A078641	001	Jun 25, 2008	May	CAHN

FAMOTIDINE PRESERVATIVE FREE

AP	PFIZER	10MG/ML	A078642	001	Jun 25, 2008	May	CAHN

PEPCID

	@ MERCK	10MG/ML	N019510	001	Nov 04, 1986	Jan	DISC

PEPCID PRESERVATIVE FREE

	@ MERCK	10MG/ML	N019510	004	Nov 04, 1986	Jan	DISC

PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER

	@ MERCK	0.4MG/ML	N020249	001	Feb 18, 1994	Jan	DISC

TABLET; ORAL
FAMOTIDINE

AB	MYLAN	20MG	A075457	001	Apr 18, 2001	Feb	CAHN
AB		40MG	A075457	002	Apr 18, 2001	Feb	CAHN

FAMOTIDINE; IBUPROFEN

TABLET; ORAL
DUEXIS

+	HORIZON PHARMA	26.6MG;800MG	N022519	001	Apr 23, 2011	Apr	NEWA

FENOFIBRATE

TABLET; ORAL
FENOGLIDE

	SHORE THERAP	40MG	N022118	001	Aug 10, 2007	Feb	CAHN
+		120MG	N022118	002	Aug 10, 2007	Feb	CAHN

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL
FENTANYL-100

AB	MALLINCKRODT INC	100MCG/HR	A077154	004	Feb 09, 2011	Jan	NEWA

FENTANYL-25

AB	MALLINCKRODT INC	25MCG/HR	A077154	001	Feb 09, 2011	Jan	NEWA

FENTANYL-50

AB	MALLINCKRODT INC	50MCG/HR	A077154	002	Feb 09, 2011	Jan	NEWA

FENTANYL-75

AB	MALLINCKRODT INC	75MCG/HR	A077154	003	Feb 09, 2011	Jan	NEWA

FENTANYL CITRATE

SPRAY, METERED; NASAL
LAZANDA

>A>	ARCHIMEDES	100MCG	N022569	001	Jun 30, 2011	Jun	NEWA
>A>	+	400MCG	N022569	002	Jun 30, 2011	Jun	NEWA

TABLET; SUBLINGUAL
ABSTRAL

	PROSTRAKAN INC	EQ 0.1MG BASE	N022510	001	Jan 07, 2011	Jan	NEWA
		EQ 0.2MG BASE	N022510	002	Jan 07, 2011	Jan	NEWA

TABLET; SUBLINGUAL
ABSTRAL
PROSTRAKAN INC EQ 0.3MG BASE N022510 003 Jan 07, 2011 Jan NEWA
\+ EQ 0.4MG BASE N022510 004 Jan 07, 2011 Jan NEWA
EQ 0.6MG BASE N022510 005 Jan 07, 2011 Jan NEWA
EQ 0.8MG BASE N022510 006 Jan 07, 2011 Jan NEWA

FIDAXOMICIN

TABLET; ORAL
DIFICID
\+ OPTIMER PHARMS 200MG N201699 001 May 27, 2011 May NEWA

FLUCONAZOLE

TABLET; ORAL
FLUCONAZOLE
AB AMNEAL PHARM 50MG A078423 001 Mar 07, 2011 Feb NEWA
AB 100MG A078423 002 Mar 07, 2011 Feb NEWA
AB 150MG A078423 003 Mar 07, 2011 Feb NEWA
AB 200MG A078423 004 Mar 07, 2011 Feb NEWA
AB MYLAN 50MG A076042 001 Jul 29, 2004 Feb CAHN
AB 100MG A076042 002 Jul 29, 2004 Feb CAHN
AB 150MG A076042 003 Jul 29, 2004 Feb CAHN
AB 200MG A076042 004 Jul 29, 2004 Feb CAHN

FLUCYTOSINE

CAPSULE; ORAL
ANCOBON
>D> VALEANT 250MG N017001 001 Jun CFTG
>A> AB 250MG N017001 001 Jun CFTG
>D> \+ 500MG N017001 002 Jun CFTG
>A> AB \+ 500MG N017001 002 Jun CFTG
>A> FLUCYTOSINE
>A> AB SIGMAPHARM LABS LLC 250MG A201566 001 Jun 28, 2011 Jun NEWA
>A> AB 500MG A201566 002 Jun 28, 2011 Jun NEWA

FLUDARABINE PHOSPHATE

TABLET; ORAL
OFORTA
\+ SANOFI AVENTIS US 10MG N022273 001 Dec 18, 2008 Apr CMFD
@ 10MG N022273 001 Dec 18, 2008 Jan DISC

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS
FLUDEOXYGLUCOSE F18
AP \+ FEINSTEIN 20-200mCi/ML N021870 001 Aug 19, 2005 Feb CTEC
AP PETNET 20-200mCi/ML A079086 001 Feb 25, 2011 Feb NEWA

FLUMAZENIL

INJECTABLE; INJECTION
FLUMAZENIL
AP PFIZER 0.5MG/5ML (0.1MG/ML) A078595 001 May 13, 2008 May CAHN
AP 1MG/10ML (0.1MG/ML) A078595 002 May 13, 2008 May CAHN

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

SYNALAR

>D>	AT	+	MEDICIS	0.01%	N012787	004		Jun	CAHN
>D>	AT	+		0.025%	N012787	005		Jun	CAHN
>D>	AT	+		0.025%	N012787	002		Jun	CAHN
>A>	AT	+	MEDIMETRIKS PHARMS	0.01%	N012787	004		Jun	CAHN
>A>	AT	+		0.025%	N012787	005		Jun	CAHN
>A>	AT	+		0.025%	N012787	002		Jun	CAHN

SYNALAR-HP

>D>		@	MEDICIS	0.2%	N016161	002		Jun	CAHN
>A>		@	MEDIMETRIKS PHARMS	0.2%	N016161	002		Jun	CAHN

OINTMENT; TOPICAL

SYNALAR

>D>	AT	+	MEDICIS	0.025%	N013960	001		Jun	CAHN
>A>	AT	+	MEDIMETRIKS PHARMS	0.025%	N013960	001		Jun	CAHN

SOLUTION; TOPICAL

SYNALAR

>D>	AT	+	MEDICIS	0.01%	N015296	001		Jun	CAHN
>A>	AT	+	MEDIMETRIKS PHARMS	0.01%	N015296	001		Jun	CAHN

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

	AP		SANDOZ	2.5GM/50ML (50MG/ML)	A091299	001	May 02, 2011	Apr	NEWA
	AP			5GM/100ML (50MG/ML)	A091299	002	May 02, 2011	Apr	NEWA
		@	VALEANT	500MG/10ML (50MG/ML)	N012209	001		Mar	DISC

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

	AB1		ALEMBIC PHARMS LTD	EQ 10MG BASE	A090223	001	Mar 19, 2009	Apr	CAHN
	AB1			EQ 20MG BASE	A090223	002	Mar 19, 2009	Apr	CAHN
	AB			EQ 40MG BASE	A090223	003	Mar 19, 2009	Apr	CAHN

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP

>D>		+	WATSON PHARMS	0.05%	N012806	002		Jun	DISC
>A>		@		0.05%	N012806	002		Jun	DISC

>D>		OINTMENT; TOPICAL							
>D>		CORDRAN							
>D>		+	WATSON PHARMS	0.025%	N012806	004		Jun	DISC
>A>		@		0.025%	N012806	004		Jun	DISC
>D>		+		0.05%	N012806	001		Jun	DISC
>A>		@		0.05%	N012806	001		Jun	DISC

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

	AB		MYLAN	125MG	A076224	001	May 09, 2003	Feb	CAHN

FLUTICASONE PROPIONATE

LOTION; TOPICAL

			CUTIVATE						
AB		+	NYCOMED US	0.05%	N021152	001	Mar 31, 2005	Apr	CFTG
			FLUTICASONE PROPIONATE						
AB			GLENMARK GENERICS	0.05%	A090759	001	May 02, 2011	Apr	NEWA

FLUVOXAMINE MALEATE

TABLET; ORAL

			FLUVOXAMINE MALEATE						
			@ MYLAN	50MG	A075950	001	Oct 15, 2001	Feb	CAHN
			@	100MG	A075950	002	Oct 15, 2001	Feb	CAHN

FOLIC ACID

TABLET; ORAL

			FOLIC ACID						
AA		+	AMNEAL PHARM	1MG	A040625	001	Jul 21, 2005	Apr	CAHN
AA			JUBILANT CADISTA	1MG	A040514	001	Jun 14, 2005	Jan	CAHN

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS

			ARIXTRA						
>D>		+	GLAXOSMITHKLINE	2.5MG/0.5ML	N021345	001	Dec 07, 2001	Jun	CFTG
>A>	AP	+		2.5MG/0.5ML	N021345	001	Dec 07, 2001	Jun	CFTG
>D>		+		5MG/0.4ML	N021345	002	May 28, 2004	Jun	CFTG
>A>	AP	+		5MG/0.4ML	N021345	002	May 28, 2004	Jun	CFTG
>D>		+		7.5MG/0.6ML	N021345	003	May 28, 2004	Jun	CFTG
>A>	AP	+		7.5MG/0.6ML	N021345	003	May 28, 2004	Jun	CFTG
>D>		+		10MG/0.8ML	N021345	004	May 28, 2004	Jun	CFTG
>A>	AP	+		10MG/0.8ML	N021345	004	May 28, 2004	Jun	CFTG
>A>			FONDAPARINUX SODIUM						
>A>	AP		DR REDDYS LABS LTD	2.5MG/0.5ML	A091316	001	Jul 11, 2011	Jun	NEWA
>A>	AP			5MG/0.4ML	A091316	002	Jul 11, 2011	Jun	NEWA
>A>	AP			7.5MG/0.6ML	A091316	003	Jul 11, 2011	Jun	NEWA
>A>	AP			10MG/0.8ML	A091316	004	Jul 11, 2011	Jun	NEWA

FORMOTEROL FUMARATE

POWDER; INHALATION

>D>			FORADIL CERTIHALER						
>D>		+	NOVARTIS	0.0085MG/INH	N021592	001	Dec 15, 2006	Jun	DISC
>A>			@	0.0085MG/INH	N021592	001	Dec 15, 2006	Jun	DISC

FOSINOPRIL SODIUM

TABLET; ORAL

			FOSINOPRIL SODIUM						
AB			AUROBINDO PHARMA LTD	10MG	A091163	001	Mar 30, 2011	Mar	NEWA
AB				20MG	A091163	002	Mar 30, 2011	Mar	NEWA
AB				40MG	A091163	003	Mar 30, 2011	Mar	NEWA

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

			FOSPHENYTOIN SODIUM						
AP		+	APP PHARMS	EQ 50MG PHENYTOIN NA/ML	A078052	001	Aug 06, 2007	Apr	CRLD
AP			PFIZER	EQ 50MG PNENYTOIN NA/ML	A078476	001	Mar 18, 2008	May	CAHN

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

AB		MATRIX LABS LTD	100MG	A090158	001	Feb 14, 2011	Jan	NEWA
AB			300MG	A090158	002	Feb 14, 2011	Jan	NEWA
AB			400MG	A090158	003	Feb 14, 2011	Jan	NEWA
AB		MYLAN	100MG	A090158	001	Feb 14, 2011	May	CAHN
AB			300MG	A090158	002	Feb 14, 2011	May	CAHN
AB			400MG	A090158	003	Feb 14, 2011	May	CAHN

SOLUTION; ORAL

GABAPENTIN

AA		HI TECH PHARMA	250MG/5ML	A078974	001	Feb 18, 2011	Feb	NEWA

NEURONTIN

AA	+	PARKE DAVIS	250MG/5ML	N021129	001	Mar 02, 2000	Feb	CFTG

TABLET; ORAL

GABAPENTIN

AB		ZYDUS PHARMS USA INC	600MG	A078926	001	Feb 11, 2011	Jan	NEWA
AB			800MG	A078926	002	Feb 11, 2011	Jan	NEWA

GRALISE

BX	+	ABBOTT PRODS	300MG	N022544	001	Jan 28, 2011	Jan	NEWA
BX	+		600MG	N022544	002	Jan 28, 2011	Jan	NEWA

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE; ORAL

HORIZANT

	+	GLAXO GRP LTD	600MG	N022399	001	Apr 06, 2011	Apr	NEWA

GADOBUTROL

SOLUTION; INTRAVENOUS

GADAVIST

	+	BAYER HLTHCARE	4.5354GM/7.5ML (604.72MG/ML)	N201277	001	Mar 14, 2011	Mar	NEWA
	+		6.0472GM/10ML (604.72MG/ML)	N201277	002	Mar 14, 2011	Mar	NEWA
	+		9.0708GM/15ML (604.72MG/ML)	N201277	003	Mar 14, 2011	Mar	NEWA
	+		18.1416GM/30ML (604.72MG/ML)	N201277	004	Mar 14, 2011	Mar	NEWA
	+		39.3068GM/65ML (604.72MG/ML)	N201277	005	Mar 14, 2011	Mar	NEWA

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE; ORAL

GALANTAMINE HYDROBROMIDE

AB		MYLAN	EQ 8MG BASE	A090900	001	Jan 24, 2011	Jan	NEWA
AB			EQ 16MG BASE	A090900	002	Jan 24, 2011	Jan	NEWA
AB			EQ 24MG BASE	A090900	003	Jan 24, 2011	Jan	NEWA
AB		SUN PHARMA GLOBAL	EQ 8MG BASE	A090178	001	Feb 02, 2011	Jan	NEWA
AB			EQ 16MG BASE	A090178	002	Feb 02, 2011	Jan	NEWA
AB			EQ 24MG BASE	A090178	003	Feb 02, 2011	Jan	NEWA

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

AB		AUROBINDO PHARMA LTD	EQ 4MG BASE	A090957	001	Mar 29, 2011	Mar	NEWA
AB			EQ 8MG BASE	A090957	002	Mar 29, 2011	Mar	NEWA
AB			EQ 12MG BASE	A090957	003	Mar 29, 2011	Mar	NEWA
AB		ZYDUS PHARMS USA INC	EQ 4MG BASE	A078898	001	Feb 17, 2011	Jan	NEWA
AB			EQ 8MG BASE	A078898	002	Feb 17, 2011	Jan	NEWA
AB			EQ 12MG BASE	A078898	003	Feb 17, 2011	Jan	NEWA

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

		GEMCITABINE						
	+	HOSPIRA INC	EQ 2GM BASE/VIAL	A079183	001	Nov 15, 2010	Feb	CRLD
		GEMCITABINE HYDROCHLORIDE						
AP		APP PHARMS	EQ 2GM BASE/VIAL	A090242	003	May 16, 2011	May	NEWA
AP		FRESENIUS KABI ONCOL	EQ 2GM BASE/VIAL	A090799	003	May 16, 2011	May	NEWA
	+	HOSPIRA INC	EQ 2GM BASE/VIAL	A079183	001	Nov 15, 2010	May	CTNA
AP		TEVA PARENTERAL	EQ 200MG BASE/VIAL	A077983	002	Jan 25, 2011	Jan	NEWA
AP			EQ 1GM BASE/VIAL	A077983	001	Jan 25, 2011	Jan	NEWA
		GEMZAR						
AP	+	LILLY	EQ 200MG BASE/VIAL	N020509	001	May 15, 1996	Jan	CFTG
AP	+		EQ 1GM BASE/VIAL	N020509	002	May 15, 1996	Jan	CFTG

GEMFIBROZIL

TABLET; ORAL

		GEMFIBROZIL						
AB		BLU CARIBE	600MG	A078012	001	Mar 26, 2007	Feb	CAHN

GENTAMICIN SULFATE

OINTMENT; OPHTHALMIC

		GENTAMICIN SULFATE						
AT		FERA PHARMS	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Feb	CAHN
AT		NYCOMED US	EQ 0.3% BASE	A065024	001	Jul 30, 2004	Jan	CAHN

SOLUTION/DROPS; OPHTHALMIC

		GENTAMICIN SULFATE						
AT		FERA PHARMS	EQ 0.3% BASE	A065121	001	Jan 30, 2004	Feb	CAHN

GLIMEPIRIDE

TABLET; ORAL

		GLIMEPIRIDE						
AB		MYLAN	1MG	A077486	001	Feb 10, 2006	Feb	CAHN
AB			2MG	A077486	002	Feb 10, 2006	Feb	CAHN
AB			4MG	A077486	003	Feb 10, 2006	Feb	CAHN

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

		GLIPIZIDE AND METFORMIN HYDROCHLORIDE						
AB		ZYDUS PHARMS USA INC	2.5MG;250MG	A078905	001	Jan 31, 2011	Jan	NEWA
AB			2.5MG;500MG	A078905	002	Jan 31, 2011	Jan	NEWA
AB			5MG;500MG	A078905	003	Jan 31, 2011	Jan	NEWA

GLUTAMINE

FOR SOLUTION; ORAL

		NUTRESTORE						
	+	EMMAUS MEDCL	5GM/PACKET	N021667	001	Jun 10, 2004	May	CAHN

GLYBURIDE

TABLET; ORAL

		GLYBURIDE						
AB		HERITAGE PHARMS INC	1.25MG	A090937	001	Feb 28, 2011	May	CAHN
AB			2.5MG	A090937	002	Feb 28, 2011	May	CAHN
AB			5MG	A090937	003	Feb 28, 2011	May	CAHN
AB		INDICUS PHARMA	1.25MG	A090937	001	Feb 28, 2011	Feb	NEWA
AB			2.5MG	A090937	002	Feb 28, 2011	Feb	NEWA

TABLET; ORAL
GLYBURIDE

AB		INDICUS PHARMA	5MG	A090937	003	Feb 28, 2011	Feb	NEWA

GRANISETRON

FILM, EXTENDED RELEASE; TRANSDERMAL
SANCUSO

>A>	+	PROSTRAKAN INC	3.1MG/24HR	N022198	001	Sep 12, 2008	Jun	CAHN
>D>	+	STRAKAN	3.1MG/24HR	N022198	001	Sep 12, 2008	Jun	CAHN

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL
FULVICIN P/G

	@	ELORAC	125MG	A061996	001		Jan	CAHN
	@		250MG	A061996	002		Jan	CAHN

FULVICIN P/G 165

	@	ELORAC	165MG	A061996	003	Apr 06, 1982	Jan	CAHN

FULVICIN P/G 330

	@	ELORAC	330MG	A061996	004	Apr 06, 1982	Jan	CAHN

HALOPERIDOL LACTATE

INJECTABLE; INJECTION
HALOPERIDOL

AP		PFIZER	EQ 5MG BASE/ML	A078347	001	Sep 14, 2009	May	CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN SODIUM

AP		SANDOZ	1,000 UNITS/ML	A091682	001	Jun 08, 2011	May	NEWA
AP			5,000 UNITS/ML	A091659	001	Jun 08, 2011	May	NEWA
AP			5,000 UNITS/ML	A091682	002	Jun 08, 2011	May	NEWA
AP			10,000 UNITS/ML	A201002	001	Jun 08, 2011	May	NEWA

HEXAMINOLEVULINATE HYDROCHLORIDE

FOR SOLUTION; INTRAVESICAL
CYSVIEW KIT

	+	GE HEALTHCARE	100MG/VIAL	N022555	001	May 28, 2010	May	CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET; ORAL
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

AB		NOVEL LABS INC	1.5MG;5MG	A091528	001	Apr 20, 2011	Apr	NEWA

TUSSIGON

AB	+	KING PHARMS	1.5MG;5MG	A088508	001	Jul 30, 1985	Apr	CTEC

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL
HYDROCHLOROTHIAZIDE

AB		ALEMBIC PHARMS LTD	12.5MG	A200645	001	Nov 30, 2010	Apr	CAHN
AB		JUBILANT CADISTA	12.5MG	A078391	001	Feb 11, 2008	Jan	CAHN

TABLET; ORAL
HYDROCHLOROTHIAZIDE

AB		JUBILANT CADISTA	25MG	A040809	001	Sep 04, 2007	Jan	CAHN
AB			50MG	A040809	002	Sep 04, 2007	Jan	CAHN

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL
AVALIDE

>A>		@ SANOFI AVENTIS	12.5MG;75MG	N020758	001	Sep 30, 1997	Jun	CAHN
>A>			12.5MG;150MG	N020758	002	Sep 30, 1997	Jun	CAHN
>A>			12.5MG;300MG	N020758	003	Aug 31, 1998	Jun	CAHN
>A>	+		25MG;300MG	N020758	004	Mar 15, 2005	Jun	CAHN
>D>		@ SANOFI AVENTIS US	12.5MG;75MG	N020758	001	Sep 30, 1997	Jun	CAHN
>D>			12.5MG;150MG	N020758	002	Sep 30, 1997	Jun	CAHN
>D>			12.5MG;300MG	N020758	003	Aug 31, 1998	Jun	CAHN
>D>	+		25MG;300MG	N020758	004	Mar 15, 2005	Jun	CAHN

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL
LISINOPRIL AND HYDROCHLOROTHIAZIDE

AB		PRINSTON PHARM LLC	12.5MG;10MG	A076230	001	Jul 01, 2002	May	CAHN
AB			12.5MG;20MG	A076230	002	Jul 01, 2002	May	CAHN
AB			25MG;20MG	A076230	003	Jul 01, 2002	May	CAHN

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB		WATSON LABS	12.5MG;50MG	A200180	001	Jan 12, 2011	Jan	NEWA
AB			12.5MG;100MG	A200180	002	Jan 12, 2011	Jan	NEWA
AB			25MG;100MG	A200180	003	Jan 12, 2011	Jan	NEWA

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET; ORAL
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		INVAGEN PHARMS	12.5MG;10MG	A201356	001	Apr 20, 2011	Apr	NEWA
AB			12.5MG;20MG	A201356	002	Apr 20, 2011	Apr	NEWA
AB			25MG;20MG	A201356	003	Apr 20, 2011	Apr	NEWA

>A> HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

>A> SOLUTION; ORAL
>A> REZIRA

>A>	+	CYPRESS PHARM	5MG/5ML;60MG/5ML	N022442	001	Jun 08, 2011	Jun	NEWA

HYDROCORTISONE

SOLUTION; TOPICAL
TEXACORT

	+	TIBER LABS	2.5%	A081271	001	Apr 17, 1992	May	CAHN

TABLET; ORAL
HYDROCORTISONE

AB		COREPHARMA	5MG	A040646	001	Mar 30, 2007	Apr	CAHN
AB			10MG	A040646	002	Mar 30, 2007	Apr	CAHN
AB			20MG	A040646	003	Mar 30, 2007	Apr	CAHN

HYDROCORTISONE ACETATE

OINTMENT; OPHTHALMIC
HYDROCORTISONE ACETATE

		@ FERA PHARMS	0.5%	A080828	001		Mar	CAHN

HYDROFLUMETHIAZIDE

TABLET; ORAL
HYDROFLUMETHIAZIDE

	@ PAR PHARM	50MG	A088850	001	May 31, 1985	May	DISC	

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL
HYDROMORPHONE HYDROCHLORIDE

AB	ELITE LABS	8MG	A076723	001	Oct 18, 2005	Feb	CAHN	

HYDROXOCOBALAMIN

INJECTABLE; INJECTION
CYANOKIT

	@ MERCK SANTE SAS	5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011	Apr	DISC	

HYDROXYAMPHETAMINE HYDROBROMIDE

SOLUTION/DROPS; OPHTHALMIC
PAREDRINE

	@ PHARMICS	1%	N000004	004		Jan	CAHN	

HYDROXYPROGESTERONE CAPROATE

SOLUTION; INTRAMUSCULAR
MAKENA

+	KV PHARM	1250MG/5ML (250MG/ML)	N021945	001	Feb 03, 2011	Feb	NEWA	

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION
IDARUBICIN HYDROCHLORIDE

AP	SANDOZ	1MG/ML	A091293	001	Mar 29, 2011	Mar	NEWA	

IFOSFAMIDE

INJECTABLE; INJECTION
IFOSFAMIDE

>A> AP	BEDFORD LABS	1GM/20ML(50MG/ML)	A076619	001	Jun 29, 2011	Jun	NEWA	
>A> AP		3GM/60ML(50MG/ML)	A076619	002	Jun 29, 2011	Jun	NEWA	

ILOPERIDONE

TABLET; ORAL
FANAPT

	NOVARTIS	2MG	N022192	002	May 06, 2009	Jan	CAHN	
		4MG	N022192	003	May 06, 2009	Jan	CAHN	
		6MG	N022192	004	May 06, 2009	Jan	CAHN	
		8MG	N022192	005	May 06, 2009	Jan	CAHN	
		10MG	N022192	006	May 06, 2009	Jan	CAHN	

ILOPROST

SOLUTION; INHALATION
VENTAVIS

>D>	+ ACTELION PHARMS LTD	20MCG/2ML (10MCG/ML)	N021779	001	Dec 29, 2004	Jun	DISC	
>A>	@	20MCG/2ML (10MCG/ML)	N021779	001	Dec 29, 2004	Jun	DISC	

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

AB	TARO	5%	A200173	001	Apr 15, 2011	Apr	NEWA
AB	TEVA PHARMS USA	5%	A200481	001	Apr 18, 2011	Apr	NEWA
AB	TOLMAR	5%	A091044	001	Feb 28, 2011	Feb	NEWA

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

AB	HETERO DRUGS LTD	25MG	A091240	001	Apr 12, 2011	Mar	NEWA
AB		50MG	A091240	002	Apr 12, 2011	Mar	NEWA

CAPSULE, EXTENDED RELEASE; ORAL

INDOMETHACIN

AB	+ SANDOZ	75MG	A074464	001	May 28, 1998	Jan	CTNA

IOFLUPANE I-123

SOLUTION; INTRAVENOUS

DATSCAN

	+ GE HLTHCARE INC	5MCI/2.5ML (2MCI/ML)	N022454	001	Jan 14, 2011	Jan	NEWA

IOPAMIDOL

INJECTABLE; INJECTION

IOPAMIDOL-200

	@ HOSPIRA	41%	A074898	001	Dec 30, 1997	Feb	DISC

IOPAMIDOL-200 IN PLASTIC CONTAINER

	@ HOSPIRA	41%	A074636	001	Dec 30, 1997	Feb	DISC

IOPAMIDOL-250

	@ HOSPIRA	51%	A074898	002	Dec 30, 1997	Feb	DISC

IOPAMIDOL-250 IN PLASTIC CONTAINER

	@ HOSPIRA	51%	A074636	002	Dec 30, 1997	Feb	DISC

IOPAMIDOL-300

	@ HOSPIRA	61%	A074898	003	Dec 30, 1997	Feb	DISC

IOPAMIDOL-300 IN PLASTIC CONTAINER

	@ HOSPIRA	61%	A074636	003	Dec 30, 1997	Feb	DISC

IOPAMIDOL-370

	@ HOSPIRA	76%	A074898	004	Dec 30, 1997	Feb	DISC

IOPAMIDOL-370 IN PLASTIC CONTAINER

	@ HOSPIRA	76%	A074636	004	Dec 30, 1997	Feb	DISC

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

AP	BIONICHE PHARMA	40MG/2ML (20MG/ML)	A090393	002	May 13, 2011	May	NEWA
AP		100MG/5ML (20MG/ML)	A090393	003	May 13, 2011	May	NEWA

IRON SUCROSE

INJECTABLE; INTRAVENOUS

VENOFER

	LUITPOLD	EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML)	N021135	002	Mar 20, 2005	Apr	CMFD

ISOSORBIDE DINITRATE

TABLET; ORAL
ISORDIL

>D>	AB		BIOVAIL	5MG	N012093	007	Jul 29, 1988	Jun	CAHN
>D>	AB			10MG	N012093	002	Jul 29, 1988	Jun	CAHN
>D>	AB			20MG	N012093	006	Jul 29, 1988	Jun	CAHN
>D>	AB	+		30MG	N012093	005	Jul 29, 1988	Jun	CAHN
>D>		+		40MG	N012093	001	Jul 29, 1988	Jun	CAHN
>A>	AB		VALEANT INTL	5MG	N012093	007	Jul 29, 1988	Jun	CAHN
>A>	AB			10MG	N012093	002	Jul 29, 1988	Jun	CAHN
>A>	AB			20MG	N012093	006	Jul 29, 1988	Jun	CAHN
>A>	AB	+		30MG	N012093	005	Jul 29, 1988	Jun	CAHN
>A>		+		40MG	N012093	001	Jul 29, 1988	Jun	CAHN

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL
ISOSORBIDE MONONITRATE

	AB		TORRENT PHARMS	30MG	A200270	001	Jun 03, 2011	May	NEWA
	AB			60MG	A200495	001	Jun 03, 2011	May	NEWA
	AB			120MG	A200495	002	Jun 03, 2011	May	NEWA

ISRADIPINE

CAPSULE; ORAL
ISRADIPINE

	AB		MIKAH PHARMA	2.5MG	A077169	001	Apr 24, 2006	Feb	CAHN
	AB			5MG	A077169	002	Apr 24, 2006	Feb	CAHN

ITRACONAZOLE

INJECTABLE; INJECTION
SPORANOX

			@ ORTHO MCNEIL JANSSEN	10MG/ML	N020966	001	Mar 30, 1999	May	DISC

TABLET; ORAL
ONMEL

		+	STIEFEL LABS INC	200MG	N022484	001	Apr 29, 2010	May	CTNA

KETOCONAZOLE

GEL; TOPICAL
XOLEGEL

		+	AQUA PHARMS	2%	N021946	001	Jul 28, 2006	May	CAHN

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION
KETOROLAC TROMETHAMINE

	AP		PFIZER	15MG/ML	A078299	001	Jul 16, 2007	May	CAHN
	AP			30MG/ML	A078299	002	Jul 16, 2007	May	CAHN

SPRAY, METERED; NASAL
SPRIX

		+	LUITPOLD	15.75MG/SPRAY	N022382	001	May 14, 2010	May	CAHN

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL
COMBIVIR

	AB	+	VIIV HLTHCARE	150MG;300MG	N020857	001	Sep 26, 1997	May	CFTG

LAMIVUDINE AND ZIDOVUDINE

	AB		TEVA PHARMS	150MG;300MG	A079081	001	May 25, 2011	May	NEWA

LAMOTRIGINE

TABLET; ORAL
LAMOTRIGINE

AB		ACTAVIS TOTOWA	25MG	A078669	001	Apr 08, 2011	Mar	NEWA
AB			100MG	A078669	002	Apr 08, 2011	Mar	NEWA
AB			150MG	A078669	003	Apr 08, 2011	Mar	NEWA
AB			200MG	A078669	004	Apr 08, 2011	Mar	NEWA
AB		ALEMBIC LTD	25MG	A090607	001	Jan 13, 2011	Jan	NEWA
AB			100MG	A090607	002	Jan 13, 2011	Jan	NEWA
AB			150MG	A090607	003	Jan 13, 2011	Jan	NEWA
AB			200MG	A090607	004	Jan 13, 2011	Jan	NEWA
AB		ALEMBIC PHARMS LTD	25MG	A090607	001	Jan 13, 2011	Apr	CAHN
AB			100MG	A090607	002	Jan 13, 2011	Apr	CAHN
AB			150MG	A090607	003	Jan 13, 2011	Apr	CAHN
AB			200MG	A090607	004	Jan 13, 2011	Apr	CAHN
AB		HIKMA PHARMS	25MG	A078134	001	Apr 19, 2011	Apr	NEWA
AB			100MG	A078134	002	Apr 19, 2011	Apr	NEWA
AB			150MG	A078134	003	Apr 19, 2011	Apr	NEWA
AB			200MG	A078134	004	Apr 19, 2011	Apr	NEWA

TABLET, CHEWABLE; ORAL
LAMOTRIGINE

AB		JUBILANT LIFE	5MG	A200220	001	Feb 28, 2011	Feb	NEWA
AB			25MG	A200220	002	Feb 28, 2011	Feb	NEWA

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC
LATANOPROST

AT		ALCON RES	0.005%	A091449	001	Mar 22, 2011	Mar	NEWA
AT		APOTEX	0.005%	A077697	001	Mar 22, 2011	Mar	NEWA
AT		BAUSCH AND LOMB	0.005%	A201006	001	Mar 22, 2011	Mar	NEWA
AT		LUITPOLD	0.005%	A200925	001	Mar 22, 2011	May	CAHN
AT		MYLAN	0.005%	A201786	001	Mar 22, 2011	Mar	NEWA
AT		PHARMAFORCE	0.005%	A200925	001	Mar 22, 2011	Mar	NEWA

XALATAN

AT	+	PHARMACIA AND UPJOHN	0.005%	N020597	001	Jun 05, 1996	Mar	CFTG

LETROZOLE

TABLET; ORAL
LETROZOLE

AB		ACCORD HLTHCARE	2.5MG	A090934	001	Jun 03, 2011	May	NEWA
AB		DR REDDYS LABS LTD	2.5MG	A091191	001	Jun 03, 2011	May	NEWA
AB		ENDO PHARMS	2.5MG	A090789	001	Jun 03, 2011	May	NEWA
AB		FRESENIUS KABI ONCOL	2.5MG	A090491	001	Jun 03, 2011	May	NEWA
AB		IMPAX LABS	2.5MG	A091638	001	Jun 03, 2011	May	NEWA
AB		INDICUS PHARMA	2.5MG	A201804	001	Jun 03, 2011	May	NEWA
AB		KUDCO IRELAND	2.5MG	A091098	001	Jun 03, 2011	May	NEWA
AB		NATCO PHARMA LTD	2.5MG	A200161	001	Jun 03, 2011	May	NEWA
AB		ROXANE	2.5MG	A090838	001	Jun 03, 2011	May	NEWA
AB		SUN PHARM INDS LTD	2.5MG	A091466	001	Jun 03, 2011	May	NEWA
>D> AB		SYNTHON PHARMS	2.5MG	A090196	001	Jun 03, 2011	Jun	DISC
>A>		@	2.5MG	A090196	001	Jun 03, 2011	Jun	DISC
AB			2.5MG	A090196	001	Jun 03, 2011	May	NEWA
AB		TEVA PHARMS	2.5MG	A090289	001	Jun 03, 2011	May	NEWA

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LEUPROLIDE ACETATE

		@	GENZYME	1MG/0.2ML	A075721	001	Nov 29, 2001	Apr	DISC

LUPRON DEPOT

>A>		+	ABBOTT ENDOCRINE	22.5MG/VIAL	N020517	001	Dec 22, 1995	Jun	CAHN
>A>		+		30MG/VIAL	N020517	002	May 30, 1997	Jun	CAHN
>A>				45MG/VIAL	N020517	003	Jun 17, 2011	Jun	NEWA
>D>		+	ABBOTT LABS	22.5MG/VIAL	N020517	001	Dec 22, 1995	Jun	CAHN
>D>		+		30MG/VIAL	N020517	002	May 30, 1997	Jun	CAHN

LEVETIRACETAM

TABLET; ORAL

LEVETIRACETAM

	AB		ACCORD HLTHCARE	250MG	A090843	001	Feb 14, 2011	Jan	NEWA
	AB			500MG	A090843	002	Feb 14, 2011	Jan	NEWA
	AB			750MG	A090843	003	Feb 14, 2011	Jan	NEWA
	AB			1GM	A090843	004	Feb 14, 2011	Jan	NEWA
	AB		AJANTA PHARMA	250MG	A201293	001	Jun 14, 2011	May	NEWA
	AB			500MG	A201293	002	Jun 14, 2011	May	NEWA
	AB			750MG	A201293	003	Jun 14, 2011	May	NEWA
	AB			1GM	A201293	004	Jun 14, 2011	May	NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

	AB		DR REDDYS LABS LTD	5MG	A090392	001	Feb 24, 2011	Feb	NEWA
	AB		GLENMARK GENERICS	5MG	A090385	001	Feb 24, 2011	Feb	NEWA

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVAQUIN

>D>		+	ORTHO MCNEIL PHARM	EQ 500MG/20ML (EQ 25MG/ML)	N020635	001	Dec 20, 1996	Jun	CFTG
>A>	AP	+		EQ 500MG/20ML (EQ 25MG/ML)	N020635	001	Dec 20, 1996	Jun	CFTG
>D>		+		EQ 750MG/30ML (EQ 25MG/ML)	N020635	004	Dec 20, 1996	Jun	CFTG
>A>	AP	+		EQ 750MG/30ML (EQ 25MG/ML)	N020635	004	Dec 20, 1996	Jun	CFTG

LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER

>D>		+	ORTHO MCNEIL PHARM	EQ 250MG/50ML (EQ 5MG/ML)	N020635	002	Dec 20, 1996	Jun	CFTG
>A>	AP	+		EQ 250MG/50ML (EQ 5MG/ML)	N020635	002	Dec 20, 1996	Jun	CFTG
>D>		+		EQ 500MG/100ML (EQ 5MG/ML)	N020635	003	Dec 20, 1996	Jun	CFTG
>A>	AP	+		EQ 500MG/100ML (EQ 5MG/ML)	N020635	003	Dec 20, 1996	Jun	CFTG
>D>		+		EQ 750MG/150ML (EQ 5MG/ML)	N020635	005	Dec 20, 1996	Jun	CFTG
>A>	AP	+		EQ 750MG/150ML (EQ 5MG/ML)	N020635	005	Dec 20, 1996	Jun	CFTG

LEVOFLOXACIN

>A>	AP		AKORN	EQ 500MG/20ML (EQ 25MG/ML)	A091644	001	Jun 20, 2011	Jun	NEWA
>A>	AP			EQ 750MG/30ML (EQ 25MG/ML)	A091644	002	Jun 20, 2011	Jun	NEWA
>A>	AP		SAGENT PHARMS	EQ 500MG/20ML (EQ 25MG/ML)	A200560	001	Jun 20, 2011	Jun	NEWA
>A>	AP			EQ 750MG/30ML (EQ 25MG/ML)	A200560	002	Jun 20, 2011	Jun	NEWA

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

>A>	AP		ACS DOBFAR INFO SA	EQ 250MG/50ML (EQ 5MG/ML)	A090343	001	Jul 07, 2011	Jun	NEWA
>A>	AP			EQ 500MG/100ML (EQ 5MG/ML)	A090343	002	Jul 07, 2011	Jun	NEWA
>A>	AP			EQ 750MG/150ML (EQ 5MG/ML)	A090343	003	Jul 07, 2011	Jun	NEWA

SOLUTION; ORAL

LEVAQUIN

>D>		+	ORTHO MCNEIL JANSSEN	250MG/10ML	N021721	001	Oct 21, 2004	Jun	CFTG

		SOLUTION; ORAL								
		LEVAQUIN								
>A>	AA	+ ORTHO MCNEIL JANSSEN	250MG/10ML		N021721	001	Oct 21, 2004	Jun	CFTG
>A>		LEVOFLOXACIN								
>A>	AA	HI TECH PHARMA	250MG/10ML		A091678	001	Jun 20, 2011	Jun	NEWA
		SOLUTION/DROPS; OPHTHALMIC								
		LEVOFLOXACIN								
	AT	HI TECH PHARMA	0.5%		A076826	001	Feb 10, 2011	Jan	NEWA
		TABLET; ORAL								
		LEVAQUIN								
>D>		ORTHO MCNEIL JANSSEN	250MG		N020634	001	Dec 20, 1996	Jun	CFTG
>A>	AB		250MG		N020634	001	Dec 20, 1996	Jun	CFTG
>D>			500MG		N020634	002	Dec 20, 1996	Jun	CFTG
>A>	AB		500MG		N020634	002	Dec 20, 1996	Jun	CFTG
>D>		+	750MG		N020634	003	Sep 08, 2000	Jun	CFTG
>A>	AB	+	750MG		N020634	003	Sep 08, 2000	Jun	CFTG
>A>		LEVOFLOXACIN								
>A>	AB	AUROBINDO PHARMA LTD	250MG		A201043	001	Jun 20, 2011	Jun	NEWA
>A>	AB		500MG		A201043	002	Jun 20, 2011	Jun	NEWA
>A>	AB		750MG		A201043	003	Jun 20, 2011	Jun	NEWA
>A>	AB	DR REDDYS LABS INC	250MG		A076710	001	Jun 20, 2011	Jun	NEWA
>A>	AB		500MG		A076710	002	Jun 20, 2011	Jun	NEWA
>A>	AB		750MG		A076710	003	Jun 20, 2011	Jun	NEWA
>A>	AB	GLENMARK GENERICS	250MG		A200250	001	Jun 20, 2011	Jun	NEWA
>A>	AB		500MG		A200250	002	Jun 20, 2011	Jun	NEWA
>A>	AB		750MG		A200250	003	Jun 20, 2011	Jun	NEWA
>A>	AB	LUPIN	250MG		A078424	001	Jun 20, 2011	Jun	NEWA
>A>	AB		500MG		A078424	002	Jun 20, 2011	Jun	NEWA
>A>	AB		750MG		A078424	003	Jun 20, 2011	Jun	NEWA
>A>	AB	MYLAN	250MG		A076276	001	Jun 20, 2011	Jun	NEWA
>A>	AB		500MG		A076276	002	Jun 20, 2011	Jun	NEWA
>A>	AB		750MG		A077097	001	Jun 20, 2011	Jun	NEWA
>A>	AB	SANDOZ	250MG		A077438	001	Jun 20, 2011	Jun	NEWA
>A>	AB		500MG		A077438	002	Jun 20, 2011	Jun	NEWA
>A>	AB		750MG		A077438	003	Jun 20, 2011	Jun	NEWA
>A>	AB	TEVA	250MG		A076361	001	Jun 20, 2011	Jun	NEWA
>A>	AB		500MG		A076361	002	Jun 20, 2011	Jun	NEWA
>A>	AB		750MG		A076361	003	Jun 20, 2011	Jun	NEWA
>A>	AB	TORRENT PHARMS	250MG		A090722	001	Jun 20, 2011	Jun	NEWA
>A>	AB		500MG		A090722	002	Jun 20, 2011	Jun	NEWA
>A>	AB		750MG		A090722	003	Jun 20, 2011	Jun	NEWA
>A>	AB	WOCKHARDT	250MG		A090367	001	Jun 20, 2011	Jun	NEWA
>A>	AB		500MG		A090367	002	Jun 20, 2011	Jun	NEWA
>A>	AB		750MG		A090367	003	Jun 20, 2011	Jun	NEWA

LEVOLEUCOVORIN CALCIUM

	POWDER; IV (INFUSION)								
	FUSILEV								
	+ SPECTRUM PHARMS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)		N020140	002	Apr 20, 2011	Apr	NEWA
	+	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)		N020140	003	Apr 20, 2011	Apr	NEWA
	SOLUTION; IV (INFUSION)								
	FUSILEV								
	+ SPECTRUM PHARMS	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)		N020140	002	Apr 20, 2011	May	CDFR

SOLUTION; IV (INFUSION)
FUSILEV
+ SPECTRUM PHARMS EQ 250MG BASE/25ML (EQ 10MG BASE/ML) N020140 003 Apr 20, 2011 May CDFR

LEVONORGESTREL

TABLET; ORAL
PLAN B
@ TEVA WOMENS 0.75MG N021045 001 Jul 28, 1999 Feb CAHN
AB + 0.75MG N021045 002 Aug 24, 2006 Feb CAHN

LEVORPHANOL TARTRATE

TABLET; ORAL
LEVO-DROMORAN
@ VALEANT PHARM INTL 2MG N008720 001 Dec 19, 1991 Mar DISC
LEVORPHANOL TARTRATE
ROXANE 2MG A074278 001 Mar 31, 2000 Mar CTEC

LEVOTHYROXINE SODIUM

**Refer to Annual Edition Preface Section 1.8 Levothyroxine Sodium for amplifying information
>A> POWDER; INTRAVENOUS
>A> LEVOTHYROXINE SODIUM
>A> + APP PHARMS 100MCG/VIAL N202231 001 Jun 24, 2011 Jun NEWA
>A> + 200MCG/VIAL N202231 002 Jun 24, 2011 Jun NEWA
>A> + 500MCG/VIAL N202231 003 Jun 24, 2011 Jun NEWA

TABLET; ORAL
LEVO-T
AB1, AB2, AB3 ALARA PHARM 0.025MG N021342 001 Mar 01, 2002 Feb CTEC
AB1, AB2, AB3 0.05MG N021342 002 Mar 01, 2002 Feb CTEC
AB1, AB2, AB3 0.075MG N021342 003 Mar 01, 2002 Feb CTEC
AB1, AB2, AB3 0.088MG N021342 004 Mar 01, 2002 Feb CTEC
AB1, AB2, AB3 0.1MG N021342 005 Mar 01, 2002 Feb CTEC
AB1, AB2, AB3 0.112MG N021342 006 Mar 01, 2002 Feb CTEC
AB1, AB2, AB3 0.125MG N021342 007 Mar 01, 2002 Feb CTEC
AB1, AB2, AB3 0.137MG N021342 012 Dec 08, 2003 Feb CTEC
AB1, AB2, AB3 0.15MG N021342 008 Mar 01, 2002 Feb CTEC
AB1, AB2, AB3 0.175MG N021342 009 Mar 01, 2002 Feb CTEC
AB1, AB2, AB3 0.2MG N021342 010 Mar 01, 2002 Feb CTEC
AB1, AB2, AB3 + 0.3MG N021342 011 Mar 01, 2002 Feb CTEC

LIDOCAINE

OINTMENT; TOPICAL
LIDOCAINE

AT	NOVOCOL INC	5%	A040911	001	May 23, 2011	May	NEWA

LIDOCAINE HYDROCHLORIDE

JELLY; TOPICAL
LIDOCAINE HYDROCHLORIDE

AT	HI TECH PHARMA	2%	A040837	001	Mar 23, 2011	Mar	NEWA

SYSTEM; INTRADERMAL
ZINGO

>D>	@ ANESIVA	0.5MG	N022114	001	Aug 16, 2007	Jun	CAHN
>A>	@ POWDER PHARMS	0.5MG	N022114	001	Aug 16, 2007	Jun	CAHN

LINAGLIPTIN

TABLET; ORAL
TRADJENTA

+	BOEHRINGER INGELHEIM	5MG	N201280	001	May 02, 2011	May	NEWA

LISINOPRIL

TABLET; ORAL
LISINOPRIL

AB	PRINSTON PHARM LLC	2.5MG	A076180	001	Jul 01, 2002	May	CAHN
AB		5MG	A076180	002	Jul 01, 2002	May	CAHN
AB		10MG	A076180	003	Jul 01, 2002	May	CAHN
AB		20MG	A076164	001	Jul 01, 2002	May	CAHN
AB		30MG	A076164	002	Jul 01, 2002	May	CAHN
AB		40MG	A076164	003	Jul 01, 2002	May	CAHN

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL
LITHIUM CARBONATE

AB	GLENMARK GENERICS	450MG	A091616	001	Feb 14, 2011	Jan	NEWA

LOSARTAN POTASSIUM

TABLET; ORAL
LOSARTAN POTASSIUM

AB	ALEMBIC PHARMS LTD	25MG	A090428	001	Oct 06, 2010	Apr	CAHN
AB		50MG	A090428	002	Oct 06, 2010	Apr	NEWA
AB		100MG	A090428	003	Oct 06, 2010	Apr	CAHN
AB	HUAHAI US INC	25MG	A091497	001	Jun 06, 2011	May	NEWA
AB		50MG	A091497	002	Jun 06, 2011	May	NEWA
AB		100MG	A091497	003	Jun 06, 2011	May	NEWA
AB	MYLAN	25MG	A091590	001	Oct 06, 2010	Jan	NEWA
AB		50MG	A091590	002	Oct 06, 2010	Jan	NEWA
AB		100MG	A091590	003	Oct 06, 2010	Jan	NEWA

LOTEPREDNOL ETABONATE

OINTMENT; OPHTHALMIC
LOTEMAX

+	BAUSCH AND LOMB	0.5%	N200738	001	Apr 15, 2011	Apr	NEWA

MECLIZINE HYDROCHLORIDE

TABLET; ORAL
MECLIZINE HYDROCHLORIDE

AA	AMNEAL PHARMS	12.5MG	A201451	001	Feb 23, 2011	Feb	NEWA
AA		25MG	A201451	002	Feb 23, 2011	Feb	NEWA
AA		50MG	A201451	003	Feb 23, 2011	Feb	NEWA
AA	JUBILANT CADISTA	12.5MG	A040659	001	Jun 04, 2010	Jan	CAHN
AA		25MG	A040659	002	Jun 04, 2010	Jan	CAHN

MELOXICAM

TABLET; ORAL
MELOXICAM

>D> AB	ACTAVIS TOTOWA	7.5MG	A077938	001	Jul 19, 2006	Jun	CAHN
>D> AB		15MG	A077938	002	Jul 19, 2006	Jun	CAHN
AB	MYLAN	7.5MG	A077934	001	Jul 20, 2006	Feb	CAHN
AB		15MG	A077934	002	Jul 20, 2006	Feb	CAHN
>A> AB	PURACAP PHARM	7.5MG	A077938	001	Jul 19, 2006	Jun	CAHN
>A> AB		15MG	A077938	002	Jul 19, 2006	Jun	CAHN

MEMANTINE HYDROCHLORIDE

TABLET; ORAL
MEMANTINE

@	SUN PHARMA GLOBAL	5MG	A090058	001	May 05, 2010	May	CAHN
@		10MG	A090058	002	May 05, 2010	May	CAHN

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

AP	BAXTER HLTHCARE CORP	10MG/ML	A081002	001	Jul 30, 1993	May	CAHN

MEPROBAMATE

TABLET; ORAL
MEPROBAMATE

AA	ALEMBIC PHARMS LTD	200MG	A090122	001	Feb 18, 2009	May	CAHN
AA		400MG	A090122	002	Feb 18, 2009	May	CAHN
AA	TARO	200MG	A200998	001	May 23, 2011	May	NEWA
AA		400MG	A200998	002	May 23, 2011	May	NEWA

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL
SOLAGE

+	AQUA PHARMS	2%;0.01%	N020922	001	Dec 10, 1999	May	CAHN

MEROPENEM

INJECTABLE; INJECTION
MEROPENEM

AP	SANDOZ	500MG/VIAL	A091201	001	Mar 29, 2011	Mar	NEWA
AP		1GM/VIAL	A091201	002	Mar 29, 2011	Mar	NEWA

MERREM

AP +	ASTRAZENECA	500MG/VIAL	N050706	003	Jun 21, 1996	Mar	CTNA
AP +		1GM/VIAL	N050706	001	Jun 21, 1996	Mar	CTNA

MESALAMINE

ENEMA; RECTAL

ROWASA

>D>	AB	+	ALAVEN PHARM	4GM/60ML	N019618	001	Dec 24, 1987	Jun	CAHN
>A>	AB	+	MEDA PHARMS	4GM/60ML	N019618	001	Dec 24, 1987	Jun	CAHN

SFROWASA

>D>	AB		ALAVEN PHARM	4GM/60ML	N019618	002	Jun 20, 2008	Jun	CAHN
>A>	AB		MEDA PHARMS	4GM/60ML	N019618	002	Jun 20, 2008	Jun	CAHN

TABLET, DELAYED RELEASE; ORAL

ASACOL

>D>		+	WARNER CHILCOTT INC	400MG	N019651	001	Jan 31, 1992	Jun	CAHN
>A>		+	WARNER CHILCOTT LLC	400MG	N019651	001	Jan 31, 1992	Jun	CAHN

ASACOL HD

>D>		+	WARNER CHILCOTT INC	800MG	N021830	001	May 29, 2008	Jun	CAHN
>A>		+	WARNER CHILCOTT LLC	800MG	N021830	001	May 29, 2008	Jun	CAHN

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

	AB		MYLAN	500MG	A075973	001	Jan 25, 2002	Feb	CAHN
	AB			850MG	A075973	002	Jan 25, 2002	Feb	CAHN
	AB			1GM	A075973	003	Jan 25, 2002	Feb	CAHN

TABLET, EXTENDED RELEASE; ORAL

FORTAMET

>D>	BX		ANDRX LABS LLC	500MG	N021574	001	Apr 27, 2004	Jun	CTEC
>A>	AB2			500MG	N021574	001	Apr 27, 2004	Jun	CTEC
>D>	BX	+		1GM	N021574	002	Apr 27, 2004	Jun	CTEC
>A>	AB	+		1GM	N021574	002	Apr 27, 2004	Jun	CTEC

GLUCOPHAGE XR

>D>	AB		BRISTOL MYERS SQUIBB	500MG	N021202	001	Oct 13, 2000	Jun	CTEC
>A>	AB1			500MG	N021202	001	Oct 13, 2000	Jun	CTEC

METFORMIN HYDROCHLORIDE

>D>	AB		ACTAVIS ELIZABETH	500MG	A076450	001	Oct 01, 2004	Jun	CTEC
>A>	AB1			500MG	A076450	001	Oct 01, 2004	Jun	CTEC
>D>	AB		AMNEAL PHARMS NY	500MG	A078596	001	Jan 03, 2008	Jun	CTEC
>A>	AB1			500MG	A078596	001	Jan 03, 2008	Jun	CTEC
>A>	AB1		APOTEX	500MG	A076706	001	Dec 14, 2004	Jun	CTEC
>A>	AB			750MG	A076706	002	Dec 29, 2005	Jun	CAHN
>D>	AB		APOTEX INC	500MG	A076706	001	Dec 14, 2004	Jun	CTEC
>D>	AB			750MG	A076706	002	Dec 29, 2005	Jun	CAHN
>D>	AB		IMPAX LABS	500MG	A076249	001	Jul 30, 2004	Jun	CTEC
>A>	AB1			500MG	A076249	001	Jul 30, 2004	Jun	CTEC
>A>	AB2		LUPIN LTD	500MG	A090692	001	Jun 29, 2011	Jun	NEWA
>A>	AB			1GM	A090692	002	Jun 29, 2011	Jun	NEWA
>D>	AB		MYLAN	500MG	A076650	001	Sep 13, 2005	Jun	CTEC
>A>	AB1			500MG	A076650	001	Sep 13, 2005	Jun	CTEC
>D>	AB		NEUROSCI INC	500MG	A078321	001	Apr 17, 2008	Jun	CTEC
>A>	AB1			500MG	A078321	001	Apr 17, 2008	Jun	CTEC
>D>	AB		NOSTRUM	500MG	A076756	001	Jul 26, 2006	Jun	CTEC
>A>	AB1			500MG	A076756	001	Jul 26, 2006	Jun	CTEC
>D>	AB		RANBAXY	500MG	A076413	001	Jun 18, 2004	Jun	CTEC
>A>	AB1		RANBAXY LABS LTD	500MG	A076413	001	Jun 18, 2004	Jun	CTEC
>D>	AB		SANDOZ	500MG	A076873	001	Dec 14, 2004	Jun	CTEC
>A>	AB1			500MG	A076873	001	Dec 14, 2004	Jun	CTEC
>D>	AB		SUN PHARM INDS (IN)	500MG	A077336	001	Feb 09, 2006	Jun	CTEC

TABLET, EXTENDED RELEASE; ORAL
METFORMIN HYDROCHLORIDE

>A>	AB1	SUN PHARM INDS (IN)	500MG	A077336	001	Feb 09, 2006	Jun	CTEC
>D>	AB	TEVA	500MG	A076269	001	Jun 18, 2004	Jun	CTEC
>A>	AB1		500MG	A076269	001	Jun 18, 2004	Jun	CTEC
>D>	AB	TORRENT PHARM	500MG	A090014	001	Dec 30, 2009	Jun	CTEC
>A>	AB1		500MG	A090014	001	Dec 30, 2009	Jun	CTEC
>D>	AB	WATSON LABS	500MG	A076818	001	Dec 14, 2004	Jun	CTEC
>D>	AB	WATSON LABS FLORIDA	500MG	A076172	001	Jun 16, 2004	Jun	CTEC
>A>	AB1		500MG	A076172	001	Jun 16, 2004	Jun	CTEC
>A>	AB1	WATSON LABS INC	500MG	A076818	001	Dec 14, 2004	Jun	CTEC
>D>	AB	ZYDUS PHARMS USA	500MG	A077060	001	Apr 20, 2005	Jun	CTEC
>A>	AB1		500MG	A077060	001	Apr 20, 2005	Jun	CTEC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL
ACTOPLUS MET

AB		TAKEDA GLOBAL	500MG;EQ 15MG BASE	N021842	001	Aug 29, 2005	Feb	CFTG
AB	+		850MG;EQ 15MG BASE	N021842	002	Aug 29, 2005	Feb	CFTG

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB		MYLAN	500MG;EQ 15MG BASE	A090406	001	Feb 25, 2011	Feb	NEWA
AB			850MG;EQ 15MG BASE	A090406	002	Feb 25, 2011	Feb	NEWA

METHOCARBAMOL

TABLET; ORAL
METHOCARBAMOL

>D>	AA	LANNETT	500MG	A084756	002	Mar 31, 2003	Jun	CAHN
>D>	AA		750MG	A084756	001		Jun	CAHN
>A>	AA	LANNETT HOLDINGS INC	500MG	A084756	002	Mar 31, 2003	Jun	CAHN
>A>	AA		750MG	A084756	001		Jun	CAHN
>D>		@ PHARMERAL	500MG	A084231	002		Jun	CAHN
>D>		@	750MG	A084471	001		Jun	CAHN
>A>		@ PURACAP PHARM	500MG	A084231	002		Jun	CAHN
>A>		@	750MG	A084471	001		Jun	CAHN

METHYLERGONOVINE MALEATE

TABLET; ORAL
METHERGINE

AB	+	NOVARTIS	0.2MG	N006035	003		Apr	CTEC

METHYLERGONOVINE MALEATE

AB		NOVEL LABS INC	0.2MG	A091577	001	May 02, 2011	Apr	NEWA

METHYLPREDNISOLONE

TABLET; ORAL
METHYLPREDNISOLONE

AB		JUBILANT CADISTA	4MG	A040189	001	Oct 31, 1997	Jan	CAHN
AB			8MG	A040189	002	Oct 31, 1997	Jan	CAHN
AB			16MG	A040189	003	Jul 20, 2007	Jan	CAHN
AB			32MG	A040189	004	Jul 20, 2007	Jan	CAHN

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
A-METHAPRED

AP		HEMOFARM	EQ 40MG BASE/VIAL	A040793	001	Nov 25, 2008	Apr	CAHN
AP			EQ 125MG BASE/VIAL	A040827	001	Nov 25, 2008	Apr	CAHN
		@ HOSPIRA	EQ 500MG BASE/VIAL	A089173	001	Aug 18, 1987	Feb	DISC

INJECTABLE; INJECTION
A-METHAPRED
@ HOSPIRA EQ 1GM BASE/VIAL A089174 001 Aug 18, 1987 Feb DISC

METRONIDAZOLE

GEL; TOPICAL
METRONIDAZOLE
AB G AND W LABS INC 0.75% A078178 001 Jan 19, 2011 Jan NEWA

INJECTABLE; INJECTION
FLAGYL I.V. RTU IN PLASTIC CONTAINER
>D> AP + GD SEARLE LLC 500MG/100ML N018353 002 Jun CAHN
>A> AP + PFIZER 500MG/100ML N018353 002 Jun CAHN

TABLET; ORAL
METRONIDAZOLE
AB ALEMBIC PHARMS LTD 250MG A079067 001 Mar 13, 2009 May CAHN
AB 500MG A079067 002 Mar 13, 2009 May CAHN

METRONIDAZOLE HYDROCHLORIDE

INJECTABLE; INJECTION
>D> FLAGYL I.V.
>D> + GD SEARLE LLC EQ 500MG BASE/VIAL N018353 001 Jun DISC
>A> @ PFIZER EQ 500MG BASE/VIAL N018353 001 Jun DISC

MICAFUNGIN SODIUM

INJECTABLE; IV (INFUSION)
MYCAMINE
+ ASTELLAS 100MG/VIAL N021506 003 Jun 27, 2006 Jan CRLD

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION
MIDOZALAM HYDROCHLORIDE
AP SAGENT STRIDES EQ 1MG BASE/ML A090316 001 May 04, 2011 Apr NEWA
AP EQ 5MG BASE/ML A090316 002 May 04, 2011 Apr NEWA

MILRINONE LACTATE

INJECTABLE; INJECTION
MILRINONE LACTATE
@ HOSPIRA EQ 1MG BASE/ML A075884 001 May 28, 2002 Feb DISC

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL
MIRTAZAPINE
AB ACTAVIS ELIZABETH 15MG A077959 001 Feb 14, 2011 Jan NEWA
AB 30MG A077959 002 Feb 14, 2011 Jan NEWA
AB 45MG A077959 003 Feb 14, 2011 Jan NEWA

MORPHINE SULFATE

INJECTABLE, LIPOSOMAL; EPIDURAL
DEPODUR
+ EKR THERAP 10MG/ML (10MG/ML) N021671 001 May 18, 2004 May CRLD
@ 15MG/1.5ML (10MG/ML) N021671 002 May 18, 2004 May DISC

SOLUTION; ORAL
MORPHINE SULFATE
>A> LANNETT HOLDINGS INC 20MG/ML N201517 001 Jun 23, 2011 Jun NEWA

MUPIROCIN

OINTMENT; TOPICAL
MUPIROCIN

AB		GLENMARK PHARMS	2%	A090480	001	Jun 08, 2011	May	NEWA

MUPIROCIN CALCIUM

CREAM; TOPICAL
BACTROBAN

+		GLAXOSMITHKLINE	EQ 2% BASE	N050746	001	Dec 11, 1997	Jan	CDFR

NABUMETONE

TABLET; ORAL
NABUMETONE

AB		LUPIN LTD	500MG	A090445	001	Jan 12, 2011	Jan	NEWA
AB			750MG	A090445	002	Jan 12, 2011	Jan	NEWA
AB		WATSON LABS	500MG	A091083	001	Jun 13, 2011	May	NEWA
AB			750MG	A091083	002	Jun 13, 2011	May	NEWA

NAFCILLIN SODIUM

INJECTABLE; INJECTION
NAFCILLIN SODIUM

>A>	AP	IBI	EQ 1GM BASE/VIAL	A090002	001	Jun 30, 2011	Jun	NEWA
>A>	AP		EQ 2GM BASE/VIAL	A090002	002	Jun 30, 2011	Jun	NEWA
	AP	INSTITUTO BIOCHEMICO	EQ 10GM BASE/VIAL	A090005	001	Apr 20, 2011	Apr	NEWA
	AP	+ SANDOZ	EQ 10GM BASE/VIAL	A062527	004	Aug 02, 1984	Apr	CTEC

NALTREXONE HYDROCHLORIDE

TABLET; ORAL
NALTREXONE HYDROCHLORIDE

AB		ELITE LABS	50MG	A075274	001	May 26, 1999	Feb	CAHN

NAPROXEN

TABLET; ORAL
NAPROXEN

AB		MARKSANS PHARMA	250MG	A091416	001	Feb 14, 2011	Jan	NEWA
AB			375MG	A091416	002	Feb 14, 2011	Jan	NEWA
AB			500MG	A091416	003	Feb 14, 2011	Jan	NEWA

NARATRIPTAN

TABLET; ORAL
NARATRIPTAN

AB		APOTEX CORP	EQ 1MG BASE	A091373	001	Apr 22, 2011	Apr	NEWA
AB			EQ 2.5MG BASE	A091373	002	Apr 22, 2011	Apr	NEWA
AB		SUN PHARM INDS LTD	EQ 2.5MG BASE	A091552	001	Feb 14, 2011	Jan	NEWA

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL
NARATRIPTAN

AB		INDICUS PHARMA	EQ 1MG BASE	A200502	001	Feb 28, 2011	Feb	NEWA
AB			EQ 2.5MG BASE	A200502	002	Feb 28, 2011	Feb	NEWA

NATEGLINIDE

TABLET; ORAL
NATEGLINIDE

AB		WATSON LABS	60MG	A077462	001	Mar 30, 2011	Mar	NEWA
AB			120MG	A077462	002	Mar 30, 2011	Mar	NEWA

NEVIRAPINE

TABLET, EXTENDED RELEASE; ORAL
VIRAMUNE XR

+		BOEHRINGER INGELHEIM	400MG	N201152	001	Mar 25, 2011	Mar	NEWA

NICARDIPINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CARDENE SR

@		EKR THERAP	45MG	N020005	002	Feb 21, 1992	May	DISC

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL
NIFEDIPINE

AB1		VALEANT INTL	30MG	A075269	001	Dec 04, 2000	Apr	CAHN
AB2			30MG	A075289	002	Feb 06, 2001	Apr	CAHN
AB2			60MG	A075289	001	Sep 27, 2000	Apr	CAHN
AB1			60MG	A075269	002	Dec 04, 2000	Apr	CAHN
AB1			90MG	A076070	001	Aug 16, 2002	Apr	CAHN

NISOLDIPINE

TABLET, EXTENDED RELEASE; ORAL
NISOLDIPINE

AB		MYLAN	8.5MG	A091001	001	Jan 26, 2011	Jan	NEWA
AB			17MG	A091001	002	Jan 26, 2011	Jan	NEWA
AB			25.5MG	A091001	003	Jan 26, 2011	Jan	NEWA
AB			34MG	A091001	004	Jan 26, 2011	Jan	NEWA

SULAR

AB	+	SHIONOGI PHARMA	8.5MG	N020356	008	Jan 02, 2008	Jan	CFTG
AB	+		17MG	N020356	007	Jan 02, 2008	Jan	CFTG
AB			25.5MG	N020356	006	Jan 02, 2008	Jan	CFTG
AB	+		34MG	N020356	005	Jan 02, 2008	Jan	CFTG

NITROFURANTOIN

SUSPENSION; ORAL
FURADANTIN

AB	+	SHIONOGI INC	25MG/5ML	N009175	001		Apr	CFTG

NITROFURANTOIN

AB		AMNEAL PHARMS	25MG/5ML	A201679	001	May 11, 2011	Apr	NEWA

NITROGLYCERIN

OINTMENT; INTRA-ANAL
RECTIV

>A>								
>A>	+	PROSTRAKAN INC	0.4%	N021359	001	Jun 21, 2011	Jun	NEWA

NIZATIDINE

CAPSULE; ORAL
NIZATIDINE

AB		MYLAN	150MG	A075934	001	Jul 09, 2002	Feb	CAHN
AB			300MG	A075934	002	Jul 09, 2002	Feb	CAHN

NYSTATIN

SUSPENSION; ORAL

NYSTATIN

AA	VISTAPHARM	100,000 UNITS/ML	A065422	001	Mar 07, 2011	Feb	NEWA

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

AP	WOCKHARDT USA	EQ 0.2MG BASE/ML	A090986	001	May 11, 2011	Apr	NEWA
AP		EQ 1MG BASE/ML	A090986	002	May 11, 2011	Apr	NEWA

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

AP	BIONICHE PHARMA USA	EQ 0.05MG BASE/ML	A079198	001	Feb 10, 2011	Jan	NEWA
AP		EQ 0.1MG BASE/ML	A079198	002	Feb 10, 2011	Jan	NEWA
AP		EQ 0.5MG BASE/ML	A079198	003	Feb 10, 2011	Jan	NEWA
AP	WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985	001	May 11, 2011	Apr	NEWA
AP		EQ 0.1MG BASE/ML	A090985	002	May 11, 2011	Apr	NEWA
AP		EQ 0.5MG BASE/ML	A090985	003	May 11, 2011	Apr	NEWA

ONDANSETRON

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

AB	RANBAXY	4MG	A078602	001	Feb 24, 2011	Feb	NEWA
AB		8MG	A078602	002	Feb 24, 2011	Feb	NEWA

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

AP	PFIZER	EQ 2MG BASE/ML	A078257	001	Apr 23, 2008	May	CAHN
AP	TEVA	EQ 2MG BASE/ML	A076876	001	Nov 22, 2006	Jan	CMFD

ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER

AP	+ HOSPIRA	EQ 0.64MG BASE/ML	A077348	001	Feb 01, 2007	Apr	CRLD

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

AP	PFIZER	EQ 2MG BASE/ML	A078244	001	Apr 23, 2008	May	CAHN

SOLUTION; ORAL

ONDANSETRON HYDROCHLORIDE

AA	AMNEAL PHARMS	EQ 4MG BASE/5ML	A091483	001	Jan 31, 2011	Jan	NEWA
AA	SILARX	EQ 4MG BASE/5ML	A091342	001	Jan 27, 2011	Jan	NEWA

TABLET; ORAL

ONDANSERTRON HYDROCHLORIDE

AB	TARO	EQ 4MG BASE	A077729	001	Mar 28, 2011	Mar	NEWA
AB		EQ 8MG BASE	A077729	002	Mar 28, 2011	Mar	NEWA
AB		EQ 24MG BASE	A077729	003	Mar 28, 2011	Mar	NEWA

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION; ORAL

TAMIFLU

>A>	ROCHE	EQ 6MG BASE/ML	N021246	002	Mar 21, 2011	Jun	NEWA

OXALIPLATIN

INJECTABLE; IV (INFUSION)

OXALIPLATIN

AP	SANDOZ	50MG/10ML (5MG/ML)	A078817	001	Jan 24, 2011	Jan	NEWA
AP		50MG/VIAL	A090849	001	Apr 28, 2011	Apr	NEWA
AP		100MG/VIAL	A090849	002	Apr 28, 2011	Apr	NEWA
AP		100MG/20ML (5MG/ML)	A078817	002	Jan 24, 2011	Jan	NEWA

OXAPROZIN

TABLET; ORAL
OXAPROZIN

AB	MYLAN	600MG	A075847	001	Feb 28, 2001	Feb		CAHN

OXYCODONE HYDROCHLORIDE

TABLET; ORAL
OXECTA

>A>	KING PHARMS R AND D	5MG	N202080	001	Jun 17, 2011	Jun		NEWA
>A>		7.5MG	N202080	002	Jun 17, 2011	Jun		NEWA

OXYCODONE HYDROCHLORIDE

AB	COASTAL PHARMS	5MG	A091313	001	Feb 18, 2011	Feb		NEWA
AB		15MG	A091313	002	Feb 18, 2011	Feb		NEWA
AB		30MG	A091313	003	Feb 18, 2011	Feb		NEWA
AB	RHODES PHARMS	5MG	A091490	001	Mar 09, 2011	Feb		NEWA
AB		10MG	A091490	002	Mar 09, 2011	Feb		NEWA
AB		15MG	A091490	003	Mar 09, 2011	Feb		NEWA
AB		20MG	A091490	004	Mar 09, 2011	Feb		NEWA
AB		30MG	A091490	005	Mar 09, 2011	Feb		NEWA

OXYMETHOLONE

TABLET; ORAL
ANADROL-50

+	MEDA PHARMS	50MG	N016848	001			May	CAHN

OXYMORPHONE HYDROCHLORIDE

TABLET; ORAL
OXYMORPHONE HYDROCHLORIDE

AB	TEVA	5MG	A091443	002	Feb 15, 2011	Jan		NEWA
AB		10MG	A091443	001	Feb 15, 2011	Jan		NEWA

TABLET, EXTENDED RELEASE; ORAL
OPANA ER

@	ENDO PHARMS	7.5MG	N021610	005	Feb 29, 2008	Feb		DISC
@		15MG	N021610	006	Feb 29, 2008	Feb		DISC

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR
INVEGA SUSTENNA

>A>	JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009	Jun		CAHN
>A>		78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009	Jun		CAHN
>A>		117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	Jun		CAHN
>A>		156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	Jun		CAHN
>A>	+	234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009	Jun		CAHN
>D>	ORTHO MCNEIL JANSSEN	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009	Jun		CAHN
>D>		78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009	Jun		CAHN
>D>		117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	Jun		CAHN
>D>		156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	Jun		CAHN
>D>	+	234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009	Jun		CAHN

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION
PAMIDRONATE DISODIUM

AP	MUSTAFA NEVZAT	30MG/10ML (3MG/ML)	A078373	001	Dec 23, 2008	May		CAHN
AP		90MG/10ML (9MG/ML)	A078373	002	Dec 23, 2008	May		CAHN

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

PANCREAZE

>A>		JANSSEN PHARMS	17,500USP/ UNITS;4,200USP/ UNITS;10,000USP/ UNITS	N022523	001	Apr 12, 2010	Jun	CAHN
>A>			43,750USP/ UNITS;10,500USP/ UNITS;25,000USP/ UNITS	N022523	002	Apr 12, 2010	Jun	CAHN
>A>			70,000USP/ UNITS;16,800USP/ UNITS;40,000USP/ UNITS	N022523	004	Apr 12, 2010	Jun	CAHN
>A>	+		61,000USP/ UNITS;21,000USP/ UNITS;37,000USP/ UNITS	N022523	003	Apr 12, 2010	Jun	CAHN
>D>		ORTHO MCNEIL JANSSEN	17,500USP/ UNITS;4,200USP/ UNITS;10,000USP/ UNITS	N022523	001	Apr 12, 2010	Jun	CAHN
>D>			43,750USP/ UNITS;10,500USP/ UNITS;25,000USP/ UNITS	N022523	002	Apr 12, 2010	Jun	CAHN
>D>			70,000USP/ UNITS;16,800USP/ UNITS;40,000USP/ UNITS	N022523	004	Apr 12, 2010	Jun	CAHN
>D>	+		61,000USP/ UNITS;21,000USP/ UNITS;37,000USP/ UNITS	N022523	003	Apr 12, 2010	Jun	CAHN

PANTOPRAZOLE SODIUM

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB		ACTAVIS TOTOWA	EQ 20MG BASE	A090797	001	Feb 07, 2011	Jan	NEWA
AB			EQ 40MG BASE	A090797	002	Feb 07, 2011	Jan	NEWA
AB		DR REDDYS LABS LTD	EQ 20MG BASE	A077619	001	Jan 19, 2011	Jan	NEWA
AB			EQ 40MG BASE	A077619	002	Jan 19, 2011	Jan	NEWA
AB		KUDCO IRELAND	EQ 20MG BASE	A078281	001	Jan 20, 2011	Jan	NEWA
AB			EQ 40MG BASE	A078281	002	Jan 20, 2011	Jan	NEWA
AB		MATRIX LABS LTD	EQ 20MG BASE	A090970	001	Jan 19, 2011	Jan	NEWA
AB			EQ 40MG BASE	A090970	002	Jan 19, 2011	Jan	NEWA
AB		TORRENT PHARMS	EQ 20MG BASE	A090074	001	Jan 19, 2011	Jan	NEWA
AB			EQ 40MG BASE	A090074	002	Jan 19, 2011	Jan	NEWA
AB		WOCKHARDT	EQ 20MG BASE	A091231	001	Jan 19, 2011	Jan	NEWA
AB			EQ 40MG BASE	A091231	002	Jan 19, 2011	Jan	NEWA

PAROMOMYCIN SULFATE

CAPSULE; ORAL

HUMATIN

@		MONARCH PHARMS	EQ 250MG BASE	A062310	001		May	CAHN

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

PAROXETINE HYDROCHLORIDE

AB		MYLAN	EQ 37.5MG BASE	A091427	001	Apr 14, 2011	Apr	NEWA

PAXIL CR

AB	+	GLAXOSMITHKLINE	EQ 37.5MG BASE	N020936	003	Dec 06, 2000	Apr	CTEC

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL

PENTOXIFYLLINE

AB		VALEANT INTL	400MG	A075028	001	Jul 20, 1998	Apr	CAHN

PHENTERMINE HYDROCHLORIDE

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

AA		ELITE LABS	37.5MG	A200272	001	Jan 31, 2011	May	CAHN
AA		EPIC PHARMA LLC	37.5MG	A200272	001	Jan 31, 2011	Jan	NEWA

>A>		TABLET, ORALLY DISINTEGRATING; ORAL							
>A>		SUPRENZA							
>A>		CITIUS PHARMS	15MG	N202088	001	Jun 13, 2011	Jun	NEWA	
>A>	+		30MG	N202088	002	Jun 13, 2011	Jun	NEWA	
		PHENYTOIN SODIUM							
		INJECTABLE; INJECTION							
		PHENYTOIN SODIUM							
	AP	X-GEN PHARMS	50MG/ML	A040573	001	Sep 13, 2006	May	CAHN	
		PILOCARPINE HYDROCHLORIDE							
		SOLUTION; OPHTHALMIC							
		ISOPTO CARPINE							
		ALCON RES	1%	N200890	001	Jun 22, 2010	May	CTNA	
			2%	N200890	002	Jun 22, 2010	May	CTNA	
	+		4%	N200890	003	Jun 22, 2010	May	CTNA	
		PIPERACILLIN SODIUM; TAZOBACTAM SODIUM							
		INJECTABLE; INJECTION							
		PIPERACILLIN AND TAZOBACTAM							
	AP	AUROBINDO PHARMA LTD	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065498	001	May 23, 2011	May	NEWA	
	AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065498	002	May 23, 2011	May	NEWA	
	AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065498	003	May 23, 2011	May	NEWA	
	AP	HOSPIRA INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065386	001	Sep 15, 2009	Jan	CAHN	
	AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065386	002	Sep 15, 2009	Jan	CAHN	
	AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065386	003	Sep 15, 2009	Jan	CAHN	
	AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A065446	001	Sep 15, 2009	Jan	CAHN	
	AP	INSTITUTO BIOCHEMICO	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065523	001	May 31, 2011	May	NEWA	
	AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065523	002	May 31, 2011	May	NEWA	
	AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065523	003	May 31, 2011	May	NEWA	
	AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A090498	001	May 31, 2011	May	NEWA	
		PIROXICAM							
		CAPSULE; ORAL							
		PIROXICAM							
		@ MYLAN	10MG	A074043	001	Sep 22, 1992	Feb	CAHN	
		@	20MG	A074043	002	Sep 22, 1992	Feb	CAHN	
		PODOFILOX							
		SOLUTION; TOPICAL							
		PODOFILOX							
>D>	AT	COLLEGIUM PHARM	0.5%	A090184	001	Jul 21, 2010	Jun	CAHN	
>A>	AT	PRECISION DERMAT	0.5%	A090184	001	Jul 21, 2010	Jun	CAHN	

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

COLYTE

>D>			@ ALAVEN PHARM	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET	N018983	005	Oct 26, 1984	Jun	CAHN
>D>			@	227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983	004	Oct 26, 1984	Jun	CAHN
>D>	AA	+		227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Jun	CAHN
>D>	AA	+		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Jun	CAHN
>D>			@	360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N018983	006	Oct 26, 1984	Jun	CAHN
>A>			@ MEDA PHARMS	120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET	N018983	005	Oct 26, 1984	Jun	CAHN
>A>	AA	+		227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	Jun	CAHN
>A>				227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET	N018983	004	Oct 26, 1984	Jun	CAHN
>A>	AA	+		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	007	Jun 12, 1987	Jun	CAHN
>A>			@	360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET	N018983	006	Oct 26, 1984	Jun	CAHN

COLYTE WITH FLAVOR PACKS

>D>	AA	+	ALAVEN PHARM	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Jun	CAHN
>A>	AA	+	MEDA PHARMS	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Jun	CAHN

COLYTE-FLAVORED

>D>	AA	+	ALAVEN PHARM	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Jun	CAHN
>D>	AA	+		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Jun	CAHN
>A>	AA	+	MEDA PHARMS	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT	N018983	008	Nov 14, 1991	Jun	CAHN
>A>	AA	+		240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	009	Nov 14, 1991	Jun	CAHN

POLYMYXIN B SULFATE

INJECTABLE; INJECTION

POLYMYCIN B SULFATE

>A>	AP		SAGENT STRIDES	EQ 500,000 UNITS BASE/VIAL	A090110	001	Jun 29, 2011	Jun	NEWA

>D> PORFIMER SODIUM

>D> INJECTABLE; INJECTION

>D> PHOTOFRIN

>D>		+	AXCAN	75MG/VIAL	N020451	001	Dec 27, 1995	Jun	DISC
>A>			@ PINNACLE BIOLGS	75MG/VIAL	N020451	001	Dec 27, 1995	Jun	DISC

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

	AB		PADDOCK LABS	8MEQ	A200185	001	May 18, 2011	May	NEWA
	AB			10MEQ	A200185	002	May 18, 2011	May	NEWA

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
MIRAPEX ER

>A>	BOEHRINGER INGELHEIM	2.25MG	N022421	006	Jun 17, 2011	Jun	NEWA
>A>		3.75MG	N022421	007	Jun 17, 2011	Jun	NEWA

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL
PREDNISOLONE SODIUM PHOSPHATE

	@ VINTAGE PHARMS	EQ 5MG BASE/5ML	A078416	001	Oct 31, 2007	May	DISC

PREDNISONE

TABLET; ORAL
PREDNISONE

AB	JUBILANT CADISTA	1MG	A040611	001	Jun 06, 2005	Jan	CAHN
AB		5MG	A040362	002	Aug 29, 2001	Jan	CAHN
AB		10MG	A040362	001	Aug 29, 2001	Jan	CAHN
AB		20MG	A040362	003	Jun 29, 2005	Jan	CAHN

PROCHLORPERAZINE MALEATE

TABLET; ORAL
PROCOMP

AB	JUBILANT CADISTA	EQ 5MG BASE	A040268	001	Feb 27, 1998	Jan	CAHN
AB		EQ 10MG BASE	A040268	002	Feb 27, 1998	Jan	CAHN

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
PROMETHAZINE HYDROCHLORIDE

AP	X-GEN PHARMS	25MG/ML	A040737	001	Apr 24, 2008	May	CAHN
AP		50MG/ML	A040737	002	Apr 24, 2008	May	CAHN

PROPANTHELINE BROMIDE

TABLET; ORAL
PROPANTHELINE BROMIDE

+	ROXANE	15MG	A080927	002		Jan	CMFD

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL
DARVON

	@ XANODYNE PHARM	65MG	N010997	003		Jan	DISC

PROPOXYPHENE HYDROCHLORIDE

	@ TEVA	65MG	A088615	001	Oct 22, 1984	Mar	DISC
	@ VINTAGE PHARMS	65MG	A040908	001	Jul 17, 2009	Mar	DISC
	@ WEST WARD	65MG	A083501	001		Jan	DISC

PROPOXYPHENE NAPSYLATE

TABLET; ORAL
DARVON-N

	@ XANODYNE PHARM	100MG	N016862	002		Jan	DISC

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
PROPRANOLOL HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	60MG	A090321	001	Mar 25, 2011	Mar	NEWA
AB		80MG	A090321	002	Mar 25, 2011	Mar	NEWA

CAPSULE, EXTENDED RELEASE; ORAL
PROPRANOLOL HYDROCHLORIDE

AB	ZYDUS PHARMS USA INC	120MG		A090321	003	Mar 25, 2011	Mar	NEWA
AB		160MG		A090321	004	Mar 25, 2011	Mar	NEWA

TABLET; ORAL
PROPRANOLOL HYDROCHLORIDE

AB	MYLAN	60MG		A070213	005	Apr 08, 2011	Mar	NEWA

PYRIMETHAMINE

TABLET; ORAL
DARAPRIM

>A>	+ COREPHARMA	25MG		N008578	001		Jun	CAHN
>D>	+ GLAXOSMITHKLINE LLC	25MG		N008578	001		Jun	CAHN

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL
QUINAPRIL HYDROCHLORIDE

AB	MYLAN	EQ 5MG BASE		A076036	001	Jan 28, 2005	Feb	CAHN
AB		EQ 10MG BASE		A076036	002	Jan 28, 2005	Feb	CAHN
AB		EQ 20MG BASE		A076036	003	Jan 28, 2005	Feb	CAHN
AB		EQ 40MG BASE		A076036	004	Jan 28, 2005	Feb	CAHN

RAMIPRIL

CAPSULE; ORAL
RAMIPRIL

AB	AUROBINDO PHARMA LTD	1.25MG		A091604	001	Jun 08, 2011	May	NEWA
AB		2.5MG		A091604	002	Jun 08, 2011	May	NEWA
AB		5MG		A091604	003	Jun 08, 2011	May	NEWA
AB		10MG		A091604	004	Jun 08, 2011	May	NEWA

TABLET; ORAL
RAMIPRIL

>A> AB	MATRIX LABS LTD	1.25MG		A090650	001	Jun 30, 2011	Jun	NEWA
>A> AB		2.5MG		A090650	002	Jun 30, 2011	Jun	NEWA
>A> AB		5MG		A090650	003	Jun 30, 2011	Jun	NEWA
>A> AB		10MG		A090650	004	Jun 30, 2011	Jun	NEWA

RANITIDINE HYDROCHLORIDE

CAPSULE; ORAL
RANITIDINE HYDROCHLORIDE

@ MYLAN	EQ 150MG BASE		A075564	001	Oct 27, 2000	Feb	CAHN
@	EQ 300MG BASE		A075564	002	Oct 27, 2000	Feb	CAHN

SYRUP; ORAL
RANITIDINE HYDROCHLORIDE

AA	HI TECH PHARMA	EQ 15MG BASE/ML		A091078	001	Mar 22, 2011	Mar	NEWA
AA	TARO	EQ 15MG BASE/ML		A077476	001	Jun 13, 2011	May	NEWA

TABLET; ORAL
RANITIDINE HYDROCHLORIDE

AB	MYLAN	EQ 150MG BASE		A074023	001	Aug 22, 1997	Feb	CAHN
AB		EQ 300MG BASE		A074023	002	Aug 22, 1997	Feb	CAHN

RIFAMPIN

INJECTABLE; INJECTION
RIFAMPIN

AP	PFIZER	600MG/VIAL		A065421	001	May 22, 2008	May	CAHN

RIFAXIMIN

TABLET; ORAL
XIFAXAN

		+	SALIX PHARMS	550MG	N022554	001	Mar 24, 2010	Feb	CRLD

RILPIVIRINE HYDROCHLORIDE

TABLET; ORAL
EDURANT

		+	TIBOTEC	EQ 25MG BASE	N202022	001	May 20, 2011	May	NEWA

RISPERIDONE

INJECTABLE; INTRAMUSCULAR
RISPERDAL CONSTA

>A>			JANSSEN PHARMS	12.5MG/VIAL	N021346	004	Apr 12, 2007	Jun	CAHN
>A>		+		25MG/VIAL	N021346	001	Oct 29, 2003	Jun	CAHN
>A>				37.5MG/VIAL	N021346	002	Oct 29, 2003	Jun	CAHN
>A>				50MG/VIAL	N021346	003	Oct 29, 2003	Jun	CAHN
>D>			ORTHO MCNEIL JANSSEN	12.5MG/VIAL	N021346	004	Apr 12, 2007	Jun	CAHN
>D>		+		25MG/VIAL	N021346	001	Oct 29, 2003	Jun	CAHN
>D>				37.5MG/VIAL	N021346	002	Oct 29, 2003	Jun	CAHN
>D>				50MG/VIAL	N021346	003	Oct 29, 2003	Jun	CAHN

SOLUTION; ORAL
RISPERDAL

>A>	AA	+	JANSSEN PHARMS	1MG/ML	N020588	001	Jun 10, 1996	Jun	CAHN
>D>	AA	+	ORTHO MCNEIL JANSSEN	1MG/ML	N020588	001	Jun 10, 1996	Jun	CAHN

RISPERIDONE

	AA		AMNEAL PHARMS	1MG/ML	A091384	001	May 25, 2011	May	NEWA
	AA		TARO	1MG/ML	A090347	001	Feb 07, 2011	Jan	NEWA

TABLET; ORAL
RISPERDAL

>A>	AB		JANSSEN PHARMS	0.25MG	N020272	008	May 10, 1999	Jun	CAHN
>A>	AB			0.5MG	N020272	007	Jan 27, 1999	Jun	CAHN
>A>	AB	+		1MG	N020272	001	Dec 29, 1993	Jun	CAHN
>A>	AB			2MG	N020272	002	Dec 29, 1993	Jun	CAHN
>A>	AB			3MG	N020272	003	Dec 29, 1993	Jun	CAHN
>A>	AB			4MG	N020272	004	Dec 29, 1993	Jun	CAHN
>A>		@		5MG	N020272	005	Dec 29, 1993	Jun	CAHN
>D>	AB		ORTHO MCNEIL JANSSEN	0.25MG	N020272	008	May 10, 1999	Jun	CAHN
>D>	AB			0.5MG	N020272	007	Jan 27, 1999	Jun	CAHN
>D>	AB	+		1MG	N020272	001	Dec 29, 1993	Jun	CAHN
>D>	AB			2MG	N020272	002	Dec 29, 1993	Jun	CAHN
>D>	AB			3MG	N020272	003	Dec 29, 1993	Jun	CAHN
>D>	AB			4MG	N020272	004	Dec 29, 1993	Jun	CAHN
>D>		@		5MG	N020272	005	Dec 29, 1993	Jun	CAHN

RISPERIDONE

	AB		CIPLA	0.25MG	A077543	001	May 18, 2011	May	NEWA
	AB			0.5MG	A077543	002	May 18, 2011	May	NEWA
	AB			1MG	A077543	003	May 18, 2011	May	NEWA
	AB			2MG	A077543	004	May 18, 2011	May	NEWA
	AB			3MG	A077543	005	May 18, 2011	May	NEWA
	AB			4MG	A077543	006	May 18, 2011	May	NEWA
		@	RATIOPHARM	0.25MG	A077784	001	Jun 08, 2010	Feb	DISC
		@		0.5MG	A077784	002	Jun 08, 2010	Feb	DISC
		@		1MG	A077784	003	Jun 08, 2010	Feb	DISC
		@		2MG	A077784	004	Jun 08, 2010	Feb	DISC

TABLET; ORAL
RISPERIDONE

	@ RATIOPHARM	3MG	A077784	005	Jun 08, 2010	Feb	DISC
	@	4MG	A077784	006	Jun 08, 2010	Feb	DISC

TABLET, ORALLY DISINTEGRATING; ORAL
RISPERIDONE

AB	MYLAN	0.5MG	A091537	001	Mar 30, 2011	Mar	NEWA
AB		1MG	A091537	002	Mar 30, 2011	Mar	NEWA
AB		2MG	A091537	003	Mar 30, 2011	Mar	NEWA
AB		3MG	A091537	004	Mar 30, 2011	Mar	NEWA
AB		4MG	A091537	005	Mar 30, 2011	Mar	NEWA
AB	WATSON LABS FLORIDA	0.5MG	A076996	001	Apr 19, 2011	Apr	NEWA
AB		1MG	A076996	002	Apr 19, 2011	Apr	NEWA
AB		2MG	A076996	003	Apr 19, 2011	Apr	NEWA
AB		3MG	A076996	004	Apr 19, 2011	Apr	NEWA
AB		4MG	A076996	005	Apr 19, 2011	Apr	NEWA

ROCURONIUM BROMIDE

INJECTABLE; INJECTION
ROCURONIUM BROMIDE

AP	SAGENT STRIDES	50MG/5ML (10MG/ML)	A091458	001	Jul 28, 2010	Jan	CAHN
AP		100MG/10ML (10MG/ML)	A091458	002	Jul 28, 2010	Jan	CAHN

ROFLUMILAST

TABLET; ORAL
DALIRESP

+	FOREST RES INST INC	500MCG	N022522	001	Feb 28, 2011	Feb	NEWA

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL
ROPINIROLE HYDROCHLORIDE

AB	PRINSTON PHARM LLC	EQ 0.25MG BASE	A078110	001	May 05, 2008	May	CAHN
AB		EQ 0.5MG BASE	A078110	002	May 05, 2008	May	CAHN
AB		EQ 1MG BASE	A078110	003	May 05, 2008	May	CAHN
AB		EQ 2MG BASE	A078110	004	May 05, 2008	May	CAHN
AB		EQ 3MG BASE	A078110	005	May 05, 2008	May	CAHN
AB		EQ 4MG BASE	A078110	006	May 05, 2008	May	CAHN

RUFINAMIDE

SUSPENSION; ORAL
BANZEL

+	EISAI INC	40MG/ML	N201367	001	Mar 03, 2011	Mar	NEWA

SECOBARBITAL SODIUM

CAPSULE; ORAL
SECONAL SODIUM

+	MARATHON PHARMS	50MG	A086101	001	Oct 03, 1983	Jan	CAHN
+		100MG	A086101	002	Oct 03, 1983	Jan	CAHN

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL
SERTRALINE HYDROCHLORIDE

	@ ROXANE	EQ 20MG BASE/ML	A076934	001	Jun 30, 2006	Mar	DISC

TABLET; ORAL
SERTRALINE HYDROCHLORIDE

	@ IVAX SUB TEVA PHARMS	EQ 25MG BASE	A075719	003	Jun 30, 2006	Apr	DISC

TABLET; ORAL
SERTRALINE HYDROCHLORIDE

	@	IVAX SUB TEVA PHARMS	EQ 50MG BASE	A075719	001	Jun 30, 2006	Apr	DISC
	@		EQ 100MG BASE	A075719	002	Jun 30, 2006	Apr	DISC
AB		MYLAN	EQ 25MG BASE	A076540	001	Mar 20, 2007	Feb	CAHN
AB			EQ 50MG BASE	A076540	002	Mar 20, 2007	Feb	CAHN
AB			EQ 100MG BASE	A076540	003	Mar 20, 2007	Feb	CAHN
	@	ROXANE	EQ 25MG BASE	A076881	001	Feb 06, 2007	Mar	DISC
	@		EQ 50MG BASE	A076881	002	Feb 06, 2007	Mar	DISC
	@		EQ 100MG BASE	A076881	003	Feb 06, 2007	Mar	DISC

SINECATECHINS

OINTMENT; TOPICAL
VEREGEN

	+	MEDIGENE AG	15%	N021902	001	Oct 31, 2006	May	CAHN

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION
FERRLECIT

AB	+	SANOFI AVENTIS US	62.5MG/5ML	N020955	001	Feb 18, 1999	Mar	CFTG

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

AB		GENERAMEDIX	62.5MG/5ML	A078215	001	Mar 31, 2011	Mar	NEWA

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS
SODIUM FLUORIDE F 18

	@	NIH NCI DCTD	10-200mCi/ML	N022494	001	Jan 26, 2011	Apr	DISC
	+		10-200mCi/ML	N022494	001	Jan 26, 2011	Jan	NEWA

SODIUM NITRITE; SODIUM THIOSULFATE

SOLUTION, SOLUTION; INTRAVENOUS, INTRAVENOUS
NITHIODOTE

	+	HOPE PHARMS	300MG/10ML(30MG/ML),N/A;N/A,12.5GM/50ML(250MG/ML)	N201444	001	Jan 14, 2011	Feb	CTNA

SODIUM NITRITE

	+	HOPE PHARMS	300MG/10ML(30MG/ML),N/A;N/A,12.5GM/50ML(250MG/ML)	N201444	001	Jan 14, 2011	Jan	NEWA

SODIUM POLYSTYRENE SULFONATE

SUSPENSION; ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE

AA		PADDOCK LABS	15GM/60ML	A090590	001	May 13, 2011	May	NEWA

>D> SPECTINOMYCIN HYDROCHLORIDE

>D> INJECTABLE; INJECTION
>D> TROBICIN

>A>	@	PFIZER	EQ 2GM BASE/VIAL	N050347	001		Jun	DISC
>A>	@		EQ 4GM BASE/VIAL	N050347	002		Jun	CAHN
>D>	+	PHARMACIA AND UPJOHN	EQ 2GM BASE/VIAL	N050347	001		Jun	DISC
>D>	@		EQ 4GM BASE/VIAL	N050347	002		Jun	CAHN

SPINOSAD

SUSPENSION; TOPICAL
NATROBA

	+	PARAPRO PHARMS	0.9%	N022408	001	Jan 18, 2011	Jan	NEWA

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

IMITREX STATDOSE

>D>		+ GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N020080	003	Dec 23, 1996	Jun	CFTG
>A>	AB	+	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N020080	003	Dec 23, 1996	Jun	CFTG

SUMATRIPTAN SUCCINATE

>A>	AB	SUN PHARM INDS INC	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A090358	001	Jun 21, 2011	Jun	NEWA

TABLET; ORAL

SUMATRIPTAN SUCCINATE

		@ ROXANE	EQ 25MG BASE	A078241	001	Aug 10, 2009	Mar	DISC
		@	EQ 50MG BASE	A078241	002	Aug 10, 2009	Mar	DISC
		@	EQ 100MG BASE	A078241	003	Aug 10, 2009	Mar	DISC

TACRINE HYDROCHLORIDE

CAPSULE; ORAL

COGNEX

>A>		@ SHIONOGI INC	EQ 10MG BASE	N020070	001	Sep 09, 1993	Jun	DISC
>A>		@	EQ 20MG BASE	N020070	002	Sep 09, 1993	Jun	DISC
>A>		@	EQ 30MG BASE	N020070	003	Sep 09, 1993	Jun	DISC
>A>		@	EQ 40MG BASE	N020070	004	Sep 09, 1993	Jun	DISC
>D>		SHIONOGI PHARMA	EQ 10MG BASE	N020070	001	Sep 09, 1993	Jun	DISC
>D>			EQ 20MG BASE	N020070	002	Sep 09, 1993	Jun	DISC
>D>			EQ 30MG BASE	N020070	003	Sep 09, 1993	Jun	DISC
>D>		+	EQ 40MG BASE	N020070	004	Sep 09, 1993	Jun	DISC

TELAPREVIR

TABLET; ORAL

INCIVEK

		+ VERTEX PHARMS	375MG	N201917	001	May 23, 2011	May	NEWA

TELBIVUDINE

SOLUTION; ORAL

TYZEKA

>D>		+ NOVARTIS	100MG/5ML	N022154	001	Apr 28, 2009	Jun	DISC
>A>		@	100MG/5ML	N022154	001	Apr 28, 2009	Jun	DISC

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

	AB	JUBILANT CADISTA	EQ 1MG BASE	A075317	001	Dec 20, 2004	Jan	CAHN
	AB		EQ 2MG BASE	A075317	002	Dec 20, 2004	Jan	CAHN
	AB		EQ 5MG BASE	A075317	003	Dec 20, 2004	Jan	CAHN
	AB		EQ 10MG BASE	A075317	004	Dec 20, 2004	Jan	CAHN

TERBINAFINE HYDROCHLORIDE

TABLET; ORAL

TERBINAFINE HYDROCHLORIDE

	AB	MYLAN	EQ 250MG BASE	A077136	001	Jul 02, 2007	Feb	CAHN
		@ ROXANE	EQ 250MG BASE	A077223	001	Jul 02, 2007	Feb	DISC

TERBUTALINE SULFATE

TABLET; ORAL
TERBUTALINE SULFATE

	AB	+	IMPAX LABS	5MG	A075877	002	Jun 26, 2001	Jan	CRLD

TESTOSTERONE

GEL, METERED; TRANSDERMAL
ANDROGEL

		+	ABBOTT PRODS	1.62% (20.25MG/1.25GM ACTIVATION)	N022309	001	Apr 29, 2011	Apr	NEWA

FORTESTA

		+	ENDO PHARMS	10MG/0.5GM ACTIVATION	N021463	001	Dec 29, 2010	Mar	CPOT

TABLET, EXTENDED RELEASE; BUCCAL
STRIANT

>A>		+	ACTIENT PHARMS	30MG	N021543	001	Jun 19, 2003	Jun	CAHN
>D>		+	COLUMBIA LABS	30MG	N021543	001	Jun 19, 2003	Jun	CAHN

TETRABENAZINE

TABLET; ORAL
XENAZINE

>D>			BIOVAIL AMERICAS	12.5MG	N021894	001	Aug 15, 2008	Jun	CAHN
>D>		+		25MG	N021894	002	Aug 15, 2008	Jun	CAHN
>A>			VALEANT INTL	12.5MG	N021894	001	Aug 15, 2008	Jun	CAHN
>A>		+		25MG	N021894	002	Aug 15, 2008	Jun	CAHN

TETRACYCLINE HYDROCHLORIDE

FIBER, EXTENDED RELEASE; PERIODONTAL
ACTISITE

>D>			@ ON SITE	12.7MG/FIBER	N050653	001	Mar 25, 1994	Jun	CAHN
>A>			@ SCHIFF AND CO	12.7MG/FIBER	N050653	001	Mar 25, 1994	Jun	CAHN

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL
THEO-24

>A>	BC		ACTIENT PHARMS	100MG	A087942	001	Aug 22, 1983	Jun	CAHN
>A>	BC			200MG	A087943	001	Aug 22, 1983	Jun	CAHN
>A>	BC			300MG	A087944	001	Aug 22, 1983	Jun	CAHN
>A>				400MG	A081034	001	Feb 28, 1992	Jun	CAHN
>D>	BC		UCB INC	100MG	A087942	001	Aug 22, 1983	Jun	CAHN
>D>	BC			200MG	A087943	001	Aug 22, 1983	Jun	CAHN
>D>	BC			300MG	A087944	001	Aug 22, 1983	Jun	CAHN
>D>				400MG	A081034	001	Feb 28, 1992	Jun	CAHN

SOLUTION; ORAL
THEOPHYLLINE

		+	SILARX	80MG/15ML	A091156	001	Apr 13, 2011	Mar	NEWA

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION
THIAMINE HYDROCHLORIDE

			@ HOSPIRA	100MG/ML	A040079	001	May 03, 1996	May	DISC

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL
TICLOPIDINE HYDROCHLORIDE

	AB		MYLAN	250MG	A075161	001	Sep 13, 1999	Feb	CAHN

TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC
TIMOLOL MALEATE

>A>	AT		APOTEX INC	EQ 0.25% BASE	A075411	001	Sep 08, 2000	Jun	CAHN
>D>	AT		NOVEX	EQ 0.25% BASE	A075411	001	Sep 08, 2000	Jun	CAHN

TOBRAMYCIN

SOLUTION/DROPS; OPHTHALMIC
TOBRAMYCIN

	AT		FERA PHARMS	0.3%	A065026	001	Sep 11, 2001	Mar	CAHN

TOLCAPONE

TABLET; ORAL
TASMAR

>D>			VALEANT PHARM INTL	100MG	N020697	001	Jan 29, 1998	Jun	CRLD
>A>		+		100MG	N020697	001	Jan 29, 1998	Jun	CRLD
>D>		+		200MG	N020697	002	Jan 29, 1998	Jun	DISC
>A>		@		200MG	N020697	002	Jan 29, 1998	Jun	DISC

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
TOPOTECAN HYDROCHLORIDE

	AP		DR REDDYS LABS LTD	EQ 4MG BASE/VIAL	A201191	001	Mar 09, 2011	Feb	NEWA
	AP		SAGENT PHARMS	EQ 4MG BASE/VIAL	A091284	001	Jan 26, 2011	Jan	NEWA

SOLUTION; INTRAVENOUS
TOPOTECAN

	AP		HOSPIRA INC	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N200582	001	Feb 02, 2011	Feb	NEWA
			SANDOZ	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N200199	001	Feb 25, 2011	Feb	NEWA
				EQ 3MG BASE/3ML (EQ 1MG BASE/ML)	N200199	002	Feb 25, 2011	Feb	NEWA
	AP	+		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	N200199	003	Feb 25, 2011	Feb	NEWA

TORSEMIDE

TABLET; ORAL
TORSEMIDE

	AB		VINTAGE PHARMS	5MG	A090613	001	Mar 22, 2011	Mar	NEWA
	AB			10MG	A090613	002	Mar 22, 2011	Mar	NEWA
	AB			20MG	A090613	003	Mar 22, 2011	Mar	NEWA
	AB			100MG	A090613	004	Mar 22, 2011	Mar	NEWA

TRAMADOL HYDROCHLORIDE

TABLET; ORAL
TRAMADOL HYDROCHLORIDE

	AB		ZYDUS PHARMS USA INC	50MG	A090404	001	Jan 31, 2011	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL
ULTRAM ER

>D>	AB	+	BIOVAIL LABS INTL	100MG	N021692	001	Sep 08, 2005	Jun	CAHN
>D>	AB			200MG	N021692	002	Sep 08, 2005	Jun	CAHN
>D>	BC			300MG	N021692	003	Sep 08, 2005	Jun	CAHN
>A>	AB	+	VALEANT INTL	100MG	N021692	001	Sep 08, 2005	Jun	CAHN
>A>	AB			200MG	N021692	002	Sep 08, 2005	Jun	CAHN
>A>	BC			300MG	N021692	003	Sep 08, 2005	Jun	CAHN

TRAVOPROST

SOLUTION/DROPS; OPHTHALMIC

TRAVATAN

	@	ALCON	0.004%	N021257	001	Mar 16, 2001	May	DISC

TRAZODONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OLEPTRO

>A>	+	ANGELINI LABOPHARM	150MG	N022411	001	Feb 02, 2010	Jun	CAHN
			300MG	N022411	002	Feb 02, 2010	May	CAHN
>D>	+	LABOPHARM	150MG	N022411	001	Feb 02, 2010	Jun	CAHN

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HYDROCHLORIDE

AP		LUITPOLD	100MG/ML	A091330	001	Mar 08, 2011	May	CAHN
AP		PHARMAFORCE	100MG/ML	A091330	001	Mar 08, 2011	Feb	NEWA

TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE

AP		LUITPOLD	100MG/ML	A091329	001	Mar 08, 2011	May	CAHN
AP		PHARMAFORCE	100MG/ML	A091329	001	Mar 08, 2011	Feb	NEWA

TRIMETHOPRIM

TABLET; ORAL

TRIMETHOPRIM

AB		NOVEL LABS INC	100MG	A091437	001	Jun 15, 2011	May	NEWA

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

TRIMIPRAMINE MALEATE

AB		MIKAH PHARMA	EQ 25MG BASE	A077361	001	Aug 02, 2006	Feb	CAHN
AB			EQ 50MG BASE	A077361	002	Aug 02, 2006	Feb	CAHN
AB			EQ 100MG BASE	A077361	003	Aug 02, 2006	Feb	CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

AB		ACTAVIS PHARMA	EQ 500MG BASE	A090370	001	Mar 16, 2011	Feb	NEWA
AB			EQ 1GM BASE	A090370	002	Mar 16, 2011	Feb	NEWA

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

AP		PFIZER	EQ 500MG BASE/VIAL	A065397	001	Dec 30, 2008	May	CAHN
AP			EQ 1GM BASE/VIAL	A065397	002	Dec 30, 2008	May	CAHN
AP			EQ 5GM BASE/VIAL	A065432	001	Dec 30, 2008	May	CAHN
>A> AP			EQ 10GM BASE/VIAL	A091469	001	Jul 01, 2011	Jun	NEWA

VANDETANIB

TABLET; ORAL

VANDETANIB

		IPR PHARMS INC	100MG	N022405	001	Apr 06, 2011	Apr	NEWA
	+		300MG	N022405	002	Apr 06, 2011	Apr	NEWA

VECURONIUM BROMIDE

INJECTABLE; INJECTION
VECURONIUM BROMIDE

	AP	PFIZER	10MG/VIAL	A090243	001	May 11, 2010	May	CAHN
	AP		20MG/VIAL	A090243	002	May 11, 2010	May	CAHN

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
VENLAFAXINE HYDROCHLORIDE

	AB	AUROBINDO PHARMA LTD	EQ 37.5MG BASE	A200834	001	Apr 14, 2011	Apr	NEWA
	AB		EQ 75MG BASE	A200834	002	Apr 14, 2011	Apr	NEWA
	AB		EQ 150MG BASE	A200834	003	Apr 14, 2011	Apr	NEWA
	AB	DR REDDYS LABS LTD	EQ 37.5MG BASE	A078421	001	May 06, 2011	Apr	NEWA
	AB		EQ 75MG BASE	A078421	002	May 06, 2011	Apr	NEWA
	AB		EQ 150MG BASE	A078421	003	May 06, 2011	Apr	NEWA
	AB	MYLAN	EQ 37.5MG BASE	A078789	001	Jun 01, 2011	May	NEWA
	AB		EQ 75MG BASE	A078789	002	Jun 01, 2011	May	NEWA
	AB		EQ 150MG BASE	A078789	003	Jun 01, 2011	May	NEWA
>A>	AB	ORCHID HLTHCARE	EQ 37.5MG BASE	A091123	001	Jul 11, 2011	Jun	NEWA
>A>	AB		EQ 75MG BASE	A091123	002	Jul 11, 2011	Jun	NEWA
>A>	AB		EQ 150MG BASE	A091123	003	Jul 11, 2011	Jun	NEWA
	AB	TORRENT PHARMS LLC	EQ 37.5MG BASE	A090899	001	Jun 01, 2011	May	NEWA
	AB		EQ 75MG BASE	A090899	002	Jun 01, 2011	May	NEWA
	AB		EQ 150MG BASE	A090899	003	Jun 01, 2011	May	NEWA
	AB	VALEANT INTL	EQ 37.5MG BASE	A090071	001	Apr 15, 2011	Apr	NEWA
	AB		EQ 75MG BASE	A090071	002	Apr 15, 2011	Apr	NEWA
	AB		EQ 150MG BASE	A090071	003	Apr 15, 2011	Apr	NEWA
	AB	WOCKHARDT	EQ 37.5MG BASE	A078865	001	Apr 14, 2011	Apr	NEWA
	AB		EQ 75MG BASE	A078865	002	Apr 14, 2011	Apr	NEWA
	AB		EQ 150MG BASE	A078865	003	Apr 14, 2011	Apr	NEWA
	AB	ZYDUS PHARMS USA INC	EQ 37.5MG BASE	A090174	001	Apr 14, 2011	Apr	NEWA
	AB		EQ 75MG BASE	A090174	002	Apr 14, 2011	Apr	NEWA
	AB		EQ 150MG BASE	A090174	003	Apr 14, 2011	Apr	NEWA

VILAZODONE HYDROCHLORIDE

TABLET; ORAL
VIIBRYD

		FOREST LABS INC	10MG	N022567	001	Jan 21, 2011	May	CAHN
			20MG	N022567	002	Jan 21, 2011	May	CAHN
	+		40MG	N022567	003	Jan 21, 2011	May	CAHN
		TROVIS PHARMS	10MG	N022567	001	Jan 21, 2011	Jan	NEWA
			20MG	N022567	002	Jan 21, 2011	Jan	NEWA
	+		40MG	N022567	003	Jan 21, 2011	Jan	NEWA

VINCRISTINE SULFATE

INJECTABLE; INJECTION
VINCRISTINE SULFATE

		@ APP PHARMS	1MG/ML	A076401	001	Oct 28, 2003	Jan	DISC

WARFARIN SODIUM

TABLET; ORAL
WARFARIN SODIUM

	AB	INVAGEN PHARMS	1MG	A090935	001	May 25, 2011	May	NEWA
	AB		2MG	A090935	002	May 25, 2011	May	NEWA
	AB		2.5MG	A090935	003	May 25, 2011	May	NEWA

TABLET; ORAL
WARFARIN SODIUM

AB	INVAGEN PHARMS	3MG	A090935	004	May 25, 2011	May	NEWA
AB		4MG	A090935	005	May 25, 2011	May	NEWA
AB		5MG	A090935	006	May 25, 2011	May	NEWA
AB		6MG	A090935	007	May 25, 2011	May	NEWA
AB		7.5MG	A090935	008	May 25, 2011	May	NEWA
AB		10MG	A090935	009	May 25, 2011	May	NEWA

ZIDOVUDINE

INJECTABLE; INJECTION
ZIDOVUDINE

AP	LUITPOLD	10MG/ML	A091457	001	May 06, 2010	Feb	CAHN

TABLET; ORAL
ZIDOVUDINE

	@ MATRIX LABS LTD	100MG	N200732	001	Feb 23, 2011	Feb	NEWA

ZOLEDRONIC ACID

INJECTABLE; IV (INFUSION)
ZOMETA

>A>	+ NOVARTIS	EQ 4MG BASE/100ML	N021223	003	Jun 17, 2011	Jun	NEWA

ZOLPIDEM TARTRATE

TABLET; ORAL
ZOLPIDEM TARTRATE

AB	MYLAN	5MG	A078016	001	Apr 23, 2007	Feb	CAHN
AB		10MG	A078016	002	Apr 23, 2007	Feb	CAHN

TABLET, EXTENDED RELEASE; ORAL
ZOLPIDEM TARTRATE

AB	ANCHEN PHARMS	6.25MG	A078148	002	Apr 14, 2011	Apr	NEWA
>A> AB	SANDOZ	6.25MG	A090107	001	Jul 01, 2011	Jun	NEWA
>A> AB		12.5MG	A090107	002	Jul 01, 2011	Jun	NEWA
AB	SYNTHON PHARMS	6.25MG	A078483	001	Apr 12, 2011	Apr	NEWA

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

SILARX	5MG/5ML	A091130	001	Apr 22, 2011	Apr	NEWA
TARO	5MG/5ML	A201546	001	May 20, 2011	May	NEWA

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

SILARX	5MG/5ML	A091130	002	Apr 22, 2011	Apr	NEWA
TARO	5MG/5ML	A201546	002	May 20, 2011	May	NEWA

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

+ CARDINAL HLTH	2%;70% (0.67ML)	N021555	001	Oct 07, 2002	Apr	CAHN

CHLORAPREP SINGLE SWABSTICK

+ CARDINAL HLTH	2%;70% (1.75ML)	N021555	002	May 10, 2005	Apr	CAHN

CHLORAPREP TRIPLE SWABSTICK

+ CARDINAL HLTH	2%;70% (5.25ML)	N021555	003	Jun 10, 2009	Apr	NEWA

FAMOTIDINE

TABLET; ORAL

FAMOTIDINE

MYLAN	10MG	A075674	001	Dec 21, 2001	Feb	CAHN

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S ALLEGRA ALLERGY

+ SANOFI AVENTIS US	30MG/5ML	N201373	001	Jan 24, 2011	Jan	NEWA

CHILDREN'S ALLEGRA HIVES

+ SANOFI AVENTIS US	30MG/5ML	N201373	002	Jan 24, 2011	Jan	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

CHILDREN'S ALLEGRA ALLERGY

+ SANOFI AVENTIS US	30MG	N021909	002	Jan 24, 2011	Jan	NEWA

CHILDREN'S ALLEGRA HIVES

+ SANOFI AVENTIS US	30MG	N021909	003	Jan 24, 2011	Jan	NEWA

TABLET; ORAL

ALLEGRA ALLERGY

SANOFI AVENTIS US	60MG	N020872	007	Jan 24, 2011	Jan	NEWA
+	180MG	N020872	010	Jan 24, 2011	Jan	NEWA

ALLEGRA HIVES

SANOFI AVENTIS US	60MG	N020872	008	Jan 24, 2011	Jan	NEWA
+	180MG	N020872	009	Jan 24, 2011	Jan	NEWA

CHILDREN'S ALLEGRA ALLERGY

SANOFI AVENTIS US	30MG	N020872	005	Jan 24, 2011	Jan	NEWA

CHILDREN'S ALLEGRA HIVES

SANOFI AVENTIS US	30MG	N020872	006	Jan 24, 2011	Jan	NEWA

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

DR REDDYS LABS LTD	30MG	A076502	004	Apr 12, 2011	Mar	NEWA
TEVA	30MG	A076447	004	Apr 13, 2011	Mar	NEWA

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	30MG	A076502	005	Apr 12, 2011	Mar	NEWA
TEVA	30MG	A076447	005	Apr 13, 2011	Mar	NEWA

FEXOFENADINE HYDROCHLORIDE ALLERGY

DR REDDYS LABS LTD	60MG	A076502	006	Apr 12, 2011	Mar	NEWA

TABLET; ORAL
FEXOFENADINE HYDROCHLORIDE ALLERGY

DR REDDYS LABS LTD	180MG	A076502	008	Apr 12, 2011	Mar	NEWA
TEVA	60MG	A076447	006	Apr 13, 2011	Mar	NEWA
	180MG	A076447	008	Apr 13, 2011	Mar	NEWA

FEXOFENADINE HYDROCHLORIDE HIVES

DR REDDYS LABS LTD	60MG	A076502	007	Apr 12, 2011	Mar	NEWA
	180MG	A076502	009	Apr 12, 2011	Mar	NEWA
TEVA	60MG	A076447	007	Apr 13, 2011	Mar	NEWA
	180MG	A076447	009	Apr 13, 2011	Mar	NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION

+ SANOFI AVENTIS US	60MG;120MG	N020786	002	Jan 24, 2011	Jan	NEWA

ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION

+ SANOFI AVENTIS US	180MG;240MG	N021704	002	Jan 24, 2011	Jan	NEWA

>A> FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

>A> DR REDDYS LABS LTD	180MG;240MG	A079043	002	Jun 22, 2011	Jun	NEWA

IBUPROFEN

TABLET; ORAL
IBUPROFEN

AVEMA PHARMA	200MG	A076460	001	Nov 26, 2003	May	CAHN
MARKSANS PHARMA	200MG	A091237	001	Feb 08, 2011	Jan	NEWA
	200MG	A091239	001	Feb 01, 2011	Jan	NEWA
MERRO PHARM	200MG	A070985	001	Oct 02, 1987	Jan	CAHN
SVADS HOLDINGS SA	200MG	A079129	001	Mar 28, 2011	Mar	NEWA
	200MG	A091355	001	Apr 04, 2011	Mar	NEWA

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

INJECTABLE; INJECTION
NOVOLIN N

+ NOVO NORDISK INC	100 UNITS/ML	N019959	001	Jul 01, 1991	Jan	CRLD

LEVONORGESTREL

TABLET; ORAL
PLAN B

+ TEVA WOMENS	0.75MG	N021045	002	Aug 24, 2006	Feb	CAHN

LOPERAMIDE HYDROCHLORIDE

SUSPENSION; ORAL
LOPERAMIDE HYDROCHLORIDE

PERRIGO R AND D	1MG/7.5ML	A091292	001	May 20, 2011	May	NEWA

MINOXIDIL

AEROSOL, FOAM; TOPICAL
MINOXIDIL

PERRIGO ISRAEL	5%	A091344	001	Apr 28, 2011	Apr	NEWA

NAPROXEN SODIUM

TABLET; ORAL
NAPROXEN SODIUM

MARKSANS PHARMA	EQ 200MG BASE	A090545	001	Mar 16, 2011	Feb	NEWA
RANBAXY LABS LTD	EQ 200MG BASE	A091183	001	May 20, 2011	May	NEWA

POTASSIUM IODIDE

TABLET; ORAL

IOSAT

ANBEX	65MG	N018664	002	May 12, 2011	Apr	NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

MYLAN	EQ 75MG BASE	A075497	001	Jan 14, 2000	Feb	CAHN
PERRIGO R AND D	EQ 150MG BASE	A091429	001	May 11, 2011	Apr	NEWA
	EQ 150MG BASE	A091429	002	May 11, 2011	Apr	NEWA
>A> SVADS HOLDINGS SA	EQ 150MG BASE	A200536	001	Jun 28, 2011	Jun	NEWA

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 6 JUNE 2011

NO JUNE 2011 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

http://www.fda.gov/orphan/designat/list.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO JUNE 2011 ADDITIONS

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ABIRATERONE ACETATE - ZYTIGA							
N202379	001	5604213	Feb 18, 2014	DS DP U-1126		NCE	Apr 28, 2016
ADAPALENE - DIFFERIN							
N021753	001	7868044	Mar 12, 2023	U-1078			
ADAPALENE; BENZOYL PEROXIDE - EPIDUO							
N022320	001	>A> 7964202	Sep 01, 2024	DP U-1078			
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO							
N022545	001					NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO							
N022545	002					NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO							
N022545	003					NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO							
N022545	004					NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE							
N200045	001	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE							
N200045	002	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE							
N200045	003	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE							
N200045	004	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE							
N200045	005	5559111	Jul 21, 2018	DS DP U-3		NCE	Mar 05, 2012
ALVIMOPAN - ENTEREG							
N021775	001	5250542	Mar 29, 2016	DS DP U-878			
AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE							
A078381	005					PC	Jul 02, 2011
AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE							
A078381	006					PC	Jul 02, 2011
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 10							
N021303	001	RE42096	Oct 21, 2018	DP			
		RE42096*PED	Apr 21, 2019				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 15							
N021303	006	RE42096	Oct 21, 2018	DP			
		RE42096*PED	Apr 21, 2019				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 20							
N021303	002	RE42096	Oct 21, 2018	DP			
		RE42096*PED	Apr 21, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 25						
N021303 004	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 30						
N021303 003	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 5						
N021303 005	RE42096	Oct 21, 2018	DP			
	RE42096*PED	Apr 21, 2019				
ARIPIPRAZOLE - ABILIFY						
N021436 001					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021436 002					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021436 003					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021436 004					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021436 005					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021436 006					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021713 001					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021729 002					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021729 003					I-633	Feb 16, 2014
ARIPIPRAZOLE - ABILIFY						
N021866 001					I-633	Feb 16, 2014
ATAZANAVIR SULFATE - REYATAZ						
N021567 001					D-130	Feb 04, 2014
ATAZANAVIR SULFATE - REYATAZ						
N021567 002					D-130	Feb 04, 2014
ATAZANAVIR SULFATE - REYATAZ						
N021567 003					D-130	Feb 04, 2014
ATAZANAVIR SULFATE - REYATAZ						
N021567 004					D-130	Feb 04, 2014
AZILSARTAN MEDOXOMIL - EDARBI						
N200796 001	5583141	Dec 10, 2013	DS DP U-3		NCE	Feb 25, 2016
	5736555	Jun 25, 2012	DS DP U-3			
	5958961	Jun 06, 2014	DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AZILSARTAN MEDOXOMIL - EDARBI							
N200796 002		5583141	Dec 10, 2013	DS DP U-3		NCE	Feb 25, 2016
		5736555	Jun 25, 2012	DS DP U-3			
		5958961	Jun 06, 2014	DP U-3			
		7157584	May 22, 2025	DS			
		7572920	Jan 07, 2025	DP U-3			
AZITHROMYCIN - ZMAX							
N050797 001		7887844	Feb 14, 2024	DP			
BOCEPREVIR - VICTRELIS							
N202258 001		7012066	Feb 22, 2022	DS DP U-1128		NCE	May 13, 2016
		7772178	Nov 11, 2027	DP U-1128			
BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT							
N021929 002		7897646	Sep 09, 2018	U-1118			
CARBAMAZEPINE - CARBATROL							
N020712 001		5326570	Jul 23, 2011	U-215			
CARBAMAZEPINE - CARBATROL							
N020712 002		5326570	Jul 23, 2011	U-215			
CARBAMAZEPINE - CARBATROL							
N020712 003		5326570	Jul 23, 2011	U-215			
CELECOXIB - CELEBREX							
N020998 001		5760068	Jun 02, 2015	U-672			
CELECOXIB - CELEBREX							
N020998 002		5760068	Jun 02, 2015	U-672			
CELECOXIB - CELEBREX							
N020998 003		5760068	Jun 02, 2015	U-672			
CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE							
N021669 001		7935093	Oct 02, 2027	DP U-1022			
CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - ADVIL ALLERGY SINUS							
N021441 001		7863287	Feb 28, 2027	DP			
CINACALCET HYDROCHLORIDE - SENSIPAR							
N021688 001	**>A>**	6011068	Mar 08, 2018	DS DP		I-634	Feb 25, 2014
						M-101	Feb 25, 2014
						ODE	Feb 25, 2018
CINACALCET HYDROCHLORIDE - SENSIPAR							
N021688 002	**>A>**	6011068	Mar 08, 2018	DS DP		I-634	Feb 25, 2014
						M-101	Feb 25, 2014
						ODE	Feb 25, 2018
CINACALCET HYDROCHLORIDE - SENSIPAR							
N021688 003	**>A>**	6011068	Mar 08, 2018	DS DP		I-634	Feb 25, 2014
						M-101	Feb 25, 2014
						ODE	Feb 25, 2018

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CLOPIDOGREL BISULFATE - PLAVIX						
N020839 001	4847265	Nov 17, 2011	DS DP		M-61	May 06, 2014
	4847265*PED	May 17, 2012			PED	Nov 06, 2014
	5576328	Jan 31, 2014	U-432	Y		
	5576328*PED	Jul 31, 2014				
	6429210	Jun 10, 2019	DS DP			
	6429210*PED	Dec 10, 2019				
	6504030	Jun 10, 2019	DS			
	6504030*PED	Dec 10, 2019				
CLOPIDOGREL BISULFATE - PLAVIX						
N020839 002	4847265	Nov 17, 2011	DS DP		M-61	May 06, 2014
	4847265*PED	May 17, 2012			PED	Nov 06, 2014
	6429210	Jun 10, 2019	DS DP			
	6429210*PED	Dec 10, 2019				
	6504030	Jun 10, 2019	DS			
	6504030*PED	Dec 10, 2019				
COLCHICINE - COLCRYS						
N022352 001	7906519	Feb 17, 2029	U-1116			
	7915269	Feb 17, 2029	U-1007			
CYANOCOBALAMIN - NASCOBAL						
N021642 001	7879349	Jun 01, 2024	DP U-1152			
DARUNAVIR ETHANOLATE - PREZISTA						
N021976 001	5843946	Dec 01, 2015	DP U-903		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-935		D-119	Dec 18, 2011
	5843946	Dec 01, 2015	DP U-744		I-578	Oct 21, 2011
	5843946*PED	Jun 01, 2016			NCE	Jun 23, 2011
	6037157	Jun 26, 2016	U-935		PED	Jun 13, 2014
	6037157*PED	Dec 26, 2016			PED	Jun 18, 2012
	6248775	Aug 13, 2014	DS		PED	Apr 21, 2012
	6248775*PED	Feb 13, 2015			PED	Dec 23, 2011
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DARUNAVIR ETHANOLATE - PREZISTA						
N021976 002	5843946	Dec 01, 2015	DP U-903		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-935		D-119	Dec 18, 2011
	5843946	Dec 01, 2015	DP U-744		I-578	Oct 21, 2011
	5843946*PED	Jun 01, 2016			NCE	Jun 23, 2011
	6037157	Jun 26, 2016	U-935		PED	Jun 13, 2014
	6037157*PED	Dec 26, 2016			PED	Jun 18, 2012
	6248775	Aug 13, 2014	DS		PED	Apr 21, 2012
	6248775*PED	Feb 13, 2015			PED	Dec 23, 2011
	6335460	Aug 25, 2012	DS DP U-903			
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
DARUNAVIR ETHANOLATE - PREZISTA						
N021976 003	5843946	Dec 01, 2015	DP U-903		D-129	Dec 13, 2013
	5843946	Dec 01, 2015	DP U-935		D-119	Dec 18, 2011
	5843946	Dec 01, 2015	DP U-744		D-118	Oct 21, 2011
	5843946*PED	Jun 01, 2016			I-578	Oct 21, 2011
	6037157	Jun 26, 2016	U-935		NCE	Jun 23, 2011
	6037157*PED	Dec 26, 2016			PED	Jun 13, 2014
	6248775	Aug 13, 2014	DS		PED	Jun 18, 2012
	6248775*PED	Feb 13, 2015			PED	Apr 21, 2012
	6335460	Aug 25, 2012	DS DP U-935		PED	Dec 23, 2011
	6335460	Aug 25, 2012	DS DP U-903			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DARUNAVIR ETHANOLATE - PREZISTA						
N021976 004	5843946	Dec 01, 2015	DP U-935		D-129	Dec 13, 2013
	5843946*PED	Jun 01, 2016			D-119	Dec 18, 2011
	6037157	Jun 26, 2016	U-935		NS	Dec 18, 2011
	6037157*PED	Dec 26, 2016			NCE	Jun 23, 2011
	6248775	Aug 13, 2014	DS		PED	Jun 13, 2014
	6248775*PED	Feb 13, 2015			PED	Jun 18, 2012
	6335460	Aug 25, 2012	DS DP U-935		PED	Dec 23, 2011
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
DARUNAVIR ETHANOLATE - PREZISTA						
N021976 005	5843946	Dec 01, 2015	DP U-935		D-129	Dec 13, 2013
	5843946*PED	Jun 01, 2016			D-119	Dec 18, 2011
	6037157	Jun 26, 2016	U-935		NS	Dec 18, 2011
	6037157*PED	Dec 26, 2016			NCE	Jun 23, 2011
	6248775	Aug 13, 2014	DS		PED	Jun 13, 2014
	6248775*PED	Feb 13, 2015			PED	Jun 18, 2012
	6335460	Aug 25, 2012	DS DP U-935		PED	Dec 23, 2011
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
DASATINIB - SPRYCEL						
N021986 005	**>A>** 6596746	Jun 28, 2020	DS DP U-780			
	>A> 6596746	Jun 28, 2020	DS DP U-748			
	>A> 7125875	Apr 13, 2020	U-780			
	>A> 7125875	Apr 13, 2020	U-779			
	>A> 7153856	Apr 28, 2020	U-780			
DASATINIB - SPRYCEL						
N021986 006	**>A>** 6596746	Jun 28, 2020	DS DP U-780			
	>A> 6596746	Jun 28, 2020	DS DP U-748			
	>A> 7125875	Apr 13, 2020	U-780			
	>A> 7125875	Apr 13, 2020	U-779			
	>A> 7153856	Apr 28, 2020	U-780			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR						
N021802 007	5837284	Dec 04, 2015	DP		D-121	Oct 23, 2012
	5908850	Dec 04, 2015	DP U-678		M-80	Oct 17, 2011
	6228398	Nov 01, 2019	DP U-676			
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP U-677			
	6730325	Nov 01, 2019	DP U-676			
	7431944	Dec 04, 2015	DP			
DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR						
N021802 008	5837284	Dec 04, 2015	DP		D-121	Oct 23, 2012
	5908850	Dec 04, 2015	DP U-678		M-80	Oct 17, 2011
	6228398	Nov 01, 2019	DP U-676			
	6355656	Dec 04, 2015	DP			
	6528530	Dec 04, 2015	DP			
	6635284	Dec 04, 2015	DP U-677			
	6730325	Nov 01, 2019	DP U-676			
	7431944	Dec 04, 2015	DP			
DICLOFENAC POTASSIUM - ZIPSOR						
N022202 001	7884095	Feb 24, 2029	U-1111			
	7939518	Feb 24, 2029	U-980			
DICLOFENAC SODIUM - SOLARAZE						
N021005 001	5929048	Jun 17, 2014	U-402			
	5985850	Aug 11, 2015	DP			
DIENOGEST; ESTRADIOL VALERATE - NATAZIA						
N022252 001	6133251	Oct 25, 2016	DP U-828	Y		
	6133251	Oct 25, 2016	DP U-112	Y		
	6133251	Oct 25, 2016	DP U-1	Y		
	6884793	Oct 25, 2016	DP	Y		
DORIPENEM - DORIBAX						
N022106 001	5317016	Jun 05, 2015	DS DP U-282			
DORIPENEM - DORIBAX						
N022106 002	5317016	Jun 05, 2015	DS DP U-282			
DOXEPIN HYDROCHLORIDE - SILENOR						
N022036 001	7915307	Aug 24, 2027	U-620			
DOXEPIN HYDROCHLORIDE - SILENOR						
N022036 002	7915307	Aug 24, 2027	U-620			
DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL						
N022574 001	5798338	Jul 10, 2015	DP			
	6441168	Apr 17, 2020	DS			
	6958326	Dec 20, 2021	DP			
	7163931	Mar 03, 2022	U-1			
ELTROMBOPAG OLAMINE - PROMACTA						
N022291 001	7547719	Jul 13, 2025	DS DP U-930			
ELTROMBOPAG OLAMINE - PROMACTA						
N022291 002	7547719	Jul 13, 2025	DS DP U-930			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELTROMBOPAG OLAMINE - PROMACTA						
N022291 003	7547719	Jul 13, 2025	DS DP U-930			
EPINASTINE HYDROCHLORIDE - EPINASTINE HYDROCHLORIDE						
A090870 001					**>A>** PC	Oct 29, 2011
ESOMEPRAZOLE MAGNESIUM - NEXIUM						
N021957 001					NPP	Feb 27, 2011
					PED	Aug 27, 2011
ESOMEPRAZOLE MAGNESIUM - NEXIUM						
N021957 002					NPP	Feb 27, 2011
					PED	Aug 27, 2011
ESOMEPRAZOLE MAGNESIUM - NEXIUM						
N022101 001					M-86	Jun 18, 2012
					PED	Dec 18, 2012
ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO						
N022511 001	5714504	Feb 03, 2015	DP U-1053			
	5714504*PED	Aug 03, 2015				
	5900424	May 04, 2016	DS U-1053			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1053			
	6369085*PED	Nov 25, 2018				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS U-1053			
	7411070*PED	Nov 25, 2018				
ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO						
N022511 002	5714504	Feb 03, 2015	DP U-1053			
	5714504*PED	Aug 03, 2015				
	5900424	May 04, 2016	DS U-1053			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1053			
	6369085*PED	Nov 25, 2018				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS U-1053			
	7411070*PED	Nov 25, 2018				
ETHINYL ESTRADIOL; LEVONORGESTREL - LOSEASONIQUE						
N022262 001	7855190	Dec 05, 2028	U-1			
	7858605	Jun 23, 2023	DP			
ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE						
N021840 001	7855190	Dec 05, 2028	U-1			
	7858605	Jun 23, 2023	DP			
ETHINYL ESTRADIOL; NORETHINDRONE - NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
N022573 001	5552394	Jul 22, 2014	U-828			
	6667050	Apr 06, 2019	DP U-828			
ETRAVIRINE - INTELENCE						
N022187 001	7887845	Mar 25, 2019	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ETRAVIRINE - INTELENCE						
N022187 002	6878717	Nov 05, 2019	U-1016		NCE	Jan 18, 2013
	7037917	Nov 05, 2019	DS DP U-1016			
	7887845	Mar 25, 2019	DP			
EVEROLIMUS - AFINITOR						
N022334 001	**>A>** 5665772	Sep 09, 2019	DS DP		I-638	May 05, 2014
					ODE	Oct 29, 2017
EVEROLIMUS - AFINITOR						
N022334 002	**>A>** 5665772	Sep 09, 2019	DS DP		I-638	May 05, 2014
					ODE	Oct 29, 2017
EVEROLIMUS - AFINITOR						
N022334 003	**>A>** 5665772	Sep 09, 2019			I-638	May 05, 2014
					NCE	Mar 30, 2014
					ODE	Oct 29, 2017
EVEROLIMUS - ZORTRESS						
N021560 001	**>A>** 5665772	Sep 09, 2019	DS DP U-1049			
EVEROLIMUS - ZORTRESS						
N021560 002	**>A>** 5665772	Sep 09, 2019	DS DP U-1049			
EVEROLIMUS - ZORTRESS						
N021560 003	**>A>** 5665772	Sep 09, 2019	DS DP U-1049			
EXENATIDE SYNTHETIC - BYETTA						
N021773 001	5424286	Dec 01, 2016	U-653			
	5424286	Dec 01, 2016	U-1108			
EXENATIDE SYNTHETIC - BYETTA						
N021773 002	5424286	Dec 01, 2016	U-653			
	5424286	Dec 01, 2016	U-1108			
EZETIMIBE - ZETIA						
N021445 001	**>A>** RE42461	Oct 25, 2016	DS DP U-473			
	>A> RE42461*PED	Apr 25, 2017				
EZETIMIBE; SIMVASTATIN - VYTORIN						
N021687 001	**>A>** RE37721	Oct 25, 2016	DS DP U-473	Y		
	>A> RE37721*PED	Apr 25, 2017		Y		
	>A> RE42461	Oct 25, 2016	DS DP U-473			
	>A> RE42461*PED	Apr 25, 2017				
EZETIMIBE; SIMVASTATIN - VYTORIN						
N021687 002	**>A>** RE37721	Oct 25, 2016	DS DP U-473	Y		
	>A> RE37721*PED	Apr 25, 2017		Y		
	>A> RE42461	Oct 25, 2016	DS DP U-473			
	>A> RE42461*PED	Apr 25, 2017				
EZETIMIBE; SIMVASTATIN - VYTORIN						
N021687 003	**>A>** RE37721	Oct 25, 2016	DS DP U-473	Y		
	>A> RE37721*PED	Apr 25, 2017		Y		
	>A> RE42461	Oct 25, 2016	DS DP U-473			
	>A> RE42461*PED	Apr 25, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EZETIMIBE; SIMVASTATIN - VYTORIN						
N021687 004	**>A>** RE37721	Oct 25, 2016	DS DP U-473	Y		
	>A> RE37721*PED	Apr 25, 2017		Y		
	>A> RE42461	Oct 25, 2016	DS DP U-473			
	>A> RE42461*PED	Apr 25, 2017				
EZOGABINE - POTIGA						
N022345 001					**>A>** NCE	Jun 10, 2016
EZOGABINE - POTIGA						
N022345 002					**>A>** NCE	Jun 10, 2016
EZOGABINE - POTIGA						
N022345 003					**>A>** NCE	Jun 10, 2016
EZOGABINE - POTIGA						
N022345 004					**>A>** NCE	Jun 10, 2016
FAMCICLOVIR - FAMVIR						
N020363 001					M-98	Jan 31, 2014
FAMCICLOVIR - FAMVIR						
N020363 002					M-98	Jan 31, 2014
FAMCICLOVIR - FAMVIR						
N020363 003					M-98	Jan 31, 2014
FAMOTIDINE; IBUPROFEN - DUEXIS						
N022519 001					NC	Apr 23, 2014
FENOFIBRATE - ANTARA (MICRONIZED)						
N021695 001	7863331	Aug 08, 2020	U-1107			
	7863331	Aug 08, 2020	U-1106			
FENOFIBRATE - ANTARA (MICRONIZED)						
N021695 003	7863331	Aug 08, 2020	U-1107			
	7863331	Aug 08, 2020	U-1106			
FENOFIBRIC ACID - FIBRICOR						
N022418 001	7915247	Aug 20, 2027	U-1061			
	7915247	Aug 20, 2027	U-1059			
	7915247	Aug 20, 2027	U-1000			
FENOFIBRIC ACID - FIBRICOR						
N022418 002	7915247	Aug 20, 2027	U-1061			
	7915247	Aug 20, 2027	U-1059			
	7915247	Aug 20, 2027	U-1000			
FENTANYL CITRATE - ABSTRAL						
N022510 001	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL						
N022510 002	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENTANYL CITRATE - ABSTRAL						
N022510 003	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL						
N022510 004	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL						
N022510 005	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - ABSTRAL						
N022510 006	6759059	Sep 24, 2019	DP U-767			
	6761910	Sep 24, 2019	DP U-767			
	7910132	Sep 24, 2019	DP U-767			
FENTANYL CITRATE - FENTORA						
N021947 001	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
FENTANYL CITRATE - FENTORA						
N021947 002	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
FENTANYL CITRATE - FENTORA						
N021947 003	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
FENTANYL CITRATE - FENTORA						
N021947 004	7862832	Jun 15, 2028	DP			
	7862833	Jun 15, 2028	DP			
FENTANYL CITRATE - LAZANDA						
N022569 001					**>A>** NDF	Jun 30, 2014
FENTANYL CITRATE - LAZANDA						
N022569 002					**>A>** NDF	Jun 30, 2014
FERUMOXYTOL - FERAHEME						
N022180 001	7871597	Mar 08, 2020	DS DP			
FESOTERODINE FUMARATE - TOVIAZ						
N022030 001	7384980	May 11, 2019	DS DP U-913			
	7855230	May 11, 2019	U-913			
FESOTERODINE FUMARATE - TOVIAZ						
N022030 002	7384980	May 11, 2019	DS DP U-913			
	7855230	May 11, 2019	U-913			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FEXOFENADINE HYDROCHLORIDE - ALLEGRA ALLERGY						
N020872 007	**>A>** 5578610	Nov 26, 2013	DS DP U-1160			
	>A> 5578610*PED	May 26, 2014				
	>A> 5855912	Feb 28, 2015	DP			
	>A> 5855912*PED	Aug 28, 2015				
	>A> 5932247	Feb 28, 2015	DP			
	>A> 5932247*PED	Aug 28, 2015				
	>A> 6037353	Mar 14, 2017	U-1160			
	>A> 6037353*PED	Sep 14, 2017				
	>A> 6113942	Feb 28, 2015	DP			
	>A> 6113942*PED	Aug 28, 2015				
	>A> 6187791	May 11, 2012	U-1160			
	>A> 6187791*PED	Nov 11, 2012				
	>A> 6399632	May 11, 2012	U-1160			
	>A> 6399632*PED	Nov 11, 2012				
	>A> 7135571	May 18, 2014	DS U-1160			
	>A> 7135571*PED	Nov 18, 2014				
	>A> 7138524	May 18, 2014	DS			
	>A> 7138524*PED	Nov 18, 2014				
FEXOFENADINE HYDROCHLORIDE - ALLEGRA ALLERGY						
N020872 010	**>A>** 5578610	Nov 26, 2013	DS DP U-1160			
	>A> 5578610*PED	May 26, 2014				
	>A> 5855912	Feb 28, 2015	DP			
	>A> 5855912*PED	Aug 28, 2015				
	>A> 5932247	Feb 28, 2015	DP			
	>A> 5932247*PED	Aug 28, 2015				
	>A> 6037353	Mar 14, 2017	U-1160			
	>A> 6037353*PED	Sep 14, 2017				
	>A> 6113942	Feb 28, 2015	DP			
	>A> 6113942*PED	Aug 28, 2015				
	>A> 6187791	May 11, 2012	U-1160			
	>A> 6187791*PED	Nov 11, 2012				
	>A> 6399632	May 11, 2012	U-1160			
	>A> 6399632*PED	Nov 11, 2012				
	>A> 7135571	May 18, 2014	DS U-1160			
	>A> 7135571*PED	Nov 18, 2014				
	>A> 7138524	May 18, 2014	DS			
	>A> 7138524*PED	Nov 18, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FEXOFENADINE HYDROCHLORIDE - ALLEGRA HIVES						
N020872 008	**>A>** 5578610	Nov 26, 2013	DS DP U-1160			
	>A> 5578610*PED	May 26, 2014				
	>A> 5855912	Feb 28, 2015	DP			
	>A> 5855912*PED	Aug 28, 2015				
	>A> 5932247	Feb 28, 2015	DP			
	>A> 5932247*PED	Aug 28, 2015				
	>A> 6037353	Mar 14, 2017	U-1160			
	>A> 6037353*PED	Sep 14, 2017				
	>A> 6113942	Feb 28, 2015	DP			
	>A> 6113942*PED	Aug 28, 2015				
	>A> 6187791	May 11, 2012	U-1160			
	>A> 6187791*PED	Nov 11, 2012				
	>A> 6399632	May 11, 2012	U-1160			
	>A> 6399632*PED	Nov 11, 2012				
	>A> 7135571	May 18, 2014	DS U-1160			
	>A> 7135571*PED	Nov 18, 2014				
	>A> 7138524	May 18, 2014	DS			
	>A> 7138524*PED	Nov 18, 2014				
FEXOFENADINE HYDROCHLORIDE - ALLEGRA HIVES						
N020872 009	**>A>** 5578610	Nov 26, 2013	DS DP U-1160			
	>A> 5578610*PED	May 26, 2014				
	>A> 5855912	Feb 28, 2015	DP			
	>A> 5855912*PED	Aug 28, 2015				
	>A> 5932247	Feb 28, 2015	DP			
	>A> 5932247*PED	Aug 28, 2015				
	>A> 6037353	Mar 14, 2017	U-1160			
	>A> 6037353*PED	Sep 14, 2017				
	>A> 6113942	Feb 28, 2015	DP			
	>A> 6113942*PED	Aug 28, 2015				
	>A> 6187791	May 11, 2012	U-1160			
	>A> 6187791*PED	Nov 11, 2012				
	>A> 6399632	May 11, 2012	U-1160			
	>A> 6399632*PED	Nov 11, 2012				
	>A> 7135571	May 18, 2014	DS U-1160			
	>A> 7135571*PED	Nov 18, 2014				
	>A> 7138524	May 18, 2014	DS			
	>A> 7138524*PED	Nov 18, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY						
N020872 005	**>A>** 5578610	Nov 26, 2013	DS DP U-1160			
	>A> 5578610*PED	May 26, 2014				
	>A> 5855912	Feb 28, 2015	DP			
	>A> 5855912*PED	Aug 28, 2015				
	>A> 5932247	Feb 28, 2015	DP			
	>A> 5932247*PED	Aug 28, 2015				
	>A> 6037353	Mar 14, 2017	U-1160			
	>A> 6037353*PED	Sep 14, 2017				
	>A> 6113942	Feb 28, 2015	DP			
	>A> 6113942*PED	Aug 28, 2015				
	>A> 6187791	May 11, 2012	U-1160			
	>A> 6187791*PED	Nov 11, 2012				
	>A> 6399632	May 11, 2012	U-1160			
	>A> 6399632*PED	Nov 11, 2012				
	>A> 7135571	May 18, 2014	DS U-1160			
	>A> 7135571*PED	Nov 18, 2014				
	>A> 7138524	May 18, 2014	DS			
	>A> 7138524*PED	Nov 18, 2014				
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY						
N021909 002	**>A>** 5578610	Nov 26, 2013	DS DP U-1158			
	>A> 5738872	Feb 28, 2015	DP			
	>A> 6037353	Mar 14, 2017	U-1158			
	>A> 6187791	May 11, 2012	U-1158			
	>A> 6399632	May 11, 2012	U-1158			
	>A> 7138524	May 18, 2014	DS			
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY						
N201373 001	**>A>** 5578610	Nov 26, 2013	DS DP U-1157			
	>A> 5578610*PED	May 26, 2014				
	>A> 6037353	Mar 14, 2017	U-1157			
	>A> 6037353*PED	Sep 14, 2017				
	>A> 6187791	May 11, 2012	U-1157			
	>A> 6187791*PED	Nov 11, 2012				
	>A> 6399632	May 11, 2012	U-1157			
	>A> 6399632*PED	Nov 11, 2012				
	>A> 7138524	May 18, 2014	DS			
	>A> 7138524*PED	Nov 18, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES						
N020872 006	**>A>** 5578610	Nov 26, 2013	DS DP U-1160			
	>A> 5578610*PED	May 26, 2014				
	>A> 5855912	Feb 28, 2015	DP			
	>A> 5855912*PED	Aug 28, 2015				
	>A> 5932247	Feb 28, 2015	DP			
	>A> 5932247*PED	Aug 28, 2015				
	>A> 6037353	Mar 14, 2017	U-1160			
	>A> 6037353*PED	Sep 14, 2017				
	>A> 6113942	Feb 28, 2015	DP			
	>A> 6113942*PED	Aug 28, 2015				
	>A> 6187791	May 11, 2012	U-1160			
	>A> 6187791*PED	Nov 11, 2012				
	>A> 6399632	May 11, 2012	U-1160			
	>A> 6399632*PED	Nov 11, 2012				
	>A> 7135571	May 18, 2014	DS U-1160			
	>A> 7135571*PED	Nov 18, 2014				
	>A> 7138524	May 18, 2014	DS			
	>A> 7138524*PED	Nov 18, 2014				
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES						
N021909 003	**>A>** 5578610	Nov 26, 2013	DS DP U-1158			
	>A> 5738872	Feb 28, 2015	DP			
	>A> 6037353	Mar 14, 2017	U-1158			
	>A> 6187791	May 11, 2012	U-1158			
	>A> 6399632	May 11, 2012	U-1158			
	>A> 7138524	May 18, 2014	DS			
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES						
N201373 002	**>A>** 5578610	Nov 26, 2013	DS DP U-1157			
	>A> 5578610*PED	May 26, 2014				
	>A> 6037353	Mar 14, 2017	U-1157			
	>A> 6037353*PED	Sep 14, 2017				
	>A> 6187791	May 11, 2012	U-1157			
	>A> 6187791*PED	Nov 11, 2012				
	>A> 6399632	May 11, 2012	U-1157			
	>A> 6399632*PED	Nov 11, 2012				
	>A> 7138524	May 18, 2014	DS			
	>A> 7138524*PED	Nov 18, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION							
N020786 002	>A>	5578610	Nov 26, 2013	DS DP U-1159			
	>A>	5578610*PED	May 26, 2014				
	>A>	5855912	Feb 28, 2015	DP			
	>A>	5855912*PED	Aug 28, 2015				
	>A>	6037353	Mar 14, 2017	U-1159			
	>A>	6037353*PED	Sep 14, 2017	U-138			
	>A>	6039974	Jul 31, 2018	DP			
	>A>	6113942	Feb 28, 2015	DP			
	>A>	6113942*PED	Aug 28, 2015				
	>A>	6187791	May 11, 2012	U-1159			
	>A>	6187791*PED	Nov 11, 2012	U-138			
	>A>	6399632	May 11, 2012	U-1159			
	>A>	6399632*PED	Nov 11, 2012	U-468			
	>A>	7135571	May 18, 2014	DS U-1159			
	>A>	7135571*PED	Nov 18, 2014				
	>A>	7138524	May 18, 2014	DS			
	>A>	7138524*PED	Nov 18, 2014				
FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION							
N021704 002	>A>	5578610	Nov 26, 2013	DS DP U-1159			
	>A>	5578610*PED	May 26, 2014				
	>A>	6037353	Mar 14, 2017	U-1159			
	>A>	6037353*PED	Sep 14, 2017				
	>A>	6187791	May 11, 2012	U-1159			
	>A>	6187791*PED	Nov 11, 2012				
	>A>	6399632	May 11, 2012	U-1159			
	>A>	6399632*PED	Nov 11, 2012				
	>A>	6613357	Dec 25, 2020	DP U-1159			
	>A>	7138524	May 18, 2014	DS			
	>A>	7138524*PED	Nov 18, 2014				
	>A>	RE39069	May 29, 2018	DP			
FIDAXOMICIN - DIFICID							
N201699 001						NCE	May 27, 2016
FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA							
N021112 001		7915243	Mar 22, 2026	DP			
		7939516	May 04, 2025	DP			
FULVESTRANT - FASLODEX							
N021344 001		6774122	Jan 09, 2021	U-596		D-126	Sep 09, 2013
		6774122*PED	Jul 09, 2021			M-103	May 17, 2014
		7456160	Jan 09, 2021	U-596		PED	Nov 17, 2014
		7456160*PED	Jul 09, 2021			PED	Mar 09, 2014
GABAPENTIN - GABAPENTIN							
A078974 001						PC	Aug 22, 2011

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GABAPENTIN - GRALISE						
N022544 001	6340475	Sep 19, 2016	DP		NP	Jan 28, 2014
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6723340	Oct 25, 2021	DP			
	7438927	Feb 26, 2024	U-1114			
	7731989	Oct 25, 2022	DP			
GABAPENTIN - GRALISE						
N022544 002	6340475	Sep 19, 2016	DP		NP	Jan 28, 2014
	6488962	Jun 20, 2020	DP			
	6635280	Sep 19, 2016	DP			
	6723340	Oct 25, 2021	DP			
	7438927	Feb 26, 2024	U-1114			
	7731989	Oct 25, 2022	DP			
GABAPENTIN ENACARBIL - HORIZANT						
N022399 001	6818787	Nov 06, 2022	DS DP		NCE	Apr 06, 2016
GADOBUTROL - GADAVIST						
N201277 001	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
GADOBUTROL - GADAVIST						
N201277 002	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
GADOBUTROL - GADAVIST						
N201277 003	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
GADOBUTROL - GADAVIST						
N201277 004	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
GADOBUTROL - GADAVIST						
N201277 005	5980864	Nov 09, 2016	DS DP U-1119		NCE	Mar 14, 2016
GADOFOSVESET TRISODIUM - ABLAVAR						
N021711 001	5362475	Nov 08, 2011	DS			
	6676929	May 26, 2015	DP			
	7011815	Feb 01, 2015	U-1112			
	7060250	May 26, 2015	DS			
	7229606	May 26, 2015	U-1112			
GADOFOSVESET TRISODIUM - ABLAVAR						
N021711 002	5362475	Nov 08, 2011	DS			
	6676929	May 26, 2015	DP			
	7011815	Feb 01, 2015	U-1112			
	7060250	May 26, 2015	DS			
	7229606	May 26, 2015	U-1112			
GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE						
A077983 001					PC	Jul 24, 2011
GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE						
A077983 002					PC	Jul 24, 2011
GEMCITABINE HYDROCHLORIDE - GEMCITABINE HYDROCHLORIDE						
A079183 001					PC	May 14, 2011

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GRANISETRON HYDROCHLORIDE - KYTRIL						
N020239 001					M-102	Apr 29, 2014
GRANISETRON HYDROCHLORIDE - KYTRIL						
N020239 002					M-102	Apr 29, 2014
GRANISETRON HYDROCHLORIDE - KYTRIL						
N020239 003					M-102	Apr 29, 2014
GRANISETRON HYDROCHLORIDE - KYTRIL						
N020239 004					M-102	Apr 29, 2014
GUANFACINE HYDROCHLORIDE - INTUNIV						
N022037 001					I-635	Feb 25, 2014
GUANFACINE HYDROCHLORIDE - INTUNIV						
N022037 002					I-635	Feb 25, 2014
GUANFACINE HYDROCHLORIDE - INTUNIV						
N022037 003					I-635	Feb 25, 2014
GUANFACINE HYDROCHLORIDE - INTUNIV						
N022037 004					I-635	Feb 25, 2014
HYDROXOCOBALAMIN - CYANOKIT						
N022041 001	5834448	Nov 14, 2016	DP		ODE	Dec 15, 2013
HYDROXYPROGESTERONE CAPROATE - MAKENA						
N021945 001					ODE	Feb 03, 2018
IBUPROFEN LYSINE - NEOPROFEN						
N021903 001	6342530	Nov 14, 2020	DP U-794			
	6342530	Nov 14, 2020	DP U-1127			
	6344479	Mar 20, 2021	DS DP U-794	Y		
IMIQUIMOD - ZYCLARA						
N022483 001					I-636	Mar 24, 2014
INDIUM IN-111 PENTETREOTIDE KIT - OCTREOSCAN						
N020314 001	5384113	Jan 24, 2012	DP			
	5753627	May 19, 2015	U-1125			
	5776894	Jul 07, 2015	DS DP			
INSULIN GLARGINE RECOMBINANT - LANTUS						
N021081 001	7918833	Sep 23, 2027	DP			
	7918833*PED	Mar 23, 2028				
INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR						
N021629 003	7918833	Sep 23, 2027	DP			
INSULIN RECOMBINANT HUMAN - HUMULIN R						
N018780 001					NR	Mar 25, 2014
INSULIN RECOMBINANT HUMAN - HUMULIN R PEN						
N018780 005					NR	Mar 25, 2014
IOFLUPANE I-123 - DATSCAN						
N022454 001					NCE	Jan 14, 2016

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IXABEPILONE - IXEMPRA KIT						
N022065 001	6670384	Jan 23, 2022	DP U-960		NCE	Oct 16, 2012
	6670384	Jan 23, 2022	DP U-959		PED	Apr 16, 2013
	6670384*PED	Jul 23, 2022				
	7022330	Jan 23, 2022	DP U-958			
	7022330*PED	Jul 23, 2022				
	7125899	May 26, 2018	DS DP U-957			
	7125899*PED	Nov 26, 2018				
	7312237	Aug 21, 2024	U-965			
	7312237*PED	Feb 21, 2025				
	RE41393	Feb 08, 2022	U-961			
	RE41393*PED	Aug 08, 2022				
	RE41911	May 26, 2018	DS DP U-961			
	RE41911*PED	Nov 26, 2018				
IXABEPILONE - IXEMPRA KIT						
N022065 002	6670384	Jan 23, 2022	DP U-960		NCE	Oct 16, 2012
	6670384	Jan 23, 2022	DP U-959		PED	Apr 16, 2013
	6670384*PED	Jul 23, 2022				
	7022330	Jan 23, 2022	DP U-958			
	7022330*PED	Jul 23, 2022				
	7125899	May 26, 2018	DS DP U-957			
	7125899*PED	Nov 26, 2018				
	7312237	Aug 21, 2024	U-965			
	7312237*PED	Feb 21, 2025				
	RE41393	Feb 08, 2022	U-961			
	RE41393*PED	Aug 08, 2022				
	RE41911	May 26, 2018	DS DP U-961			
	RE41911*PED	Nov 26, 2018				
LAMOTRIGINE - LAMICTAL ODT						
N022251 001	7919115	Jan 04, 2029	DS DP			
LAMOTRIGINE - LAMICTAL ODT						
N022251 002	7919115	Jan 04, 2029	DS DP			
LAMOTRIGINE - LAMICTAL ODT						
N022251 003	7919115	Jan 04, 2029	DS DP			
LAMOTRIGINE - LAMICTAL ODT						
N022251 004	7919115	Jan 04, 2029	DS DP			
LANREOTIDE ACETATE - SOMATULINE DEPOT						
N022074 001	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
LANREOTIDE ACETATE - SOMATULINE DEPOT						
N022074 002	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
LANREOTIDE ACETATE - SOMATULINE DEPOT						
N022074 003	5595760	Mar 08, 2020	DP U-831		D-131	Mar 04, 2014
LANSOPRAZOLE - PREVACID						
N021428 001	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LANSOPRAZOLE - PREVACID						
N021428 002	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
LENALIDOMIDE - REVLIMID						
N021880 001	7855217	Nov 24, 2024	DS DP			
LENALIDOMIDE - REVLIMID						
N021880 002	7855217	Nov 24, 2024	DS DP			
LENALIDOMIDE - REVLIMID						
N021880 004	7855217	Nov 24, 2024	DS DP			
LEUPROLIDE ACETATE - LUPRON DEPOT						
N020517 003					**>A>** D-132	Jun 17, 2014
					>A> NS	Jun 17, 2014
LEVOLEUCOVORIN CALCIUM - FUSILEV						
N020140 001					I-637	Apr 29, 2014
LEVOLEUCOVORIN CALCIUM - FUSILEV						
N020140 002	6500829	Dec 31, 2019	DS DP		I-637	Apr 29, 2014
					ODE	Mar 07, 2015
LEVOLEUCOVORIN CALCIUM - FUSILEV						
N020140 003	6500829	Dec 31, 2019	DS DP		I-637	Apr 29, 2014
					ODE	Mar 07, 2015
LINAGLIPTIN - TRADJENTA						
N201280 001	6303661	Apr 24, 2017	U-774		**>A>** NCE	May 02, 2016
	6890898	Feb 02, 2019	U-493			
	7078381	Feb 02, 2019	U-493			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-493			
LOTEPREDNOL ETABONATE - LOTEMAX						
N200738 001					NDF	Apr 15, 2014
					PED	Oct 15, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LOVASTATIN; NIACIN - ADVICOR						
N021249 001	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1131			
	6469035	Mar 15, 2018	U-1130			
	6676967	Sep 20, 2013	U-1132			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-548			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			
LOVASTATIN; NIACIN - ADVICOR						
N021249 002	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1131			
	6469035	Mar 15, 2018	U-1130			
	6676967	Sep 20, 2013	U-1132			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-548			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LOVASTATIN; NIACIN - ADVICOR						
N021249 003	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1131			
	6469035	Mar 15, 2018	U-1130			
	6676967	Sep 20, 2013	U-1132			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-548			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			
LOVASTATIN; NIACIN - ADVICOR						
N021249 004	6080428	May 27, 2017	U-1133			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-447			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-1132			
	6129930	Sep 20, 2013	DP U-1133			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-448			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1129			
	6469035	Mar 15, 2018	U-1131			
	6469035	Mar 15, 2018	U-1130			
	6676967	Sep 20, 2013	U-1132			
	6676967	Sep 20, 2013	U-1133			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-548			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1135			
	7011848	Sep 20, 2013	U-1136			
	7011848	Sep 20, 2013	U-1137			
METFORMIN HYDROCHLORIDE - FORTAMET						
N021574 001	7919116	Mar 20, 2018	DP			
METFORMIN HYDROCHLORIDE - FORTAMET						
N021574 002	7919116	Mar 20, 2018	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR						
N022024 001	7919116	Mar 20, 2018	U-973			
	7919116	Mar 20, 2018	U-1120			
	>A> 7959946	Jul 31, 2026	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR						
N022024 002	7919116	Mar 20, 2018	U-973			
	7919116	Mar 20, 2018	U-1120			
	>A> 7959946	Jul 31, 2026	DP			
METRONIDAZOLE - VANDAZOLE						
N021806 001	7456207	Sep 22, 2024	DP			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N022256 001	7888342	Nov 05, 2021	U-882			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N022256 002	7888342	Nov 05, 2021	U-882			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N022256 003	7888342	Nov 05, 2021	U-882			
MILNACIPRAN HYDROCHLORIDE - SAVELLA						
N022256 004	7888342	Nov 05, 2021	U-882			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 001	7919483	Feb 28, 2027	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 002	7919483	Feb 28, 2027	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 003	7919483	Feb 28, 2027	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 004	7919483	Feb 28, 2027	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 005	7919483	Feb 28, 2027	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 006	7919483	Feb 28, 2027	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 007	7919483	Feb 28, 2027	U-1078			
MINOCYCLINE HYDROCHLORIDE - SOLODYN						
N050808 008	7919483	Feb 28, 2027	U-1078			
MOMETASONE FUROATE MONOHYDRATE - NASONEX						
N020762 001					M-99	Jan 19, 2014
MOXIFLOXACIN HYDROCHLORIDE - MOXEZA						
N022428 001	7671070*PED	Mar 29, 2020				
MUPIROCIN CALCIUM - BACTROBAN						
N050746 001	6025389	Oct 20, 2014	DP U-1122			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NALTREXONE - VIVITROL						
N021897 001	7919499	Oct 15, 2029	U-1124			
	7919499	Oct 15, 2029	U-1123			
NEVIRAPINE - VIRAMUNE XR						
N201152 001	5366972	Nov 22, 2011	DS DP U-167		NDF	Mar 25, 2014
	5366972*PED	May 22, 2012				
NIACIN - NIASPAN						
N020381 002	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6129930	Sep 20, 2013	DP U-1138			
	6129930	Sep 20, 2013	DP U-1139			
	6129930	Sep 20, 2013	DP U-1140			
	6129930	Sep 20, 2013	DP U-1141			
	6129930	Sep 20, 2013	DP U-354			
	6406715	Sep 20, 2013	DP U-450			
	6469035	Mar 15, 2018	U-1145			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1144			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1143			
	6676967	Sep 20, 2013	U-1138			
	6676967	Sep 20, 2013	U-1139			
	6676967	Sep 20, 2013	U-1140			
	6676967	Sep 20, 2013	U-1146			
	6676967	Sep 20, 2013	U-548			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1140			
	7011848	Sep 20, 2013	U-1141			
	7011848	Sep 20, 2013	U-1147			
	7011848	Sep 20, 2013	U-1148			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NIACIN - NIASPAN						
N020381 003	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6129930	Sep 20, 2013	DP U-1138			
	6129930	Sep 20, 2013	DP U-1139			
	6129930	Sep 20, 2013	DP U-1140			
	6129930	Sep 20, 2013	DP U-1141			
	6129930	Sep 20, 2013	DP U-354			
	6406715	Sep 20, 2013	DP U-450			
	6469035	Mar 15, 2018	U-1145			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1144			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1143			
	6676967	Sep 20, 2013	U-1138			
	6676967	Sep 20, 2013	U-1139			
	6676967	Sep 20, 2013	U-1140			
	6676967	Sep 20, 2013	U-1141			
	6676967	Sep 20, 2013	U-1146			
	6676967	Sep 20, 2013	U-548			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1140			
	7011848	Sep 20, 2013	U-1141			
	7011848	Sep 20, 2013	U-1147			
	7011848	Sep 20, 2013	U-1148			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NIACIN - NIASPAN						
N020381 004	6080428	May 27, 2017	U-1139			
	6080428	May 27, 2017	U-1140			
	6080428	May 27, 2017	U-1141			
	6080428	May 27, 2017	U-331			
	6080428	May 27, 2017	U-1138			
	6129930	Sep 20, 2013	DP U-1138			
	6129930	Sep 20, 2013	DP U-1139			
	6129930	Sep 20, 2013	DP U-1140			
	6129930	Sep 20, 2013	DP U-1141			
	6129930	Sep 20, 2013	DP U-354			
	6406715	Sep 20, 2013	DP U-450			
	6469035	Mar 15, 2018	U-1145			
	6469035	Mar 15, 2018	U-1142			
	6469035	Mar 15, 2018	U-1144			
	6469035	Mar 15, 2018	U-768			
	6469035	Mar 15, 2018	U-1143			
	6676967	Sep 20, 2013	U-1138			
	6676967	Sep 20, 2013	U-1139			
	6676967	Sep 20, 2013	U-1140			
	6676967	Sep 20, 2013	U-1141			
	6676967	Sep 20, 2013	U-1146			
	6676967	Sep 20, 2013	U-548			
	6746691	Sep 20, 2013	DP U-586			
	7011848	Sep 20, 2013	U-712			
	7011848	Sep 20, 2013	U-1140			
	7011848	Sep 20, 2013	U-1141			
	7011848	Sep 20, 2013	U-1147			
	7011848	Sep 20, 2013	U-1148			
NIACIN; SIMVASTATIN - SIMCOR						
N022078 001	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-862			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-1132			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1149			
	6469035	Mar 15, 2018	U-1129			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-862			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-1150			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NIACIN; SIMVASTATIN - SIMCOR						
N022078 002	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-862			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-1132			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1149			
	6469035	Mar 15, 2018	U-1129			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-862			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-1150			
NIACIN; SIMVASTATIN - SIMCOR						
N022078 003	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-1132			
	6129930	Sep 20, 2013	DP U-862			
	6129930	Sep 20, 2013	DP U-1134			
	6129930	Sep 20, 2013	DP U-1132			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1149			
	6469035	Mar 15, 2018	U-1129			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-862			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-1150			
NIACIN; SIMVASTATIN - SIMCOR						
N022078 004	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-1132			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1149			
	6469035	Mar 15, 2018	U-1129			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-862			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-1150			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NIACIN; SIMVASTATIN - SIMCOR						
N022078 005	6080428	May 27, 2017	U-862			
	6080428	May 27, 2017	U-1134			
	6080428	May 27, 2017	U-1132			
	6469035	Mar 15, 2018	U-863			
	6469035	Mar 15, 2018	U-1149			
	6469035	Mar 15, 2018	U-1129			
	6676967	Sep 20, 2013	U-862			
	6676967	Sep 20, 2013	U-1134			
	6676967	Sep 20, 2013	U-1132			
	7011848	Sep 20, 2013	U-862			
	7011848	Sep 20, 2013	U-1151			
	7011848	Sep 20, 2013	U-1150			
NITROGLYCERIN - RECTIV						
N021359 001					>A> NP	Jun 21, 2014
OLANZAPINE - ZYPREXA ZYDIS						
N021086 001					NPP	Dec 04, 2012
					PED	Jun 04, 2013
OLANZAPINE - ZYPREXA ZYDIS						
N021086 002					NPP	Dec 04, 2012
					PED	Jun 04, 2013
OLANZAPINE - ZYPREXA ZYDIS						
N021086 003					NPP	Dec 04, 2012
					PED	Jun 04, 2013
OLANZAPINE - ZYPREXA ZYDIS						
N021086 004					NPP	Dec 04, 2012
					PED	Jun 04, 2013
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N021087 001	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N021087 002	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N021087 003	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
OSELTAMIVIR PHOSPHATE - TAMIFLU						
N021246 001	5763483	Dec 27, 2016	DS U-376			
	5763483	Dec 27, 2016	DS U-1113			
	5952375	Feb 27, 2015	DS DP			
	5952375*PED	Aug 27, 2015				
PACLITAXEL - ABRAXANE						
N021660 001	7923536	Dec 09, 2023	U-1117			
	RE41884	Aug 14, 2016	U-1117			
PALIPERIDONE - INVEGA						
N021999 001					NPP	Apr 06, 2014
					PED	Oct 06, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PALIPERIDONE - INVEGA						
N021999 002					NPP	Apr 06, 2014
					PED	Oct 06, 2014
PALIPERIDONE - INVEGA						
N021999 003					NPP	Apr 06, 2014
					PED	Oct 06, 2014
PALIPERIDONE - INVEGA						
N021999 004					NPP	Apr 06, 2014
					PED	Oct 06, 2014
PALIPERIDONE - INVEGA						
N021999 006					NPP	Apr 06, 2014
					PED	Oct 06, 2014
PALONOSETRON HYDROCHLORIDE - ALOXI						
N021372 001	7947724	Jan 30, 2024	DP			
	7947725	Jan 30, 2024	DP			
PALONOSETRON HYDROCHLORIDE - ALOXI						
N021372 002	7947724	Jan 30, 2024	DP			
	7947725	Jan 30, 2024	DP			
PAROXETINE HYDROCHLORIDE - PAROXETINE HYDROCHLORIDE						
A091427 001					PC	Nov 01, 2011
PEMETREXED DISODIUM - ALIMTA						
N021462 001					M-61	Mar 17, 2014
					PED	Sep 17, 2014
PEMETREXED DISODIUM - ALIMTA						
N021462 002					M-61	Mar 17, 2014
					PED	Sep 17, 2014
PERFLUTREN - DEFINITY						
N021064 001	5527521	Feb 22, 2015	DP U-665			
	5585112	Dec 17, 2013	DP			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN						
N050684 001	7915229	Apr 14, 2023	DP			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN						
N050684 002	7915229	Apr 14, 2023	DP			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN						
N050684 003	7915229	Apr 14, 2023	DP			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN						
N050684 004	7915229	Apr 14, 2023	DP			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER						
N050750 001	7915229	Apr 14, 2023	DP			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER						
N050750 002	7915229	Apr 14, 2023	DP			
PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER						
N050750 003	7915229	Apr 14, 2023	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PLERIXAFOR - MOZOBIL							
N022311	001	7897590	Jul 22, 2023	U-936			
		RE42152	Dec 10, 2013	DP			
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX							
N020667	001					**>A>** M-104	May 13, 2014
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX							
N020667	002					**>A>** M-104	May 13, 2014
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX							
N020667	003					**>A>** M-104	May 13, 2014
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX							
N020667	005					**>A>** M-104	May 13, 2014
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX							
N020667	006					**>A>** M-104	May 13, 2014
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX							
N020667	007					**>A>** M-104	May 13, 2014
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER							
N022421	006	**>A>** 7695734	Apr 26, 2028	DP		**>A>** I-623	Mar 19, 2013
						>A> NDF	Feb 19, 2013
PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER							
N022421	007	**>A>** 7695734	Apr 26, 2028	DP		**>A>** I-623	Feb 19, 2013
						>A> NDF	Feb 19, 2013
RALTEGRAVIR POTASSIUM - ISENTRESS							
N022145	001	7169780	Oct 03, 2023	DS DP			
RANOLAZINE - RANEXA							
N021526	001	6369062	May 27, 2019	DP	Y		
RETAPAMULIN - ALTABAX							
N022055	001	7875630	Feb 14, 2027	DS			
		RE39128	Apr 12, 2021	DS DP U-805			
RIFAXIMIN - XIFAXAN							
N021361	001	7902206	Jun 19, 2024	DS DP			
		7906542	Jun 01, 2025	DS DP			
		7928115	Jul 24, 2029	U-1121			
RIFAXIMIN - XIFAXAN							
N022554	001	7612199	Jun 19, 2024	DS DP			
		7902206	Jun 19, 2024	DS DP			
		7906542	Jun 01, 2025	DS DP			
RILPIVIRINE HYDROCHLORIDE - EDURANT							
N202022	001	6838464	Feb 26, 2021	DS DP		NCE	May 20, 2016
		7067522	Dec 20, 2019	DS DP			
		7125879	Apr 14, 2023	DS DP U-1153			
		7638522	Apr 14, 2023	DP			
RIZATRIPTAN BENZOATE - MAXALT							
N020864	001	5602162	Feb 11, 2014		Y		
RIZATRIPTAN BENZOATE - MAXALT							
N020864	002	5602162	Feb 11, 2014		Y		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RIZATRIPTAN BENZOATE - MAXALT-MLT						
N020865 001	5602162	Feb 11, 2014	U-240	Y		
RIZATRIPTAN BENZOATE - MAXALT-MLT						
N020865 002	5602162	Feb 11, 2014	U-240	Y		
ROFLUMILAST - DALIRESP						
N022522 001	5712298	Jan 27, 2015	DS DP U-1115		NCE	Feb 28, 2016
ROPINIROLE HYDROCHLORIDE - REQUIP XL						
N022008 001	7927624	Dec 02, 2021	DP U-20			
ROPINIROLE HYDROCHLORIDE - REQUIP XL						
N022008 002	7927624	Dec 02, 2021	DP U-20			
ROPINIROLE HYDROCHLORIDE - REQUIP XL						
N022008 003	7927624	Dec 02, 2021	DP U-20			
ROPINIROLE HYDROCHLORIDE - REQUIP XL						
N022008 004	7927624	Dec 02, 2021	DP U-20			
ROPINIROLE HYDROCHLORIDE - REQUIP XL						
N022008 005	7927624	Dec 02, 2021	DP U-20			
ROPINIROLE HYDROCHLORIDE - REQUIP XL						
N022008 006	7927624	Dec 02, 2021	DP U-20			
ROTIGOTINE - NEUPRO						
N021829 001	6699498	Nov 27, 2020	DP			
ROTIGOTINE - NEUPRO						
N021829 002	6699498	Nov 27, 2020	DP			
ROTIGOTINE - NEUPRO						
N021829 003	6699498	Nov 27, 2020	DP			
RUFINAMIDE - BANZEL						
N201367 001	6740669	Aug 17, 2020	DS DP		NCE ODE	Nov 14, 2013 Nov 14, 2015
SAPROPTERIN DIHYDROCHLORIDE - KUVAN						
N022181 001	**>A>** 7947681	Nov 17, 2024	U-1156			
SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA						
N022350 001	**>A>** 7951400	Nov 30, 2028	DP			
SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA						
N022350 002	**>A>** 7951400	Nov 30, 2028	DP			
SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE						
N201444 001					ODE	Jan 14, 2018
SODIUM OXYBATE - XYREM						
N021196 001	7668730	Jun 16, 2024	U-1110			
	7895059	Dec 17, 2022	U-1110			
SORAFENIB TOSYLATE - NEXAVAR						
N021923 001	7897623	Jan 12, 2020	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SPINOSAD - NATROBA							
N022408 001		5496931	Mar 05, 2013	DS U-1105		NCE	Jan 18, 2016
		6063771	Jun 22, 2019	DP U-1105			
		6342482	Jun 22, 2019	DP U-1105			
		7030095	Jul 02, 2021	DP U-1105			
SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO							
N022239 001		7776007	Nov 28, 2026	DP			
		7901385	Jul 31, 2026	DP			
SUNITINIB MALATE - SUTENT							
N021938 001	>A>	6573293	Feb 15, 2021	DS DP U-1154		I-639	May 20, 2014
SUNITINIB MALATE - SUTENT							
N021938 002	>A>	6573293	Feb 15, 2021	DS DP U-1154		I-639	May 20, 2014
SUNITINIB MALATE - SUTENT							
N021938 003	>A>	7125905	Feb 15, 2021	DS DP		I-639	May 20, 2014
SUNITINIB MALATE - SUTENT							
N021938 004	>A>	6573293	Feb 15, 2021	DS DP U-1154		I-639	May 20, 2014
TECHNETIUM TC-99M MERTIATIDE KIT - TECHNESCAN MAG3							
N019882 001		5573748	Nov 12, 2013	DP			
TELAPREVIR - INCIVEK							
N201917 001						NCE	May 23, 2016
TELBIVUDINE - TYZEKA							
N022011 001		7858594	Sep 11, 2023	DS DP U-999			
TESTOSTERONE - ANDROGEL							
N022309 001		6503894	Aug 30, 2020	U-1103		NP	Apr 29, 2014
TESTOSTERONE - FORTESTA							
N021463 001		6319913	Nov 09, 2018	U-490			
		6579865	Nov 09, 2018	DP			
TESTOSTERONE - TESTIM							
N021454 001		7935690	Apr 21, 2023	U-1009			
THALIDOMIDE - THALOMID							
N020785 001		7874984	Aug 28, 2018	U-733			
		7874984	Aug 28, 2018	U-732			
		7874984	Aug 28, 2018	U-442			
		7874984	Aug 28, 2018	U-371			
		7874984	Aug 28, 2018	U-1109			
	>A>	7959566	Oct 23, 2020	U-1155			
THALIDOMIDE - THALOMID							
N020785 002		7874984	Aug 28, 2018	U-733			
		7874984	Aug 28, 2018	U-732			
		7874984	Aug 28, 2018	U-442			
		7874984	Aug 28, 2018	U-371			
		7874984	Aug 28, 2018	U-1109			
	>A>	7959566	Oct 23, 2020	U-1155			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
THALIDOMIDE - THALOMID						
N020785 003	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
	>A> 7959566	Oct 23, 2020	U-1155			
THALIDOMIDE - THALOMID						
N020785 004	7874984	Aug 28, 2018	U-733			
	7874984	Aug 28, 2018	U-732			
	7874984	Aug 28, 2018	U-442			
	7874984	Aug 28, 2018	U-371			
	7874984	Aug 28, 2018	U-1109			
	>A> 7959566	Oct 23, 2020	U-1155			
TIGECYCLINE - TYGACIL						
N021821 001	7879828	Feb 05, 2029	DP			
TIOTROPIUM BROMIDE MONOHYDRATE - SPIRIVA						
N021395 001	6908928	Sep 24, 2021	DS DP U-762			
	6908928	Sep 24, 2021	DS DP U-566			
	7309707	Sep 24, 2021	DS DP			
	7694676	Mar 12, 2027	DP			
TRANEXAMIC ACID - LYSTEDA						
N022430 001	7947739	Mar 04, 2025	DP			
VANDETANIB - VANDETANIB						
N022405 001	7173038	Aug 14, 2021	DS DP		NCE	Apr 06, 2016
	RE42353	Sep 23, 2017	DS DP		ODE	Apr 06, 2018
VANDETANIB - VANDETANIB						
N022405 002	7173038	Aug 14, 2021	DS DP		NCE	Apr 06, 2016
	RE42353	Sep 23, 2017	DS DP		ODE	Apr 06, 2018
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N022567 001	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N022567 002	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N022567 003	5532241	Sep 29, 2014	DS DP		NCE	Jan 21, 2016
	7834020	Jun 05, 2022	DS DP U-839			
ZOLEDRONIC ACID - RECLAST						
N021817 001	7932241	Feb 05, 2028	DP			
	7932241*PED	Aug 05, 2028				
ZOLEDRONIC ACID - ZOMETA						
N021223 003	**>A>** 7932241	Feb 05, 2028	DP			
ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE						
A078148 001					PC	Jun 04, 2011

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 6 - June 2011

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.
3. **** The expiration date for U.S. Patent No. 5,608,075 is March 4, 2009.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 31st Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm